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Summary
The structural and functional integrity of the brain relies on a close balance 
between the metabolic demands of neurons and supporting glia, and substrate 
delivery in the form of blood flow. Disruption of the communication of neural cells 
and vascular smooth muscle, controlling the dilation and delivery of blood to 
specific brain regions may exacerbate the negative consequences of 
neurodegenerative and neuroinflammatory conditions. However, there has been 
little research done to measure the relationship between neural activity and 
changes in blood flow, or neurovascular coupling. Disruption of neurovascular 
coupling could lead to hypoxic conditions in the brain, or more precisely ‘virtual 
hypoxic’ conditions. Conditions such as these, if severe enough can go on to cause 
apoptosis or necrosis; particularly during periods of increased metabolic stress such 
as inflammation. 
In this thesis, I begin by exploring how cerebrovascular reactivity, the process 
behind normal neurovascular coupling, is affected in the neuro-inflammatory 
condition – multiple sclerosis (chapter 5). I use this as the basis for beginning my 
attempt to empirically define neurovascular coupling in the healthy brain, using 
non-invasive neuroimaging techniques. I begin to define neurovascular coupling in 
the 6th chapter, using a multiple methods of measuring neural activity and blood 
flow changes using a graded visual task in MEG and fMRI environments. In the 7th
chapter I focus on refining this protocol, and assess the repeatability of my 
empirical neurovascular coupling measure. Finally, using this protocol, I examine if 
and how this crucial process is altered during an inflammatory disease like multiple 
sclerosis.
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1Chapter 1: General Introduction
2The structural and functional integrity of the brain relies on the close balance between energy 
demands and substrate delivery in the form of blood flow. While the energy demands of the brain are 
extremely high, there is little capacity for energy storage. Therefore, increases in neuronal activity 
must be matched with local increases in cerebral blood flow (CBF), referred to as functional 
hyperaemia. The link between changes in neuronal activity and associated increases in CBF is termed 
neurovascular coupling (NVC) and underlies the functional hyperaemic response. It is not just blood 
flow to be affected by changes in neuronal activity. Vessel dilation also leads to a change in cerebral 
blood volume, which is known to have an impact on certain MRI measures used to investigate blood 
flow; particularly Blood Oxygenation Dependent (BOLD)-weighted imaging. Decoupling of NVC has 
been seen in both acute and chronic conditions such as stroke and Alzheimer’s disease (AD). There is 
a large body of evidence investigating how blood flow and neuronal responses are characterised in 
healthy adults and in pathological states. However, in humans what is often called neurovascular 
coupling is rarely more than task-induced increases in blood flow, or coupling a neuronal measure 
with blood flow changes at a single stimulus intensity. In vivo work using invasive murine or primate 
test subjects have been able to establish more representative measures of NVC, but which vary 
depending on the method of measuring neuronal activation (i.e. local field potentials (LFP) vs. spike 
recording). The work presented here aims to provide a non-invasive method for determining NVC in 
humans across a wide stimulus intensity, and to demonstrate how this can be affected in an 
inflammatory disease state such as multiple sclerosis. 
In this thesis, I aim to obtain BOLD- and perfusion-weighted images using MRI and
magnetoencephalography (MEG) to measure CBF and neuronal activation, to assess the relationship 
between these two modalities in humans. The motivation behind this stems from an initial study using 
data collected from the Sapienza Institute in Rome, and described in chapter 5, suggesting an 
alteration to cerebrovascular reactivity (CVR) in an inflamed brain. This study also revealed a 
difference in the vascular reactivity of patients demonstrating acute inflammation, who were noted 
to have increased vascular reactivity compared to healthy controls. Patients without acute 
3inflammation, however, were found to have a larger reduction in their vascular reactivity compared 
to controls. I will determine the extent NVC is altered using a visual task known for eliciting graded 
neural, and blood flow responses. 
Chapter 2 contains an overview of both the gross pathophysiology of multiple sclerosis, its clinical 
presentations, along with an overview of the molecular markers and histological alterations found in 
both living and post mortem tissues. The aim is to provide some background to the disease, along with 
allowing some conclusions to be drawn from any alterations in vascular reactivity or NVC that might 
be seen later in this thesis.
Chapter 3 provides an overview of cerebral vascular architecture, the components of the 
neurovascular unit, and finally explaining the molecular mechanisms underlying the communication 
between neurons and blood vessels. The overall aim here is to give some background to the principles 
of cerebrovascular reactivity and neurovascular coupling, as these are the two mechanisms I focus on 
in this thesis. I also want to demonstrate the complexity of the signalling mechanisms between neural 
tissue and blood vessels to illustrate what can be disrupted during a pathological process like 
inflammation.
The experimental imaging methods used in this thesis are summarised in chapter 4. The two process 
of measuring blood flow using Blood Oxygenation Level Dependent (BOLD) contrast and arterial spin 
labelling (ASL) – for a qualitative or semi quantitative, and quantitative means of assessing blood flow 
respectively – are explained here. This chapter also covers the principles of magnetoencephalography 
(MEG) and how it is used for measuring neuronal activation, via evoked responses and neuronal 
oscillations as well as describing the mechanisms behind these measures.
In chapter 5 using data collected from the Sapienza Institute in Rome vascular reactivity is investigated 
in multiple sclerosis, along with the effects the administration of anti-inflammatory disease modifying 
treatments has in restoring the vasodilatory response to CO2. This chapter underlies the rationale 
behind the need to search for a reliable measure of NVC. Attempting to determine if and how coupling 
4between neurons and blood flow is affected in disease states would provide extra insight into the 
efficacy of new treatment options, as well as possibly allowing for a new measure of disease activity. 
Establishing and refining the protocol for measuring NVC is provided in chapters 6 and 7. An initial 
pilot is described in chapter 6, with chapter 7 aiming to build and refine the protocol, along with 
testing the new measure’s repeatability. In chapter 6, two stimuli are used; a reversing checkerboard 
and a moving grating. Both are shown in MEG and fMRI settings at 6 contrast levels. In MEG, the 
reversing checkerboard is used to gather visual evoked field (VEF) responses, whereas the grating was 
used to elicit gamma oscillatory event related synchronisations (ERS). During the MR sessions, BOLD-
and perfusion-weighted images were collected to assess cerebral blood flow responses (CBF). 
Regression is used to compare neural signals recorded in MEG to CBF responses for each task, with 
the aim being to empirically define neurovascular coupling. 
Chapter 7 contains a refinement of this protocol, where the focus shifts to comparing VEF responses 
to gamma oscillatory power, and BOLD weighted images to ASL data for neural and blood flow 
measures respectively. Only one stimulus is used here, with a wider range of intensities to allow for a 
full characterisation of the NVC response. I also assess the repeatability of each component used in 
defining NVC, as well as the repeatability of the measure overall.
Without ensuring the repeatability of a measure it would have no clinical or research benefits. If 
variability of a response can be confounded with an uncontrollable variable such as time, diminishes 
the ability of comparing results between cohorts or study groups.
Chapter 8 is the final experimental chapter, where I apply the NVC protocol from chapter 7 to multiple 
sclerosis patients. Here I aim to establish the extent to which NVC is altered in this disease state by 
comparing patients’ results to healthy volunteers. More specifically, I investigate the changes in 
gamma oscillatory power between healthy volunteers and patients, as well as BOLD and ASL-based 
CBF measures. Finally, a comparison is made between the overall NVC measure in healthy volunteers 
and patients. 
5The final chapter contains a summary of the results and findings of this thesis. Further developments 
are also discussed with further refinements to the NVC protocol and experimental design used in
chapters 7 and 8. 
6Chapter 2: Multiple Sclerosis
72-1 Introduction
Multiple sclerosis (MS) is an autoimmune demyelinating disease, first described by French neurologist 
Jean-Martin Charcot in 18681. The disease typically starts to present in the second and third decade 
of life, with a 2:1 ratio of women to men being affected2. While women are more likely to present 
with MS, the disease progression in men tends to be faster and more aggressive3,4. This disparity 
between the sexes only appears to occur in youth. Once over 50 years old, affliction rates tend to 
remain equal between men and women. 
2-2 Symptoms
As MS is a demyelinating disease of the central nervous system (CNS), it is characterised histologically 
by a loss of the fatty myelin sheath that wraps around and protects neurons. Loss of myelin on T1 
weighted scans shows as dark “holes” in the normally appearing white matter5 (fig. 2-1). The main 
functions of myelin are the increased conduction speed of action potentials down axons, which is 
achieved by allowing action potentials to be propagated via salutatory conduction (fig. 2-2), the 
increased efficiency by reducing energy demands from repeated axonal firing and the protection of 
axons1,6.
Figure 2-1 MRI showing lesions in a brain afflicted with MS. A) T1 weighted scan showing dark “holes” in the white matter 
indicative axonal loss. B) A FLAIR image of the same patient showing larger volumes and numbers of lesions than the T1
scan. Image taken from http://www.diagnijmegen.nl/images/d/db/Mriwebsite.png
8The symptoms of MS are varied, ranging from visual and sensory disturbances, motor and sphincteric 
dysfunction, cognitive impairment and mood-related disorders. However, in many cases symptoms 
can appear and disappear along with ‘relapses’ of the disease. This is characterised clinically by a the 
development of new symptoms or the sudden worsening or recurrence of pre-existing ones7. 
Investigation of patients undergoing a relapse usually show an increase in circulating inflammatory 
markers, as well as an increase in the volume or number of lesions present on an MRI7–9. Normally the 
meninges, or blood-brain-barrier (BBB) provide an impermeable layer to large molecules and 
circulating cells through the use of tight interlocking epithelial cells. Breakdown of the connecting 
junctions during relapses leads to increased permeability of the BBB and allows diffusion of 
inflammatory molecules and other immune cells into the delicate environment of the CNS10–12.
Gadolinium (Gd) is used as a contrast agent to assess the structural integrity of the BBB. As BBB 
permeability increases, intravenously injected Gd will diffuse into any sites of active inflammation in 
Figure 2-2 Schematic example of saltatory conduction. A) Influx of sodium ions (Na+) depolarise the first node of Ranvier, 
myelin prevents any leak of Na+ extracellularly allowing efficient diffusion to the next node. Movement of Na+ causes an 
increase in the membrane potential, enough to trigger the activation of voltage gated sodium channels (Nav) causing full 
depolarisation and propagation of the action potential. B) Loss of the myelin sheath slows conduction speed. The 
presence of Na+/K+ ATPases causes ‘leakage’ of Na+ extracellularly meaning the time taken for sufficient diffusion of Na+
to trigger Na is increased. Image taken from http://faculty.pasadena.edu/dkwon/chap%208_files/images/image47.png
9the CNS and show as the hyper-intense lesions seen in fig.2-1b. Following cessation of the acute 
inflammatory attack the BBB can repair itself and reduce its permeability back to normal levels. 
Therefore, Gd only shows the presence of new sites of inflammatory activity, rather than all lesions 
present through the CNS. It is still unknown what causes the breakdown of the BBB, whether the 
slightly elevated levels of inflammation damages the epithelial layers, causes a positive feedback loop 
leading to more inflammation and injury, or if an external stimulus causes the damage, leading to the 
inflammation.
As the disease progresses, patients present with increasing physical and cognitive disabilities. In 
addition, disturbances such as depression, mental and physical fatigue, sleep disturbances and pain 
are also common4,13,14.
The Kurtzke expanded disability score (EDSS) is used clinically to score disability of MS patients on a 
scale from 1-10. Scores below 6.0 represent patients who are still ambulatory14,15. These patients tend 
to present with: 
 Stiffness or weakness in the limbs
 Sensory disturbances (numbness or tingling, as well as visual or auditory alterations)
 Ataxia (lack of coordination of voluntary muscle groups, arising from dysfunction in the 
nervous system rather than within the muscle itself).
 Problems with speech or swallowing
 Bowel or bladder dysfunction
Above 6.0, patients require assistance with day-to-day walking. While this test has often been 
criticised for its overreliance on walking as a measure of disability, it is still commonly used clinically.
2-3 Clinical courses
Initial presentations of MS are referred to as clinically isolated syndromes (CIS). For a diagnosis of MS 
to be made, the MacDonald criteria are often used:
10
  2 attacks must be present, either evidence of 2 new lesions, or 1 lesion and historical 
evidence of another attack. 
 2 attacks and clinical evidence of 1 lesion
 1 attack and clinical evidence of  2 lesions
 For a diagnosis of primary progressive MS, a follow up period of 1 year in which constant 
disease progression must be present.
However, revisions suggested by Polman et al. (2011) are now commonly used. The key points here 
are that a dissemination of both time (DIT) and space (DIS) of lesion presence i.e.  new lesions must 
Figure 2-3 Changes to the MacDonald criteria as suggested by Polman et al. (2011). The main additions relate to the need 
for a dissemination of lesion presence in both time and space. As other neurological disorders present in a similar manner 
to MS, in order for a diagnosis of MS to be made Polman suggests that new lesions must present in a different are of the 
CNS than current, or historical lesions have done. If new lesions present in follow up scans compared to baseline, this is 
classified as a dissemination in time. Image adapted from Polman et al. (2011).
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present in different areas of the CNS or present during a follow up MRI scan compared to a baseline. 
Gadolinium is used as a contrast agent as it highlights areas of blood brain barrier (BBB) breakdown15.  
The revisions suggested by Polman et al. (2011) are shown in fig 2-3. Numbers of patients presenting 
with CIS going on to develop MS vary: anywhere between 30% to 70% of CIS patients have been 
reported to progress to MS16,17. 
There are 2 main ways of categorising MS, which can then be divided further into subcategories
according to the revisions put forth by Lublin et al. 201418 and summarised in fig 2-4: 
2-3-1 Relapsing remitting
Relapsing remitting MS (RRMS) is the most common form of MS. The name refers to the nature of 
patients exhibiting ‘relapses’. Patients experience ‘relapses’, characterised by either worsening of 
existing symptoms or the presentation of new ones. These attacks then can go into remission with 
either a lessening of symptoms back to a level comparable to before the relapse, or disappearing 
altogether.
It is thought that the relapsing-remitting nature of this type of MS represents remyelination of 
damaged axons19. Other theories include adaptation of the brain to cope with myelin/neuronal loss, 
or just the removal of the inflammatory attack allows at least partial restoration of brain function20. 
Disease modifying treatments aimed at reducing inflammation have, in many cases, been shown to 
lengthen the time taken from initial CIS to full MS, or prevent it altogether1,17,21. RRMS can be divided 
into two categories – active, and non-active. Activity is determined by either clinical relapses or the 
addition of new or enlarging contrast-enhancing T2 MRI lesions when assessed annually18 (fig. 2-5).
12
2-3-2 Progressive MS
Progressive MS is the second category MS phenotypes can take, which is broadly split into primary 
and secondary progressive forms. These are further split to define the disease activity and 
progression; these are summarised in fig. 2-4. 
2-3-2-1 Secondary progressive
Defined as the progressive accumulation of symptoms or disability after a period of an initial relapsing 
phenotype. 65% of patients with RRMS will eventually move onto the secondary progressive form, 
about 5-7 years after CIS. Disability proceeds continuously14,21. It is thought that progression to SPMS 
represents the exhaustion in the brain’s ability to repair or respond to new damage. 
Figure 2-4 Schematic of disability progression in the two most common forms of MS. In relapsing remitting MS (RRMS) a pre-
clinical period contains a clinically isolated syndrome precedes a period of relapses characterised by worsening of disability, or 
presentation of new symptoms associated with MS, followed by a remission. This is when patients are typically presented with 
treatment options. Disease modifying drugs/treatments (DMD/Ts) are used which take the form of interferon-β, glatiramer 
acetate, oral treatments or monoclonal antibodies. The RRMS stage can last from years to decades, 65% of patients form 
secondary progressive forms of the disease (SPMS), where the disease progresses, sometimes with relapses, but remissions do 
not result in a disappearance of symptoms like in the early phases of RRMS. Image modified from167.
13
2-3-2-2 Primary progressive
Only 10%-20% of patients present with phenotype14,22. It differs from SPMS in that PPMS is not 
preceded by a relapsing-remitting form. As the disability progresses, continuously from the initial CIS, 
it is not surprising that patients with this subtype more quickly develop disability.
Figure 2-5 Schematic of defining MS phenotypes according to the revisions presented by Lublin et al. 2014. Active is defined as 
either a clinical relapse annually, or an increase in the number or size of T2 hyperintense lesions in MRI follow up scans. 
Progression
14
2-3-3 Causes
To date no single cause of MS has been found. Instead, many studies have concluded that a 
combination of genetic and environmental (infections, vitamin D deficiency etc.) factors.  
Geographically, MS is more common in northern latitudes, where lower levels of sunlight, causing 
decreased vitamin D level have been implicated1,14,23. Indeed, lower activation of vitamin D-associated 
genes has been linked to increased MS risk. Twin studies have noted a link between the place of birth 
and MS affliction rate, subjects who moved to new countries before the age of 15 had the same risk 
of developing MS as a subject born there1,23,24. 
Certain infections are also noted to cause an increased risk of MS. Oligoclonal bands in the 
cerebrospinal fluid (CSF) of patients, typical of viral infection correlated well with disease severity13. 
Several demyelinating diseases similar to MS are also known to be caused by viral infection. However, 
no person-person transmission has ever been proven. 
As mentioned previously, a genetic factor is known to play a part. The incidence of MS rises along a 
family line. In non-identical twins, if one develops MS, the risk of the other also developing the disease 
increases by 5%. This rises to 30% in identical twins. Mutations affecting the human leukocyte antigen 
(HLA) on chromosome 6 have some commonality with MS diagnosis along with other autoimmune 
diseases. In total, mutations in 12 other genes on chromosome 6 outside of HLA also correlate highly 
with MS incidence. 
2-4 Pathophysiology
The name multiple sclerosis means “many scars” in Latin. Histologically, the classic marker for MS has 
been the formation of ‘plaques’ or ‘lesions’ in the white matter. These have been found in anatomical 
MRI scans, where dark “holes” appear corresponding to the locations of axonal loss25. 
There have been many studies conducted surrounding the role that inflammation plays in MS. With 
this in mind a multitude of inflammatory markers have been shown to be elevated in MS, with the 
oxidative- and nitrosative-stress pathways both shown to play a role. Increases in interleukins (IL) -
15
1β, IL-4, IL-6 and IL-10, reactive oxygen species (ROS), nitric oxide metabolites (NO), C-reactive protein 
(CRP), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-)7,8,26–31. 
Lymphocytes (particularly T-cells) infiltrating through a normally impermeable BBB recognise myelin 
as a foreign body, which must be removed. This attack on the myelin seems to start the inflammatory 
process that results in further BBB disruption and allows cytokines and antibodies to be released, as 
well as allowing other immune cells, most notably macrophages, to pass through the BBB12. Increased 
permeability of the BBB allows larger molecules to diffuse through, such as gadolinium (Gd) when 
contrast is administered for MRI. Gadolinium is used as a marker of BBB disruption. When used with 
a T1 MRI scan Gadolinium shows bright white (hyperintense) on areas of the brain or spinal cord with 
enhanced BBB permeability, and therefore active inflammatory sites5. 
The mechanism through which BBB permeability first increases is still up for debate. It is unclear 
whether there is increased inflammation, which leads to BBB permeability, allowing infiltration of 
lymphocytes or whether the BBB gets damaged, causing infiltration and this leads to inflammation. 
MS can be characterised by two main aspects: 
1. Destruction of myelin in the CNS
2. Inflammation
Which order these steps occur in is still unclear. 
Myelin is key for normal neuronal function, as it allows for more efficient action potential 
transmission. By wrapping around axons in sections, leaving only small sections of axons exposed 
(nodes of Ranvier), myelin causes action potentials to propagate through salutatory conduction. This 
increases the speed of transmission while reducing energy demands on neurons32. Resting membrane 
potentials are maintained through the actions of a variety of channels and pumps, but the 
sodium/potassium ATPase (Na+/K+ ATPase) is by far the most numerous. It acts to remove intracellular 
sodium ions (Na+i) in exchange for extracellular potassium ions (K+o) against their respective 
16
concentration gradients using the energy released through ATP hydrolysis to assist32. During 
salutatory conduction, only the nodes of Ranvier become depolarised, meaning Na+/K+ ATPases only 
need be concentrated around these sections. 
Following demyelination conduction speed slows. To compensate, neurons up-regulate voltage gated 
sodium, potassium and calcium channels (Nav, Kv and Cav respectively) along with the associated 
ATPases to remove the ions and restore proper resting membrane potentials33–37. The increased ATP 
demand puts a strain on neuronal mitochondria to produce more ATP to run these enzymes. It is 
unclear how detrimental this reduction in ATP generation is on its own, but when compounded with 
the effects of inflammatory mediators, a significant strain is put on normal neuronal functions. 
Nitric oxide inhibits respiratory chain enzymes, reducing ATP generation and causing increases in 
ROS37,38. The increased levels of ROS help set up a positive feedback loop, as ROS increase damage of 
mitochondria, further inhibiting their ability to keep up with increased ATP demand. Eventually, as 
ATP becomes scarce, ATPases can no longer maintain appropriate concentrations of intracellular 
sodium ([Na+]i), potassium ([K+]i) or calcium ([Ca2+]i). Calcium is very important in neurotransmission, 
but is also toxic to cells and as such its intracellular concentration is kept under strict regulation. 
However, upregulation of Na+ channels (particularly Nav1.6 – known for causing large and persistent 
currents)33,37 leads to large rises in [Na+]i which cannot be cleared via the Na+/K+ ATPase, resulting in 
reversal of the Na+/Ca2+ exchanger. The reversal causes large influxes of Ca2+, inhibiting mitochondrial 
function further leading to excitotoxicity and neuronal cell death. 
It has been noted that white matter lesion count, or volume correlates poorly with disability in PPMS, 
SPMS and to some extent RRMS. It is becoming clear that grey matter (GM) demyelination is playing 
a greater role in determining disease severity than canonical WM lesions volume, but has been hard 
to characterise using conventional MRI4,39,40. Techniques such as 3D-FLAIR and double inversion 
recovery (DIR) have proved key to demonstrating cortical lesions. RRMS tends to be characterised by 
WM periventricular lesions. Grey matter pathology becomes far more extensive in progressive forms
17
of the disease, where demyelination of axons in the cortex is met with increasing levels of perivascular 
and BBB inflammation4. As GM demyelination appears to occur more readily in primary and secondary 
progressive forms of MS compared to RRMS, it could be that GM pathology might instead be occurring 
secondary to WM damage. This is part of the ‘virtual hypoxia’ hypothesis proposed by Stys et al. It 
postulates that degradation in cortical GM may be the results from WM degeneration and 
inflammation combined with increased energy demand from the upregulation of Na+ channels 31,33–
35,37 (fig. 2-6). For the virtual hypoxia theory to be the sole cause of damage seen in MS, cerebral 
perfusion would need to be maintained. ‘Traditional’ hypoxia or ischaemia is where a reduction in 
cerebral blood supply restricts oxygen and glucose delivery to neurons. However, the virtual hypoxia 
theory stipulates that a normal level of blood supply is maintained to the neurons, but due to the 
increased energy demands imposed by the upregulation of ATPases and other ion channels glucose 
and oxygen delivery cannot be maintained as blood is diverted to other areas currently undergoing 
use. 
In the early stages of MS, lesions appear to form due to a combination of low perfusion and oxidative 
stress. During these stages neurons exhibit an accumulation of oxidative lipids and mitochondrial 
injury41–43. Neurons that exhibit these morphological changes tend to show signs of acute injury, 
characterised by axonal and dendritic fragmentation and either controlled (apoptosis) or uncontrolled 
(necrosis) death of the neuron. These alterations tend to be found in actively demyelinating lesions, 
implying that in early MS at least, acute oxidative injury appears to start the demyelinating process. 
Another type of injury, one associated more with axonal transection is also present. This type of 
damage tends to appear more in areas directly overlaying subcortical demyelinating lesions44. 
Neurons showing the type of degradation associated with axonal transection tend to be localised in 
cortical areas and sulci, but also contain a high number of mitochondria with DNA deletions. A 
phenotype commonly associated with high levels of oxidative stress45. When damaged, mitochondria 
are transported to the cell body, which may amplify further damage due to electron leakage. These 
data imply that the formation of demyelinating lesions lead to further increases in oxidative stress and 
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axonal damage. The resolution of this inflammation and the removal of oxidative stress helps to 
partially resolve this, and could give rise to the RRMS subtype45. In progressive forms of MS, 
accumulation of oxidative damage and axonal transection could cause apoptosis or necrosis of whole 
neurons leading to the cortical lesions associated with disease progression and disability.
There is overwhelming evidence that cerebral blood flow is altered in MS. Several studies have 
reported increases in nitric oxide synthase (NOS) activity, along with increases in NO metabolites in 
cerebrospinal fluid (CSF). As NO is a potent vasodilator, this would point to MS patients being 
cerebrally hyper-perfused, which would reflect the expected hyper-perfusion of tissues during an 
inflammatory response. Current evidence indicates however, that MS sufferers are chronically 
hypoperfused, particularly in WM, as an increase in the expression of hypoxia-related genes has been 
noted in histological samples46–50. It is unclear though, whether the hypoxia-related genes are being 
activated due to the virtual hypoxia mechanism mentioned previously, or is instead being caused by 
MS patients being chronically hypoperfused.
Figure 2-6 Virtual hypoxia hypothesis of multiple sclerosis. In ‘normal’ ischaemia, the demand for substrates such as 
oxygen and glucose by neurons is no different from in a healthy brain, but a reduction in blood supply causes a reduction 
in delivery causing hypoxia, neuronal stress and apoptosis/necrosis. In ‘virtual hypoxia’ demyelination leads to an 
upregulation of Nav channels (particularly Nav 1.2 and 1.6) as well as Na+/K+ and Na+/Ca2+ ATPases. Increases in the 
latter lead to a vastly increased demand for ATP, glucose and oxygen. The demand cannot be met with a ‘normal’ 
supply leading to ‘virtual’ hypoxia, where blood flow appears unaffected but tissues remain hypoxic due to increased 
demand. Image taken from34
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Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by endothelial cells in response to release of 
TNF- and IL-1b47. The actions of ET-1 are mediated through two receptors; ET-a and ET-b. ET-1 levels 
have been found to be increased in cerebral ischemia, traumatic brain injury and subarachnoid 
haemorrhages, with circulating plasma levels of ET-1 being correlated with higher incidence of 
stroke51. The vasoconstrictory effects of ET-1 are mediated through the ET-a receptor (ET-aR) found 
on vascular smooth muscle cells. In addition to the actions on smooth muscle cells, ET-1 also inhibits 
the production of NO via endothelial nitric oxide synthase (eNOS)51,52. Under normal circumstances 
tonic action of eNOS regulates blood flow through many parts of the body. However, the actions of 
ET-1 to inhibit eNOS activity, as well as increasing vasoconstriction of vascular smooth muscle cells 
(VSMCs)51,52. This would support the evidence that MS patients are chronically hypoperfused, with 
hypoperfusion exacerbating damage caused by lymphocyte infiltrations and mitochondrial 
dysfunction, but does not offer any explanation for the hyperperfusion seen by some studies. 
Endothelial NOS is not the only producer of NO. However, two other isoforms; inducible NOS (iNOS) 
and neuronal NOS (nNOS) are also present in the brain, of which iNOS is of particular relevance. While 
ET-1 has inhibitory actions on eNOS, iNOS is unaffected and indeed some studies suggest iNOS activity 
is enhanced via interactions with ET-153,54. TNF- and IFN- - the same inflammatory cytokines that 
elicits production of ET-1 also stimulates iNOS, further increasing acitivity55,56. This means that while 
tonic actions of eNOS might be halted in MS, vasodilatory actions of NO produced via iNOS might still 
continue, and lend some explanatory mechanisms to the possible hyperperfusion seen57. 
Overproduction of NO via iNOS is not without problems. Acutely, NO severely inhibits mitochondrial 
function. Nitric oxide has a high affinity for the cytochrome C oxidase enzyme, where it outcompetes 
O2 for binding and leads to ROS generation37. As NO is a highly diffusible, lipid soluble gas its half-life 
is usually tightly controlled through its reaction with oxyhaemoglobin (oxy-Hb) in red blood cells, 
where it is converted to nitrate30,58,59. As we have seen previously, ROS are produced as a consequence 
of the inflammatory response and mitochondrial dysfunction. When NO and ROS interact they 
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produce a powerful oxidant, peroxynitrite52. Under inflammatory conditions the rate of peroxynitrite 
production can increase up to 1,000,000-fold30. Luckily peroxynitrite reacts quite slowly with biological 
molecules, but can diffuse far from its production site. Sustained increases in peroxynitrite have been 
found to cause irreversible damage to mitochondria, disrupt signalling pathways and the induction of 
cell death through apoptosis and necrosis37,38,52.
Neuronal activation is well known to lead to an increase in blood flow to the region being activated –
known as the functional hyperaemia. Disruption here leading to hypoperfusion (through the actions 
of ET-1) would in the short term causes extreme stress to neurons as they are not able to respire 
anaerobically. 
In the longer term, significant increases in peroxynitrite production would result, as insufficient levels 
of oxy-Hb would be available to break down NO into nitrate. Neurons already under significant strains 
from inflammation, mitochondrial dysfunction, and decreased oxygen and glucose delivery would be 
put under further pressure and lead to their death. Indeed, increases in peroxynitrite are found to be 
abundant in lesions of acute experimental autoimmune encephalomyelitis (EAE) animals, along with 
increases in both CBF and cerebral blood volume (CBV) preceding lesion formation60–62. This suggests 
that excessive NO production plays a significant part in lesion formation and disease progression. 
Treatments with IFN-β1a reduces NO production and slow lesion formation and disease 
progression59,63. 
So far I have discussed changes in neuronal activity and cerebral blood flow (CBF) individually, with no 
association being made between synaptic activity and functional hyperaemia. With both neurons and 
blood flow being affected, it would be rash to assume the link between neurons and CBF would be 
unaffected in this disease. It is not clear whether the basal hypoperfusion seen in normal appearing 
white matter (NAWM) is due to the primary actions of circulating ET-1, or if it is in fact secondary to 
decreased neuronal firing. Using a link between neuronal activation and changes in CBF could prove 
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extremely useful in improving our understanding of the pathophysiology of MS, establishing new 
biomarkers disease evolution and identify targets for treatments.
2-5 Treatment
As MS is an inflammatory autoimmune disease of the CNS (central nervous system), there is a limited 
number of approved treatments available. During acute relapses, inflammation is initially controlled 
using corticosteroids with the aim of limiting the inflammatory damage. Following from this, 
additional disease modifying treatments are available to slow disease course and aim to reduce 
further relapses: 
 Interferon-beta 1a (IFN-1a) and 1b (IFN-1b)
 Glatiramer acetate
 Oral treatments (dimethyl fumarate, teriflunomide, fingolimod)
 Humanised monoclonal antibodies (hmAbs) (natalizumab, alemtuzumab)
While IFN- and IFN- are both inflammatory mediators IFN- acts to reduce inflammation through 
reduction of tumour necrosis factor- (TNF-) and interleukins-4 and -6 (IL-4 and IL-6). The 
interferons’ efficacy has been well documented in slowing the progression from CIS to MS, as well as 
in reducing relapse rate in RRMS patients by 30%64. Unfortunately, these treatments are not 
particularly effective in slowing disease progression, once patients reach the secondary progressive 
phase, nor are they effective in treating primary progressive forms of MS. 
Glatiramer acetate (GA) comprises of 4 amino acids found in myelin basic protein, namely lysine, 
tyrosine, alanine and glutamic acid. It is not clear on the exact mechanism of action of GA, but there 
is evidence to suggest that GA shifts the population of lymphocytes from Th1 (pro-inflammatory) to 
Th2 (regulatory), thereby reducing inflammation. It is also thought that by using amino acids found in 
myelin basic protein, these will act as a decoy for the immune system, thereby slowing the disease 
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course. However, studies have demonstrated that while the number of relapses does decrease with 
the administration of GA, disability progression does not slow in RRMS disease types. 
Dimethyl Fumarate (DMF) is the methyl ester form of fumeric acid which has been found to reduce 
relapse rate and time to progression of full MS. As such it is marketed in the EU under the name 
Tecfidera and is generally only prescribed to patients who do not have a highly active form of RRMS. 
Like the interferons, DMF inhibits the production of pro-inflammatory cytokines to aid slowing of 
disease progression. Teriflunomide is another oral DMT which has been shown to reduce relapse rate 
by 30% with less severe side effects compared to DMF. While the mechanism of action of 
Teriflunomide is not completely understood, it is thought that as it inhibits rapidly dividing cells such 
as activated T-cells thereby reducing the relapse rate in RRMS patients. Finally, Fingolimod is a 
sphingosine-1-phosphate (S1P) receptor modulator. S1P1 is used in lymph nodes to help with egress 
of lymphocytes out into the circulation. Fingolimod causes internalisation of the S1P1 receptor and 
thereby sequestering lymphocytes to the lymph nodes and preventing them from taking part in an 
ongoing immune reaction.
Humanised monoclonal antibodies have been available for the treatment of MS since 2004, when 
Natalizumab was first introduced followed by Alemtuzumab. They work with extreme specificity, from 
reducing immunoreactivity of CD4+ lymphocytes and marking CD52 antigen-carrying lymphocytes for 
destruction (Natalizumab and Alemtuzumab, respectively)14,65. By reducing immunoreactivity of T-
cells, Natulizumab helps to prevent activated T-cells from crossing the BBB, further worsening 
inflammation, while destruction of lymphocytes with Alemtuzumab helps to reduce overall 
immunoreactivity. From their mechanisms of action, however, use of mAbs tends to be reserved as a 
treatment option for aggressive forms of MS. The suppression of vital parts of the immune system by 
mAbs opens patients up to opportunistic infections, notably progressive multifocal 
leukoencephalopathy. 
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Chapter 3: Neurovascular Coupling
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3-1 Introduction
The structural and functional integrity of the brain relies on the close balance between energy 
demands and substrate delivery in the form of blood flow. While the energy demands of the brain are 
extremely high, there is little capacity for energy storage. Therefore increases in neuronal activity must 
be matched with local increases in cerebral blood flow (CBF), referred to as functional hyperaemia66. 
Breakdown of signalling between neural or glial cells and blood vessels, and the resulting hypoxia have 
been implicated in several other CNS disorders such as stroke, Alzheimer’s and amyotrophic lateral 
sclerosis (ALS)67–70. This effect has been extensively studied in Alzheimer’s disease (AD), where hypoxia 
leads to altered ATP synthesis, Na+/K+ ATPase activity, pH alterations and electrolyte imbalances. All 
these lead to the accumulation of proteinaceous toxins – like hyperphosphorylated tau and amyloid-
 - know to be associated with AD, but also white matter lesions and oedema, two classic symptoms 
of MS67.
fMRI has provided some insight into brain activity through non-invasive measurement of task-related 
blood flow changes, however, this still relies on the communication between neurons/glia and 
arterioles. As functional hyperaemia appears to be involved and altered in the pathophysiology of 
many disease states, establishing a method of measuring this coupling would be extremely useful to 
aid diagnosis and treatment. First, the signalling methods underlying this response need to be 
established and examined more closely. 
3-2 Neuronal regulation of local blood flow
Arterial supply to the brain can be considered at several levels (fig. 3-1). Pial arteries branching off 
large suppling arteries split further into penetrating arteries. These burrow down into brain tissues 
and eventually split again into capillary beds where oxygen exchange can occur with surrounding 
parenchyma. The largest increases in vascular resistance is found in the penetrating arteries, where 
smooth muscles cells surrounding the vessel provide regulation of luminal diameter, and therefore 
CBF to the underlying regions71,72. As these vessels are found in areas of synaptic activity these 
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arterioles are likely to be targets of local pathways regulating the functional hyperaemic response. 
The individual network of neurones and supporting glial surrounding a penetrating artery/capillary 
cells is called a neurovascular unit (fig. 3-2).
Initially it was thought that coupling was mediated by an increase in metabolic demand from neurons, 
or that neurons could directly signal and control vascular smooth muscle. Increases in haemodynamic 
activity occur within 1-3 seconds following task onset, far faster than any meaningful increase in the 
production of oxidative metabolic products73,74. Increased arterial CO2 also causes basal 
hyperperfusion. Recent studies investigating the effects of inspired CO2 to induce hypercapnia in 
healthy volunteers found a reduction in percentage change in CBF during a graded visual task, 
compared to the responses measured during normocapnia75. However, no change in absolute CBF was 
detected between normo- and hypercapnic challenges at any contrast of the visual task. So, while the 
metabolic demands of neurons remain the same between normo- and hyper-capnia during the visual 
task, absolute CBF is maintained depending on the stimulus strength. Hypercapnia also results in a 
reduction in broadband neuronal rhythmicity (and therefore neuronal metabolism) and blood flow in 
the resting default mode network and during tasks76–79. The increase in arterial CO2 decreases pH and 
Figure 3-1 Schematic of levels in the brain vasculature. Large arteries splitting off the Circle of Willis pass over the cortical 
surface, these split into penetrating arteries that burrow into the cortex where they begin to be surrounded by interneurons 
and astrocytes. As no oxygen exchange takes place at these larger arterioles, vascular smooth muscle surrounds the vessel 
walls, regulating luminal width and being a key regulator of local CBF. Finally, these split again to form capillary beds where 
oxygen exchange can take place. As capillaries are too small to be surrounded by vascular smooth muscle, they instead 
have pericytes which are slightly contractile and provide an extra level of regulation for CBF. Image taken from227
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causes the release of adenosine – a molecule shown to reduce cortical excitability as well as causes 
vasodilation80–82.  This implies that CBF alteration might be occurring through a range of intermediaries 
(such as calcium and potassium ions, lipid soluble gases like nitric oxide, pH, and purines such as 
adenosine) rather than being directly affected by metabolic signalling. 
Formation of the blood brain barrier (BBB) ensures the isolation of the delicate CNS from circulating 
substances, including those that could potentially be harmful, such as bacterial or viral infections, or 
metabolic products that could interfere with normal neuronal signalling. This is done through the use 
of tight adherens junctions which prevents the transfer of any molecule between cells. Any signalling 
used to elicit NVC must therefore pass via endothelial cells (ECs) forming the BBB before acting on 
vascular smooth muscle cells (VSMCs). Neurons do not form a direct connection with the ECs making 
up the BBB83. Astrocytes, while lying abluminally to ECs do form numerous connections to the BBB 
through their end feet, which are known to be able to excrete many substances for altering vascular 
smooth muscle contractility and BBB permeability81,84–86.
Figure 3-2 A similar schematic to figure 3-1, but with the neurovascular unit shown on the right. Larger arterioles are 
surrounded by vascular smooth muscle which helps support vessel integrity against intra-luminal pressures from blood flow. 
These vessels are surround by astrocytic end feet which provide trophic support as well as being key regulators of myogenic 
tone for VSMCs. Further down at the capillary level, pericytes take over the role of VSMCs and provide some level of 
contractility and therefore micro control over CBF. Pericytes are similarly surrounded by astrocytic end feet which again 
provide signals passed through from neurons as to the amount of CBF required. Image taken from67.
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Several studies have indicated that neurotransmitter release might be crucial to signalling for 
increases in CBF, particularly the excitatory neurotransmitter glutamate8,34,81,87,88. Ionotropic 
glutamate receptor activation may mediate some CBF increases through the action of calcium-
activated synthesis of nitric oxide (notably via the inducible isoform of the nitric oxide synthase 
enzyme – iNOS but some brain areas use neuronal NOS – nNOS), as well as the release of 
prostaglandins (PGE2) and epoxyeicosatrienoic acids (EETs)81,82,86,89,90. Presynaptic release of 
glutamate, while having a main purpose of transmitting action potentials to a neighbouring neuron, 
would also cause the activation of astrocytes with endfeet lying close to any synapse. Neuronally 
derived NO is also produced during action potential firing (although which isoform of the synthase 
responsible appears to differ depending on the brain region87,91). Being such a lipid soluble gas, but 
with a short half-life, it would have direct vasodilatory control over nearby vessels. This method of 
functional hyperaemia is not the complete story, however67,90,92,93
Histological studies have concluded that many processes of vascularly active interneurons, especially 
those expressing noradrenaline, synapse onto astrocytes rather than directly onto the vascular 
smooth muscle cells (VSMCs) of blood vessels.  Indeed, vascular smooth muscle is rich in inwardly 
rectifying potassium channels (Kir 2.1 and 2.2) and purinergic receptors, the former of which has been 
demonstrated to be crucial to the alteration of luminal diameter94. The morphological set up of the 
neurovascular unit examined here suggests that all signalling molecules required for vascular control 
must first pass through astrocytes before an effect on the vasculature can occur – the most notable 
exception of course, being gaseous transmitters such as NO. 
3-3 Astrocytic responses
Astrocytes unlike neurons are electrically unexcitable, meaning they cannot convey information 
through the use of action potentials like neurons. Instead astrocytes rely on the release of Ca2+ as a 
means of controlling and communicating information to other cells. Brain slice studies have shown 
that astrocytes, when excited through either an external influence, or through neuronal firing trigger 
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the release of calcium from internal stores, resulting in the dilation or constriction of surrounding 
vessels85,95. 
Whether an astrocyte causes the dilation or constriction of vessels is determined by the secondary 
messengers released during the brief increase in intracellular calcium ([Ca2+]i). Dilation it seems, is 
mediated through the actions of metabotropic glutamate receptors (mGluR) resulting in the release 
of either cyclooxygenase related compounds, or the combined effects of the Kir channels causing local 
changes to the concentration of extracellular potassium ([K+]o) mentioned previously. Constriction of 
vessels appears to be a little more complex, with several other messengers having been found to cause 
this effect. The conversion of arachidonic acid to 20-hydroexyeicosatetraneoic acid (20-HETE) by the 
cytochrome P450 enzyme has been found in smooth muscle cells around vessel walls found to cause 
vasoconstriction. Other studies have suggested the release of NO to be important in determining 
whether a vessel dilates or constricts (indeed this has been mentioned previously in chapter 2, the 
tonic actions of endothelial NOS – eNOS – is well known to be crucial to the maintenance of vascular 
tone, with stimulation of iNOS also having the resultant dilatory effect). 
In vivo studies looking at the time course of intracellular calcium concentrations of astrocytes have 
been able to determine that both sensory stimulation, or direct electrical stimulation of neurones 
elicited transient increases in astrocytic [Ca2+]i in cortical layer II. Astrocytic responses also appear to 
modulate in response to local synaptic input. Stronger neuronal firing (as determined through LFP 
recordings) resulted in higher astrocytic responses96. The timing of these responses appears to differ 
depending on the study and the region of interest. The changes in [Ca2+]i vary between 1-6s from 
stimulus onset, with functional hyperaemia is known to take approximately 2s from stimulus onset. 
Delays of peak calcium concentration in the visual cortex were found to be on the order of 3-4s, a 
higher latency than that of functional hyperaemia. It is known that quantitative dyes used to measure 
changes [Ca2+] have trouble detecting modest changes in [Ca2+] due to the dual-wavelength nature of 
these dyes97,98. Dyes loaded within neurons are also known to accumulate in the cell bodies, or 
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sometimes larger processes meaning the area where Ca2+ would be taking effect; i.e. astrocytic 
endfeet are likely to have a lower concentration of dye and be unable to detect subtle shift in [Ca2+]99. 
Finally, as calcium is such an important signalling molecule, its concentration is kept under strict 
control. Therefore, all cells have a significant buffering capacity for free calcium which would reduce 
a dye’s ability to accurately report changes in [Ca2+]i. This means that early, modest rises in [Ca2+]i
could go undetected for some time, but may be of a significant level to cause the functional 
hyperaemic response98. 
Another scenario is possible, however, astrocytic [Ca2+]i rises might indeed be slower than the 
functional hyperaemic response. The presence of extra-astrocytic vasoactive substances such as NO, 
released from interneurons which are known to occupy a similar space to astrocytic endfeet, but not 
to the same concentration, could be responsible for an initial rise in CBF. This initial rise would present 
itself as the functional hyperaemic response seen within 1-2s of stimulus onset, astrocytes however 
are required to maintain the response and their effects come into play 3-6s after stimulus onset, 
releasing less potentially toxic and damaging substances such as NO84.
3-4 Astrocytic activation
The excitatory neurotransmitter glutamate has been shown to be the only relevant neuron-derived 
substance that can elicit both an increase in astrocytic [Ca2+]i and is released following sensory 
stimulation in vivo. Glutamate released by neurons acts on metabotropic glutamate receptors found 
on astrocytes (namely mGluR1 and mGluR5) to mediate the functional hyperaemic response. The 
blockade of these receptors leads to attenuation of calcium rises in astrocytes as well as local increases 
in CBF without affecting either pre- or post-synaptic activity. These instead rely on the ionotropic 
NMDA and AMPA receptors.
The contribution of synaptic glutamate to astrocyte activation is still under discussion. Recent results 
looking into the role that ionotropic glutamate receptor activation plays in astrocyte activation 
showed blockade of NMDA and AMPA receptors (NMDAr and AMPAr respectively) to have no effect 
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on astrocytic calcium levels, contradicting early results showing postsynaptic glutamate to have a large 
contribution to astrocytic signalling100,101. Further work has led to the possibility that two mechanisms 
exist to mediate functional hyperaemia depending on stimulus strength. Studies using rodent 
olfactory bulbs revealed a predominate role of presynaptic glutamate release to be mediating local 
CBF changes when low concentration odorants were used. A following study noted that stronger and 
more widespread activation relied heavily on postsynaptic glutamate release as global – but not local 
– blockade of postsynaptic responses ameliorated CBF responses84,101. 
This differing method of activation could be in response to altering metabolic trends. Postsynaptic 
receptor responses account for just 0.3% of the brain energy budget when activation is low, but 
increases to 33% when under heavy utilisation100. 
Figure 3-3 Summary of the role astrocytes and neurons play in NVC. Activation of astrocytic mGluRs cause a rise in intracellular 
calcium. This results in the generation of AAs by phospholipase A (PLA) and the activation of membrane Bk channels. AAs 
quickly converted to EET and PGE2 where, along with rises in extracellular K+ they cause relaxation of vascular smooth muscle 
and vasodilation. Activation of post synaptic neurons through AMPArs and NMDArs causes the activation of either iNOS or 
nNOS depending on the brain region in question. This highly diffusible gas has a direct effect on local vascular smooth muscle 
and pericytes, causing relaxation and vasodilation. Shear stress generated by the flow of red blood cells (RBCs) through the 
vessel leads to the release of acetylcholine (ACh) and the activation of endothelial NOS (eNOS). This tonic action of eNOS 
constantly generates low levels of NO and provides very low levels of vascular homeostasis, independent of neuronal or 
astrocytic control. When constriction is required, such as during high O2 episodes, AA  is transported to VSMCs where it gets 
converted to 20-HETE. This is a vasoconstrictor and is the main method of astrocytes to induce this response. NO inhibits the 
production of 20-HETE, as does the production of lactate, meaning that levels of 20-HETE are always kept to a minimum 
unless more than enough oxygen and glucose is being supplied. Image adapted from86.
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3-5 Signalling for a higher blood flow
It has been established that neuronal activation leads to [Ca2+]i rises in astrocytes. I have not yet 
discussed how these calcium rises result in a change in smooth muscle contraction. Using brain slice 
preparations, it was determined that during low [O2]o Ca2+ rises, triggered via an mGluR agonist, lead 
to vasodilation. During high [O2]o the same stimulus lead to constriction of local blood vessels (fig.3-3 
and 3-4).
Rises in astrocytic [Ca2+]i through mGluR activation causes production of arachidonic acid (AA) in a 
phospholipase A (PLA)-mediated manner. Arachidonic acid then converts to prostaglandin-2 (PGE2) 
Figure 3-4 During high O2 periods, 20-HETE is produced leading to constriction of dilated vessels. In vitro studies using 
pharmacological pre-constriction of vessels noted that astrocytic activation lead to the production of PGE2 instead, resulting
in vasodilation. A feedback mechanism is in place the prevents vessels from over dilating, even when O2 is in high supply. 
During periods of hypoxia however, the production of lactate also causes adenosine production. This inhibits the conversion 
of AA to 20-HETE, instead favouring the PGE2 route. This then leads to maximal dilation. Image taken from89.
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and epoyeicosatrienoic acids (EETs) through cyclooxygenase-1 and cytochrome P450 enzymes 
respectively. Both of these vasoactive compounds, when released from astrocytes they exert their 
effects on VSMCs to cause vasodilation67,81,86,102. Oxygen levels themselves are not sufficient to switch 
between dilatory or constrictive effects of astrocytes. During hypoxia, the production and 
accumulation of extracellular lactate and adenosine helps tip the balance of PGE2 to exert a larger 
vasodilatory effect on vessels by blocking prostaglandin transporters in astrocytes. Finally, rises in 
intra-astrocytic Ca2+ levels cause the activation of calcium-activated potassium (BK) channels located 
in astrocytic endfeet wrapped around vessel walls81,94. Potassium ions released here are allowed to 
enter through Kir channels mentioned previously, located in vascular smooth muscle, influx of K+ leads 
to relaxation of muscle cells89.
In high O2 environments lactate and adenosine are not produced in significant quantities, making 
inhibition of prostaglandin transporters negligible. Therefore, when activated, the increases in 
astrocytic [Ca2+] result in the production of 20-HETE via the same PLA-dependent mechanism by which
AA is produced. As PGE2 and EETs are not able to enter the perivascular space in large quantities as 
they would during hypoxia, the vasoconstrictive effects of 20-HETE are able to proceed103.
In vitro studies into the regulation of vessel tone have limitations however. Many are performed on 
brain slice preparations, which have the notable lack of any blood flowing through the vessels in 
question. It is well known that vessels used in these kinds of preparations are maximally dilated as any 
myogenic tone that would be present due to intraluminal pressure is missing104. To counter this, 
studies tend to use a pharmacological method for pre-constricting vessels, but this comes with the 
caveat that substances used to artificially constrict vessels could interfere with the timing or strength 
of any vessel response. Finally, the length of time taken for vessels and astrocytes to respond to a 
stimulus comes with another major confound; in vitro studies of brain slices rely heavily on assuming 
that the time taken for changes in vascular tone to been seen is equal to what would occur in vivo. 
They are unable to take into account any effects the lack of perfusion, temperature changes or the 
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possibility of interference from pharmacological pre-constriction/maximally dilated vessels might 
have on the experiment. It should be noted that the arguments and conclusions presented in this 
chapter on the role of astrocytes or the method for NVC relying on evidence gathered from brain slice 
preparations be subject to these confounds.
This differential selection of vascular responses being dependent on the concentration of O2, or more 
specifically oxyhaemoglobin (oxyHb) lacks much in vivo support by the studies mentioned so far. 
Fortunately, the advent of functional neuroimaging techniques has allowed the qualitative (and more 
lately quantitative) measurement of CBF. Several studies have made mention to the initial alterations 
of [oxyHb] and [deoxyHb] around 300-500ms following stimulus onset, due to the activation of 
neurons and astrocytes105–108. The decrease in [oxyHb] following stimulus onset was first seen using 
blood oxygenation level dependent contrast (BOLD) fMRI, a technique still used to measure the 
relative changes in blood flow105,108. BOLD contrast will be discussed further in chapter 4, but it relies 
on the ratio between oxyHb and deoxyHb and the differing magnetic properties between the two. 
Thereby allowing a non-quantitative way of measuring blood flow and relative oxygen changes. BOLD 
fMRI studies revealed a bi-phasic response of blood flow to prolonged neuronal activation. Following 
on from the ‘initial dip’ in oxyHb, BOLD signal then increases sharply, representing an increase in 
[oxyHb] to the local area which could only be coming from an increase in CBF and presumed 
vasodilation. 
So far this chapter has covered a brief overview of the current trends in neurovascular coupling along 
with evidence to support how the mechanisms could work in biological systems. There is growing 
evidence for the neurovascular unit, and therefore neurovascular coupling to be affected by loss of 
BBB integrity and permeability in other degenerative diseases such as AD and ALS67,69,70. In chapter 2
I proposed a hypothesis for how multiple sclerosis progresses along with some of the molecular and 
morphological changes occurring throughout the disease. It should be without question that there is 
disruption of normal vascular function in MS, as well as an alteration in normal neuronal function. A 
34
direct link between the two however, has not been discussed or proposed. Being able to provide a 
marker that can measure neuronal activity, and couple this to a quantitative measure of CBF would 
be extremely useful for gaining further insight into NVC, and how this is affected in a 
neurodegenerative disease state such as MS. 
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Chapter 4: Imaging Methods
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4-1 MRI
4-1-1 Principles of MRI
The main component of the MRI scanner is a large superconducting electromagnet. By cooling large 
loops of wire down to 4K, all electrical resistance is lost. Passing a current through the wire generates 
a perpetual, and large, magnetic field called B0. Additional, smaller radiofrequency (RF) coils are 
situated throughout the bore of the scanner, allowing transmission and detection of RF pulses. These 
can temporarily induce a magnetic field at perpendicular to the main B0 field, called B1.
Magnetic resonance imaging (MRI) relies on the properties of atomic nuclei to create maps and images 
of organisms and objects. As the human body is composed of around 80% water, a molecule that 
contains two hydrogen and an oxygen atom, hydrogen is therefore the most abundant element in the 
body. 99.99% of all hydrogen in the human body is hydrogen-1 (1H); and is composed of a single proton 
and electron, but more importantly exhibits a net ‘spin’.
Under normal conditions spins are randomly orientated and therefore the magnetic components of 
these spins cancel each other out. When placed in the strong B0 field, spins align either parallel, or 
anti-parallel to the B0 direction. A greater proportion of spins (around 0.00001% more) align parallel, 
rather than anti-parallel to the magnetic field. Once aligned in a parallel fashion, atoms are in a lower 
energy state (as opposed to a ‘high’ energy state for those aligned anti-parallel), and gives the object 
(or tissue) a net longitudinal magnetisation (figure 4-1). When aligned in the B0 field, 1H atoms precess 
at the Larmor frequency. This is calculated through the multiplication of the gyromagnetic ratio of the 
atom (the ratio of the nuclear dipole moment to the angular momentum), with the strength of the B0
field in tesla, hydrogen has a gyromagnetic ratio of 42.6MHz/Tesla, so the Larmor frequency in a 3 
Tesla environment would be 127.5MHz.
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Using transmitter coils RF pulses are rapidly switched on and off to create fields perpendicular to B0. 
When emitted at an atom’s resonant or Larmor frequency, spins align with the new magnetic field 
(B1). The angle of the B1 pulse (e.g. 90) ‘flips’ the protons and changes the net magnetisation from 
longitudinal, to transverse. When B1 is stopped, spins re-align back along the B0 releasing RF energy 
as they do so.  This process is known as relaxation and is quantified from the changes in voltage 
detected in receiver coils tuned to the Larmor frequency.
4-1-2 Relaxation
After removing the B1 field, net magnetisation returns along the longitudinal axis- following B0 and 
therefore a lower energy state compared to being aligned transversely.
There are two relaxation process occurring here: the recovery of longitudinal magnetisation along B0 
(T1); and the decay of transverse magnetisation provided by B1 (T2). Both have two very different times 
to relaxation. T1 has a relaxation time on the order of seconds, whereas T2 is generally orders of 
magnitude smaller (milliseconds). The rate of relaxation is also dependent on the type of tissue (due 
Figure 4-1 Schematic of hydrogen atoms and spin directions following application of a main B0 field. When spins are aligned 
parallel to the B0 field they are said to be in a ‘lower’ energy state than those aligned anti-parallel. For this reason slightly 
more hydrogen atoms align parallel to the main magnetic field. Image adapted from:
http://www.expertsmind.com/topic/proton-nuclear-magnetic-resonance-spectroscopy/external-magnetic-field-
913940.aspx
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to differing molecular compartments) and the B0 field strength, but refers to the time taken for 
magnetisation to return to 63% of its original value. 
In addition to creating transverse magnetisation, application of a radio frequency (RF) pulse along B1
forces spins into phase. Loss of B1 causes magnetisation to be lost quickly though dephasing of these 
spins (spin-spin relaxation) this is caused by interaction of protons with each other causing phase 
angles to alter leading to the loss of spin coherence or phase, and therefore transverse magnetisation. 
In spin echo readouts (SE), the initial 90 pulse is followed by a 180 refocussing pulse. This reverses 
the decay of transverse magnetisation causing spins to come back into phase at the same time delay 
as the interval between pulses. The refocussing of the net magnetisation is referred to as the echo. 
The time between the initial 90 pulse and the maximum echo amplitude is referred to as the echo 
time (TE). Spin-spin relaxation mentioned previously is not rephased following this refocussing pulse, 
so any transverse magnetisation will be affected by T2 relaxation.
The interactions of protons with each other means dephasing is also reliant on thermal motions of the 
molecules within the tissue as well as imperfections in the B0 field. By accounting for these, T2* creates 
an additional form of contrast, however, T2* dephasing occurs faster than normal T2. For T2* sensitive 
images to be acquired, a gradient echo (GRE) sequence is used. This differs from spin echo in that, 
rather than using a 180 refocussing pulse following the initial excitation, a bipolar gradient is applied 
instead. The initial gradient accelerates dephasing, the polarity of the gradient is quickly reversed 
thereby refocussing only those spins affected by the first gradient. The ability of GRE to detect changes 
in T2* is used later in this thesis, as it forms the basis of functional MRI (fMRI), and the ability to detect 
changes in Blood Oxygenation Level Dependent (BOLD) signal.
4-1-3 Functional MRI (FMRI)
4-1-3-1 Blood oxygenation dependent (BOLD) signal
An endogenous contrast can be obtained using the differing magnetic properties of haemoglobin 
according to levels of oxygenation. When deoxygenated (deoxy-Hb), haemoglobin is paramagnetic; 
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meaning it interferes with magnetic fields. However, when oxygenated (oxy-Hb) haemoglobin is 
diamagnetic therefore does not cause field inhomogeneities. Using these properties; it is possible to 
measure the relative changes in oxy-Hb levels in the tissue, increases in local deoxy-Hb concentration
creates a less homogenous magnetic field, thereby decreasing T2*. 
BOLD fMRI can be used to indirectly identify regions of enhanced neural activity. As previously 
mentioned in chapter 3, activation of neurons results in a rise in metabolic demand for substrates 
such as glucose and oxygen. It would be assumed that this would lead to an increase in deoxy-Hb and 
a decrease in T2* signal. However, regions of activation show an increase in T2*- weighted signal109,110. 
This is due to the previously mentioned haemodynamic response. Regions of activation have a large 
increase in cerebral blood flow (CBF), far above the rise in oxygen extraction of surrounding local 
tissue, because of this the ratio of oxy-Hb outweighs that of deoxy-Hb, reducing magnetic field 
inhomogeneity and increasing T2*-weighted signal. As BOLD signal relies on the total amount of deoxy-
Hb in an imaging voxel, anything that alters this can affect BOLD signal, including changes in cerebral 
blood volume (CBV), CBF and cerebral metabolic rate of oxygen consumption (CMRO2). BOLD is 
therefore an indirect, non-quantitative measure of neural activity. While a quantitative measure of 
CBF would be far more useful clinically, BOLD represents the combination of CBF, CBV and CMRO2 
and can therefore be argued to represent a more complete but complex picture of the vascular and 
metabolic changes occurring in a region rather than focussing solely on CBF. The BOLD response has 
been shown to have correlations with changes in certain neural oscillatory bands, and local field 
potential recordings (described further in section 4-1-2) and appears to be primarily affected by 
changes in the excitation-inhibition balance of different neuronal populations106.
4-1-3-2 Arterial spin labelling (ASL)
Instead of using the innate contrast afforded by haemoglobin, exogenous contrast can also be applied. 
By selectively sensitising or labelling blood coming into the tissue within a region of interest maps of 
perfusion-weighted signal can be obtained. When blood is labelled magnetically this is a technique 
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called arterial spin labelling (ASL). Here 1H of blood is labelled at a lower point away from the imaging 
plane, usually in the neck. Labelling is done through either inverting, or saturating the longitudinal 
magnetisation of 1H in blood water before it flows into an imaging plane. After a period of time (transit 
time) has passed to allow the magnetically labelled blood to perfuse the region of interest, labelled 
blood water exchanges with water already present in the tissues. This alters the tissue magnetisation, 
reducing it and thereby altering MR signal in a perfusion-dependent manner111,112.  
A minimum of three images must be taken to achieve a quantitative measure of CBF; a tag and a 
control image as well as a calibration (M0) image containing a map of longitudinal tissue magnetisation 
(fig. 4-2). The tag image is taken in the presence of labelled blood; the control image is taken when no 
labelling is performed. The M0 image is required to calibrate both images to a normalised, standard 
scale and therefore is essential for perfusion quantification and inter-subject comparisons. The 
difference between these two images is proportional to tissue perfusion, and therefore CBF.
Additional calculations need to be performed to get a measure of cerebral blood flow (CBF) as ml/100g 
of tissue/minute. Figure 4-3 shows the change in signal in an ASL-acquired image over time also known 
as the kinetic curve. It is important to note that there are 3 stages to this figure:
1. No signal change is present before the arrival of labelled blood.
2. After a transit time of t labelled blood water starts to arrive and reaches a peak at  tag width.
3. Signal starts to dissipate as blood is cleared through venous drainage, and longitudinal 
relaxation.
This has a mathematical representation and has been described in113. Throughout these calculations 
there is the assumption that each voxel only contains tissue and that exchange of labelled hydrogen 
occurs immediately with the arrival of labelled blood water. In conventional spin-echo sequences the 
first 90 flip is followed by a 180 refocussing pulse which leads to the formation of the echo at time 
TE. Inversion recovery sequences contain an initial 180 inversion pulse before that first 90 flip. This 
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initial 180 pulse inverts the longitudinal magnetisation of all tissues to the opposite direction of B0, 
following which the affected tissues begin to undergo T1 relaxation. The time between the first 180
pulse and the 90 flip is called the inversion time (TI). Throughout this thesis when CBF is quantified, 
a multiple inversion time (MTI) sequence is used to calculate resting CBF. This is done because there 
are four unknown parameters when fitting the equation stated in113,114 – arterial blood volume, transit 
time (the time taken for labelled blood to reach the imaging plane), arterial input and CBF. Therefore, 
to fit the kinetic curve correctly, sampling must be performed in at least 4 points. To do this multiple
inversion times are used which allows sampling at different points along the kinetic curve (fig. 4-3).
Figure 4-2 Example schematic of the principles of ASL. First by tagging blood entering through the neck either saturating or 
inverting the magnetisation of blood water reduces the net magnetisation in the imaging plane. After a time delay allowing 
blood to flow into the region of interest, and blood water to mix with tissue water, imaging of that slice is performed. For 
results to be meaningful a control image must be taken to get a baseline magnetisation of the tissue. Subtracting the two 
tag/control images results in a perfusion-weighted map of tissue magnetisation. Image taken from 
http://fmri.ucsd.edu/Research/whatisfmri.html
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4-2 MEG
MRI is useful for detecting changes in cerebral blood flow, but whether using BOLD or ASL imaging 
techniques MRI can only be used for indirect inferences of neuronal activity. Changes in blood flow 
co-localise with areas of neuronal activation, but cannot be used by itself to directly measure the level 
of local neuronal activity. If decoupling exists between neuronal activation and the haemodynamic 
response, either through an altered stimulus parameter or in disease states, this will not be evident 
from MRI alone.
All forms of electrical current generate magnetic fields. Post synaptic currents generated by apical 
pyramidal cell dendrites have been proposed to be the principle source of measurable magnetic fields 
outside the scalp. Recording magnetic fields generated from neuronal populations has the advantage 
over measuring electrical activity directly through electroencephalography, as magnetic fields are not 
blurred during transmission through the scalp. This allows for a potentially better source localisation 
Figure 4-3 Kinetic curve for a pulsed arterial spin labelling dataset. 1) No signal change is detected during arterial transit time. 2) 
After transit time (t) labelled blood arrives in the imaging plane where signal increases as labelled hydrogen atoms are 
exchanged with the tissue. 3) As blood clears through venous drainage and through longitudinal relaxation, the signal tapers off 
again. Image taken from 
https://www.researchgate.net/profile/Patricia_Figueiredo11/publication/7835906/figure/fig1/AS:277673537490972@1443213
938526/Figure-1-Definition-of-the-arterial-transit-delay-t-and-the-tag-width-in-a.png
1 2 3
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solution due to the larger number of detectors available, along with added sensitivity to subtle 
changes in event-related potentials/fields (ERP/ERFs).
Under resting conditions neurons can fire spontaneously and without any synchronicity. 
Asynchronous firing means local magnetic fields are either far too small to detect, or easily cancel out 
one another and no net magnetic field can be detected. When a stimulus is applied, large volumes of 
neurons start firing together. Propagation of local spiking activity is achieved through 
neurotransmitter release – in the case of visual stimulation from superficial layers of the cortex, to 
deeper layers – to pyramidal cells where local inhibition (provided by inhibitory interneurons) is 
overcome to allow propagation of excitatory post synaptic potentials (EPSPs). Due to the regular 
morphology of pyramidal cells, EPSP firing creates dipole, rather like a bar magnet. Stellate cells and 
other interneurons with no regular morphology have no net magnetisation during firing due to the 
random orientation of electrical activity (figure 4-4). Pyramidal cells lying parallel with each other, and 
in close proximity cause summation of individual dendritic magnetic fields, magnifying the effect of 
the synchronous firing and appear as a single dipole on the scalp. Indeed, it has been estimated that 
between 10,000-50,000 synchronous synaptic currents from individual dendrites are required to 
generate a sufficient magnetic field to be detectable.
These magnetic fields can be detected using superconducting quantum interferences devices 
(SQUIDs). These are loops of wire with a small gap or junction, which when cooled sufficiently to allow 
Figure 4-4 Examples of the changes in morphology of neurons at different layers. Layer I and IV contain irregular stellate cells, 
meaning no net magnetisation is detected on the scalp. Pyramidal cells in layers II, III, V and VI show a regular shape with 
long axons projecting to more superficial layers. Image taken from 
http://changelog.ca/quote/2013/09/02/many_types_of_neurons
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superconduction to take place the passing of an external magnetic field (perpendicular to the SQUID) 
generates a detectable current. Modern magnetoencephalographs have between 100-300 SQUIDs; 
this helps produce a better estimate the magnetic field’s source compared to EEG as these tend to be 
limited to the number of electrodes that can be reliably placed. MEG signals are on the order of <100 
fT, to make sure the signals detected are not due to environmental noise MEG systems are housed in 
magnetically shielded room (MSR). This in addition to loops of wire larger than the SQUIDs suppresses 
high, and low frequency noise respectively. Pickup coils tend to be either magnetometer, or 
gradiometers. The latter is used in modern MEG systems, which itself is split into two varieties; axial 
and planar. Magnetometers and gradiometers differ in that whilst magnetometers have a single loop 
of wire in their detectors, gradiometers have an additional loop wound in the opposite direction. The 
additional loop confers a higher sensitivity, along with superior noise rejection, compared to 
magnetometers. 
4-1-1 Event related potentials/fields
With the advent of MEG, resulting data has often been compared to EEG literature. In this respect,
there is a slight difference in the nomenclature, when referring to electrical activity measured using 
EEG we tend to refer to the potentials generated in these recordings (i.e. event related potentials –
ERPs). However, in MEG these potentials are not measured; instead the magnetic field activity is 
detected and therefore the presence/strength of the field is referred to (i.e. event related field – ERF). 
The visual system has been thoroughly studied in both EEG and MEG. This is mostly due to the ease 
with which non-invasive but simple stimuli can be applied to generate a reliable, graded response. The 
primary visual cortex (V1) is separated into 6 layers by the types of cells it contains (represented by 
the roman numerals I-VI). Input from the lateral geniculate nucleus arrive into layer IV, containing 
stellate cells, which have connections to pyramidal cells in layers II, III and V. Pyramidal cells tend to 
have two sets of dendrites: one large apical dendrite, branching up into higher levels in the cortex; as 
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well as a large number of basal dendrites, originating below the cell body. As these types of cell only 
have one axon, which can be very long, they are outputs to other parts of the cortex.
Much of the MEG/EEG signal is composed of apical dendrite activity in layers II, III, V and VI. It is these 
connections and dendritic currents that sum and magnify the magnetic field to appear as a single 
dipole. Evoked fields have several components, denoted as either being positive (P) or negative (N), 
followed by the average latency in milliseconds. In the case of visual evoked fields (VEFs) there are 3 
main components: the first, N70, is a negative deflection at 70ms- a positive peak around 100ms; 
P100; and finally another negative peak at 140ms, N140115. Event related potentials/fields are 
generated following the onset of a brief, sharp stimulus, or stimulus change. For example, an audible 
tone, or the presentation/reversal of a visual checkerboard. There is a general separation of ERFs into 
those occurring <100ms from stimulus onset and those after 300ms. Early ERFs are thought to 
represent only sensory processing, whereas those after 300ms instead represent cognitive processing. 
The nature of ERFs mean they are highly transient116–118. However, they are also phase- and time-
locked to the onset of a stimulus, because of this trials can be merged and averaged over time. This is 
particularly useful for establishing magnitude and latency values attached to ERFs. 
4-1-2 Neuronal oscillations
Two types of neuronal oscillations have been noted; evoked and induced oscillatory activity. Evoked 
oscillations are time-locked to the onset of a given stimulus. Induced (or sustained) oscillations 
continue after the onset of the stimulus, and remain for as long as the stimulus is present. These differ 
because the initial spike in evoked activity is thought to represent overcoming the initial inhibition of 
neuronal firing. Induced oscillatory activity has been thought to participate in the modulation of 
attention, memory and multisensory integration. 
Oscillations are referred to as either showing synchronised or desynchronised behaviour with respect 
to stimulus presentation. This is because some responses are not phase locked to the stimulus onset, 
meaning that averaging trials can result in a ‘flattening out’ of the peaks and troughs making averaged 
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responses appear reduced compared to averaging of a time- and phase-locked stimulus. Therefore,
for these types of responses time-frequency estimation within a certain bandwidth is required to 
determine the power of each bandwidth prior to averaging. Increases in power are referred to as 
event-related synchronisation (ERS), with reductions in power called event-related desynchronization 
(ERD). 
Neural oscillations occur at a wide range of frequencies, from 1-200Hz, split into several bands; θ (4–
8Hz), α (8–13 Hz), β (13– 30 Hz),  (>30 Hz)119. Several groups have demonstrated that a positive BOLD 
response is correlated to an increase in event-related gamma synchronisation, as well as 
desynchronisation in the alpha and beta bands105,120–123. Gamma power has an interesting property 
that the others do not appear to share; the level of synchronisation (power) recorded in the gamma 
band correlates to the strength of the stimulus i.e. in a visual task, the amount gamma power increases 
by is dependent on the contrast of the visual task124–127. Indeed, Stevenson et al (2011) found no 
correlations with the level of β-band desynchronization and contrast of a visual checkerboard, nor 
were any correlations found to the strength of the post stimulus β-rebound observed after the 
cessation of the stimulus. During tasks, there also appears to be increased synchronisation recorded 
in the theta band along with the increases in gamma power. But while alpha, beta and gamma bands 
have been shown to be somehow related to the BOLD signal (whether positively or negatively), theta
band activity does not appear show any correlation124.
BOLD has been thought of as representing an indirect measure of enhanced neuronal activity due to 
previous studies performed by Logothetis et. al (2001), among others, where local field potential (LFP) 
recordings were found to be a more reliable predictor of the BOLD response than single or multi-unit 
activity (MUA)105,124,128,129. Cortical LFPs have been thought to reflect the average of synchronised 
pyramidal synaptic signals which are also the basis of the oscillatory recordings in MEG/EEG124.   Other 
groups have built on the work done by Logothetis using simultaneous EEG/fMRI as well as offline 
correlations of neuronal oscillatory activity to explore the neural basis of the BOLD signal. As I 
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mentioned in the previous paragraph some MEG studies have suggested that event related 
desynchronisations (ERDs) in the α and β are closely associated with increases in BOLD signal123,130,131.  
This gives rise to the idea that the idling β-band activity seen during rest represents cortical inhibition 
which needs to be released, stimulation to cortical inputs therefore need to be strong enough to 
overcome this inhibition and lead to increases in output in the  band and therefore exhibits a strong 
on/off property not exhibited by  band synchronisations131–133. Gamma band event related 
synchronisations (ERS) have been found to be highly spatially correlated with the BOLD response 
giving further support to the evidence that  oscillatory activity is at least partially responsible for the 
BOLD response124,131,134,135.
For this thesis, I will be focussing on  band oscillatory activity for one of my neuronal measures to
define NVC. Unlike the other bands, it has shown to be robust in its presentation, the level of 
synchronisation can be manipulated by stimulus strength, and finally, increases in  synchronisation 
are known to be positively correlated with the BOLD response. Gamma oscillations are thought to play 
a crucial role in sensory processing, and are elicited in several sensory paradigms including visual 
stimulation, but also modulated by attention136,137
Gamma oscillations are thought to arise from fast firing interactions between pyramidal cells and 
inhibitory interneurons, known as the pyramidal interneuron gamma (PING) network128,138. These 
neurons both utilise AMPA and GABAA receptors as these are fast acting ionotropic channels capable 
of supporting high frequency spiking activity. Gamma frequency and power of this network is thought 
to be reliant on the excitatory/inhibitory balance between pyramidal cells and interneurons. Initially 
an external excitatory drive (from a stimulus for example) overcomes the inhibition imposed by 
interneurons to allow the propagation of EPSPs, but these are quickly shut off again by the inhibitory 
activity of interneurons. As stimulus intensity increases, so does the excitatory drive, meaning the 
time between EPSP firing, inhibition and firing again is reduced. This cycling of events creates the 
band oscillations, as well as increasing power with increasing stimulus intensity.
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Models of the PING network have shown that pyramidal cells alone are not capable of supporting the 
high frequency oscillations seen in the  band. Adding an external high frequency stimulus directly to 
modelled pyramidal cells results in a brief increase in  band activity, but was not sustained in a way 
that is shown in MEG recordings139,140. The addition of inhibitory interneurons in a ratio of 4:1 
(pyramidal cells:interneurons) caused the formation of sustained  band activity138. Several studies 
have suggested the types of interneurons that can be at work in this model. Optogenetic studies have 
shown interneurons expressing a calcium binding protein (parvalbumin) are the only ones capable of 
supporting the high frequency firing seen in  oscillations140. 
4-1-3 MEG signal analysis
MEG experimental designs tend to be trial based. This means they are either a repeating stimulus or 
task given to participants, trials response signals can then be averaged over time. A notable exception 
however is in resting state scans, where no trial is provided, and one continuous block of data is 
collected instead. Averaging poses a challenge to analysing data however. If data collected is in phase 
i.e. the peaks and troughs of the response waves are locked to the stimulus onset, then when each 
trial is averaged the resulting waveform is similar to individual response waveforms. However, if 
responses are not phase locked to the stimulus onset then averaging of trials will result in a flattening 
out of the waves, and averaging to the baseline recording. These types of responses are instead time-
locked to the stimulus onset, and therefore are called induced responses (as opposed to evoked 
responses, when waveforms are phase-locked to a stimulus). Two types of analysis must be performed 
to measure each type of activity; time-frequency analysis and event-related field (ERF) analysis (or 
event related potential – ERP – in EEG studies) respectively. For time-frequency analysis a measure of 
the power in a certain frequency bandwidth can be obtained prior to averaging. Techniques such as 
the Hilbert transform allow this, and is done by plotting a line over the peaks of responses at a given 
frequency bandwidth, meaning the phase of responses does not affect resulting power estimations 
during averaging.
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Following collection, a number of procedures must be taken to make use of the data generated by the 
SQUID array. Generally, studies need to localise the source of any data collected to make sense of 
where the signals that have been measured are coming from. To do this a 3D reconstruction must be 
made from an essentially 2D array of sensors. It is here that we encounter the forward, and inverse 
problems. The forward problem is: given a known source of signal – its position, strength and 
orientation – in this case neuronal currents, how would this be recorded by the SQUID array given the 
conductivity of the subjects’ scalp. The inverse problem is more difficult to solve, and is required for 
source localisation. Given an external magnetic field, such as the ones recorded from the SQUID array, 
what is the source of the underlying current? As the possible combinations of any current source 
generating a particular magnetic field is infinite, any solution is constrained using apriori 
knowledge141–143. 
The technique used in this thesis to solve the inverse problem is a spatial filtering technique known as 
beamforming, specifically synthetic-aperture magnetometry (SAM) beamforming using a multiple 
spheres model to solve the forward problem142,144. Beamforming is a technique that acts to localise 
sources by comparing two states, active and baseline. In SAM beamforming, an attempt to solve the 
inverse problem is approached by matching dipoles within a grid containing source locations while 
attempting attenuating signals from all other sensors. SAM is different from other beamforming 
methods in that the algorithm attempts to match a dipole orientation that delivers the maximal source 
to noise power ratio by applying a weighting to each sensor individually, altering the contribution this 
makes to any statistical map. Weighting is calculated using a series of covariances from each sensor 
and the covariance matrix between sensors142. Statistical parametric maps are generated to 
differentiate between active and rest/control periods (pseudo-T statistic).
From this a ‘virtual sensor’ can be created over a region of interest (ROI) with a high pseudo-T statistic 
i.e. a region which has been calculated to have a high signal and dipole orientation solution from the 
available data, data is then generated according to this ROI. 
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A 3D anatomical T1 MRI image is used to spatially constrain the SAM beamformer144. This is done by 
estimating the shape and conductance of the scalp at each sensor, by registering sensor locations to 
the anatomical MRI image. This helps to solve the forward problem mentioned earlier and aids in the 
generation of weights for any possible source of magnetic field measured. 
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Chapter 5: Impaired cerebrovascular reactivity in Multiple Sclerosis
and its restoration with immunomodulation measured using breath-
hold functional MRI
Disclaimer: Data shown in this chapter was collected by a collaborating research group, along with supervisor 
Dr. Valentina Tomassini at the Sapienza institute in Rome. The trial design was developed by Valentina. Patients 
were recruited, and the breath hold task were all performed and recorded by the collaborating group. The data 
was analysed by me (Marek Allen) to test my hypothesis that cerebrovascular reactivity is altered in multiple 
sclerosis patients.
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5-1 Abstract
Cerebrovascular reactivity (CVR) is the ability of blood vessels to dilate in response to a vasoactive 
stimulus, resulting in an increase in cerebral blood flow (CBF). Preserved CVR is crucial to maintaining 
proper neurovascular coupling in healthy brains. There have been some studies to suggest that 
vascular function may be compromised in multiple sclerosis (MS), but to my knowledge none has 
investigated the effects of treatment on CVR in these patients. Here I aimed to use a hypercapanic 
challenge (breath holding) to observe how CVR is altered in MS patients compared to healthy 
volunteers, as well as assessing how CVR is altered in MS patients both before and after 
commencement of treatment with interferon-beta 1a (IFN-beta). Patients were scanned twice prior 
and once after commencement of IFN-beta 1a treatment. CVR was calculated as a percentage increase 
in BOLD response /mmHg during a series of breath holds, with end-tidal CO2 being recorded 
throughout. Group analysis was performed for global and regional CVR alterations in patients 
compared to controls. A significant decrease in gray matter (GM) CVR was observed in patients’ first 
scan compared to controls. Further analysis revealed patients with enhancing gadolinium lesions had 
a significantly higher CVR than those not currently exhibiting active inflammation (p<0.05). CVR was 
normalised in both patient groups (those with, and without gadolinium enhancing lesions), following 
commencement of IFN-beta 1a treatment. My findings suggest an impairment of vascular function in 
MS patients due to inflammation, and that this can be restored following treatment of an immuno-
modulator.
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5-2 Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous 
system (CNS). MS is generally considered a T-cell mediated disease, but macrophages, B-cells and 
monocytes all play a crucial role during inflammation. Degradation of the endothelial blood brain 
barrier (BBB) around blood vessels allows entry of immune cells into the brain parenchyma leading to 
demyelination and the classical lesions seen in post mortem tissue samples and ‘black hole’ lesions on 
T1 MRI images9,27,64
Cerebrovascular reactivity (CVR) – a process essential for neurovascular coupling – is the capacity of 
blood vessels to alter flow within the brain in response to a vasoactive stimulus. Previous work by 
other groups has demonstrated disruption to CVR in inflammatory conditions, including multiple 
sclerosis90,145–147.  Basal tonic action of endothelial nitric oxide synthase (eNOS) producing low levels 
of nitric oxide (NO) is crucial to maintaining vascular tone and regulation of vascular resistance in 
response to CO252,148. Disruption of the endothelium, as seen during inflammation, and breakdown of 
the BBB – primarily mediated by IFN- and TNF-α – causes a reduction in endothelial-derived NO, as 
well as an increase in endothelin-1 expression, a potent vasoconstrictor52,149. An inability to regulate 
vascular tone would lead to disruption of basal cerebral perfusion, as well as disruption of CVR. 
Without adequate supply of essential metabolic substrates during neuronal activity, further cerebral 
damage and cerebral degradation could ensue, because of this, maintenance of CVR is vital to reducing 
any damage caused during demyelination36,47,51.  
While the mechanism of CVR attenuation is unknown, there is the increasing evidence of inflammation 
playing a key role48,150. Alteration of CVR by an immunomodulator would provide evidence for 
inflammation being a cause of CVR attenuation, and can be assessed through several techniques such 
as hypercapnia elicited through either CO2 inhalation, breath hold (BH) task or through administration 
of acetazolamide28,146,151. 
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Here I investigated how CVR is affected in MS and if any attenuation can be linked to inflammation. 
This was done using a breath hold task to elicit hypercapnia-induced hyperaemia, through which CVR 
can be assessed in MS patients. Patients were administered with an immunomodulator as part of their 
treatment, and returned for an additional scan and a repetition of the breath hold task. CVR measures 
were compared to healthy controls to examine the effect MS has on CVR and if any attenuation is 
restored to normal levels following immunomodulator administration.
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5-3 Methods
5-3-1 Participants
25 patients with a diagnosis of MS (mean age 36±7 years, range 29-46, mean EDSS 1.5 range 0-3, 5 
males 20 females, disease duration 22±31 months, range 3-138 months) according to the revised 
diagnostic criteria (Polman C et al, 2005) and eligible to start IFN beta treatment, and 19 healthy 
volunteers (mean age 34±8 years, range 28-51, 6 males, 13 females) were recruited at Sapienza 
University of Rome (table 5-1). Steroid administration and relapse within 3 months were exclusion 
criteria. Patients were assessed using behavioural and MRI measures twice before (at session 1, week 
-6±1, and at session 2, baseline) and once after (at session 3, week +12±1) the beginning of IFN beta 
1a treatment (44 mcg (Rebif®, Merck Serono) subcutaneously administered 3 times weekly). Age- and 
sex-matched healthy volunteers were assessed behaviourally and with MRI at baseline only. 
Participants were not asked to alter their lifestyle habits prior to scanning. Participants' consent was 
obtained according to the Declaration of Helsinki. All participants gave written informed consent 
according to the protocol approved by the local Ethics Committee.
5-3-2 MRI acquisitions
Functional and structural MR measurements were acquired using a Siemens Magnetom Verio 
3T/70cm bore magnet (Siemens healthcare, Siemens, Germany). Whole brain functional images with 
BOLD (T2*) contrast during the breath-hold task were obtained using gradient echo echo-planar 
imaging during the breath-hold (BH) task (TR/TE = 3000/30ms, 64x64 matrix, 50 transverse interleaved 
3mm slices, voxel size 3x3x3mm, FOV 192mm, flip angle 89°, 92 volumes). Field maps were generated 
(TR = 488ms, TE1 = 4.92ms, TE2 = 7.38ms, 3mm slice thickness, 36x3mm interleaved transverse slices, 
FOV 250mm, 64x64 matrix, flip angle 60°) for each individual to aid registration. 
Patients underwent conventional MRI acquisitions that included T1-weighted images (T1-WIs) (TR = 
550 ms; TE = 9.8 ms; FOV =240 mm; matrix=320×320; 25 axial slices, 4 mm thickness; 30% gap), 
acquired 5 minutes after the administration of Gd to detect the presence and quantify the number of 
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Gd-enhancing lesions; proton density and T2-WIs (TR= 3320 ms; TE1= 10 ms; TE2= 103 ms; FOV= 220 
mm; matrix= 384 × 384; 25 axial slices; 4 mm thickness; 30% gap) to quantify T2-hyperintense lesions. 
High-resolution anatomical (1mm voxel size) T1-weighted scans (TR/TE = 1900/2.93ms, 256x256 
matrix, FOV 260mm, 176 1mm sagittal slices, flip angle 9°) and whole brain diffusion images (72 
interleaved slices at 2mm thick, FOV 192mm, TR/TE 12200/94ms, 30 directions, 96x96 matrix, b-value 
1 = 9s/mm2, b-value 2 = 1000s/mm2) were also acquired to quantify grey and white matter integrity.
5-3-3 Acquisition and analysis of CO2 traces
During the fMRI, participants were asked to perform a breath-hold task. To ensure subjects performed 
the task adequately, participants were trained to perform it prior to scanning. The breath-hold task 
consisted of 5 repeats of 16s of end-expiration breath-hold alternated with 34s paced breathing as a 
recovery152. In the scanner, task instructions and pacing were visually presented using a MRI-
compatible stimulus-presentation system with the use of goggles (VisuaStim Digital system from 
Resonance Technology Inc, Northridge, California). End tidal CO2 (EtCO2) was measured via nasal 
cannula (Veris monitor, Medrad). 
The CO2 traces (figure 5-1 shows average CO2 traces for patients and controls) were used to model 
blood oxygenation level dependent (BOLD) functional MRI time courses to give the CVR maps. 
Individual CO2 peak delays were calculated to determine how far each CO2 trace had to be shifted 
prior to being used as a regressor in a later GLM analysis. This was done by extracting individual GM 
time series data using fslmeants (part of the FSL toolbox) from BOLD data and performing a cross 
correlation with corresponding end tidal CO2 traces from that subject’s scan session. Each delay was 
used to positively shift CO2 traces before being added to a GLM model. In addition to this end tidal 
CO2 traces were averaged across controls and patients to create an average time delay for patients 
and controls. If cross correlation could not find an optimal time delay or an individual subjects’ delay
was greater than 2 standard deviations away from the group mean, CO2 traces were shifted using a 
delay within 2 standard deviations and with the highest correlation with the group average.
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5-3-4 MRI analysis
fMRI data were analysed with FSL-FEAT153. Pre-processing of data was performed prior to model fitting 
of the participants’ time series. This included: a high pass cut-off of 100s was used, motion correction 
using MCFLIRT 154, non-brain removal using BET 155 and B0 unwarping using PRELUDE and FUGUE (EPI 
echo spacing 0.53ms, EPI TE 30ms, unwarp in –y and signal loss intensity threshold of 10%). Functional 
images were linearly registered using FLIRT154, first to subject’s T1 structural scan limited to 6 degrees 
of freedom, then to the Montreal Neurological Institute (MNI) 152 space with 12 degrees of freedom. 
The time series was analysed using a general linear model (GLM) approach with local autocorrelation 
correction. To obtain a BOLD response map for each participant, shifted end tidal CO2 traces were 
demeaned and entered as regressor in the GLM. Gamma convolution was applied to model 
haemodynamic response function (HRF) along with an additional temporal derivative (to represent a 
regressor of no interest) and temporal filtering. Group level analysis comparing healthy volunteers to 
patients at each time point incorporating GM density (by creating a 4D image containing each subjects’ 
GM segmented masks) and the presence of gadolinium enhancing lesions (a marker of acute 
inflammation) as covariates was performed (appendix A). This allowed for the assessment of the effect 
GM density and the presence of active inflammation might have on CVR. All analyses used a corrected 
threshold of p <0.05, Z > 2.3. GM density images were generated as part of FSL VBM structural analysis 
outlined below, these were included in the group analysis to account for GM density differences 
between patients and controls. Percent BOLD signal change was extracted using FEATQuery, part of 
the FSL toolbox156.
Region of interest analysis (ROI) was performed to determine GM CVR values. Masks were created by 
overlaying MNI masks on to BOLD response maps generated as part of first level analysis. Masks were 
generated by transforming MNI masks to functional space to avoid interpolation errors. Registration 
was achieved using FSL-FLIRT, functional images were first registered to high resolution space, then 
to MNI space, resulting transformation matrices were inverted and applied to the registration154. Only 
non-empty masks were reported. Subject data were then divided into groups based on those with and 
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those without Gd enhancing lesions (determined using T2-WIs) to assess the extent inflammation 
altered CVR. All brain functional activations were labelled using the Harvard-Oxford Structural, and 
subcortical atlases (http://www.fmrib.ox.ac.uk/fsl/data/atlas-descriptions.html). Here I generated 
masks corresponding to the anterior and posterior cingulate, insula, thalamus, frontal, occipital, 
parietal and temporal lobes.
5-3-4-1 Structural analysis
We tested the relationship between grey and white matter integrity and changes in CVR in the 
patients.  High resolution T1-WIs were analysed with FSL-VBM 157 with an optimised protocol158. T1 
images were brain extracted, segmented using the FAST segmentation tool and registered to MNI152 
standard space using non-linear registration. A grey matter (GM) template was created using all 19 
controls and 19 randomly selected patients’ session 1 or 2 scans. GM images were then registered to
this template and corrected for local distortions due to registration. These were smoothed with an 
isotropic Gaussian kernel (=3mm). VBM was then performed on all subject datasets, comparing GM 
density of each patient’s session scans to controls. 
Voxelwise statistical analysis of the T2 images to extract FA values was carried out using TBSS (Tract-
Based Spatial Statistics159), part of FSL156 and was used to assess WM tract integrity. TBSS projects all 
subjects' FA data onto a mean FA tract skeleton, before applying voxelwise cross-subject statistics. 
Voxelwise GLM was applied, testing for differences in FA between healthy volunteers and patients at 
each time point, using permutation-based non-parametric testing set at a threshold of p<0.05 
corrected for family-wise error. 
Brain volume estimation at baseline (session 1) was performed using SienaX160 part of FSL153. Following 
brain and skull extraction the brain was affine registered to MNI-152 space using the skull to 
determine scaling. Tissue was segmented using FAST and partial volume estimation was performed to 
calculate total volume brain tissue and allowing separate estimates for GM, WM and CSF. Gd lesion 
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volume and presence was assessed using T2 images obtained following gadolinium administration, 
images were analysed using JIM software (Xinapse Systems Ltd, Essex, UK). 
5-3-5 Statistics
A two-way ANOVA, modelling changes in GM CVR across time-points and presence of active 
inflammatory lesions was carried out to investigate CVR differences at a group level, the factors 
considered in these models were time and the presence of Gd-enhancing lesions. From this, a 
repeated measures one-way ANOVA was performed on each ROI, investigating the effect of time-
point on GM CVR. Individual percent BOLD signal change values were used in each ANOVA. Pearson 
correlation between WM FA values and CVR values extracted from BH data was performed to 
investigate any correlations between WM FA, lesion volume, lesion presence, and time-point was also 
done. Finally, student t-tests were performed comparing pairs of patient CVR at each time-point and 
ROI for differences between those with active inflammation and those without. 
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5-4 Results
5-4-1 Behavioural task
To determine that subjects were performing the breath hold task adequately T-tests were performed 
on extracted time delays to compare means of each group (fig. 5-1). Both patients and controls 
performed all 5 BH challenges with no significant difference in delay times either between groups or 
before and after treatment. 4 EtCO2 files (3 patients, 1 controls) were corrupted and replaced with a 
substitute from another scan by those subjects (where available). Of the 25 patients, only 19 
completed all 3 scan sessions with the largest drop out seen between scan 2 and 3. 2 of these patients 
had one EtCO2 file replaced with another from a different scan. 14 patients were found to have 
gadolinium (Gd)-enhancing lesions in their first scan with 11 patients exhibiting the lesions during their 
second scan. During treatment and the third scan, this number was reduced to only 3 patients’ scans 
containing Gd-enhancing lesions (figure 5-2). There was no alteration to the EDSS scores assigned prior 
to any of the 3 scan sessions. In patients, the mean time intervals were 45±2 days, 85±2 days and 73±3 
days for scan 1-scan 2, scan 2-scan 3 and commencement of treatment-scan 3 respectively. The mean 
duration between scan 2 and onset of IFN-β1a treatment was 11±2 days. 
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5-4-1 Grey matter, white matter and brain volume
A grey matter (GM) voxel-based morphometry (VBM) comparison revealed a decrease in GM density 
bilaterally in the thalamus of patients compared to controls (FWE corrected, TFCE thresholded p<0.05) 
(figure. 5-3). FSL TBSS demonstrated widespread decreases in white matter FA in patients compared 
to controls (figure. 5-4). Patients demonstrated a significantly lower WM FA on all three scan sessions 
(3.6±1% p=0.01, 4.3±2% p<0.05, 3.5±1% p=0.01 for scan session 1, 2 and 3 respectively) compared to 
controls.
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Figure 5-1 Averaged CO2 traces of healthy volunteers (blue) and MS patients (red) from their first scan. Shaded areas represent 
each group’s respective standard deviations. Each peak in end tidal CO2 represents each rise in CO2 concentration following a 
breath hold. Healthy volunteers had a slightly higher end tidal CO2 than patients, but this difference was not statistically 
significant.
62
Figure 5-2 Number of patients entering final analysis showing gadolinium-enhancing lesions. 14 and 12 patients 
at the first and second time points showing gadolinium enhancing lesions respectively. Following treatment with 
interferon-β only 3 patients exhibited enhancing lesions.
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5-4-2 Vascular reactivity
Patients exhibited a significantly lower whole brain grey matter BOLD response, my index of vascular 
reactivity, during breath hold compared to controls during their first scan session (19.9±9.4% lower 
CVR, p<0.05). A strong trend for a 12.5% (±6.3%) lower GM CVR was detected during the second scan 
Controls (19) Patients (25) p
Agemean (Range) 34 (28-51) 36 (29-46) 0.4
Males/females 5/14 5/20 0.3
EDSS score, median (Range) - 1.5 (0-3) -
Disease duration in months, 
mean (Range)
- 22±6 -
Number of gadolinium 
enhancing scans, total (scan 1,2 
and 3)
- 14 11 3 0.4
Lesion volume (mm3), mean ± SE
-
1708.6
±418.6
1819.7
±428.7
1841.7
±451.8
0.4
25 foot walk, mean ± SE 
(seconds)
5.3 5.8 5.8 5.5
9-hole peg test, mean ± SE 
(seconds)
15.78 17.8 16.8 15.8
PASAT 3 seconds, mean ± SE 
(seconds)
49.1±2.2 43.1±1.9 48.5±1.9 50.3±1.5
PASAT 2 second, mean ± SE 
(seconds)
40.7±2.4 33.8±2.2 36.7±1.7 40.3±2.1
Table 5-1 Demographic, clinical and MRI characteristics of the participants. The 9-HPT and T25-FW are expressed as the mean of two 
trials. T-tests were performed for between group comparisons, one-way RM ANOVA was used for between timepoint comparison.
Abbreviations: EDSS=Expanded Disability Status Scale; 9-HPT= 9-hole peg test; PASAT= Paced Auditory Serial Addition Test; 
SE=standard error; T25-FW= timed 25-foot walk.
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session compared to controls (p=0.07). This was partially normalised following commencement of IFN 
beta treatment with only an 8.7% lower (±5.5%) GM CVR, compared to controls, exhibited in the third 
scan session (p=0.3). One-way within subjects (repeated measures) ANOVA confirmed no significant 
Figure 5-3 Visualisation of TBSS results comparing WM FA in patients to controls. A significant global decrease in WM FA is 
observed in patients (TFCE thresholded FWE corrected P<0.05).
Figure 5-4 Visualistion of VBM results comparing GM densities of patients to healthy controls. A significant decrease in grey 
matter density was observed bilaterally in the thalamic region in patients (TFCE thresholded, FWE corrected p<0.05).
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difference in whole-brain GM CVR between patient groups at any time point was noted (p=0.5) (figure 
5-5).
Patients with and without active inflammation were then separated and compared to controls, this 
revealed large differences in the CVR within time points. Overall patients exhibited a 20% lower GM 
CVR (p<0.05) during their first scan session, however those patients with active inflammatory lesions 
only demonstrated a 9.5%(±10.4% N.S.) lower GM CVR compared with controls. Patients without 
active inflammation had a significantly reduced GM CVR compared to controls of 29.4%(±15.2% 
p=0.01). A similar trend was observed in the second time point; those with active inflammation 
displayed a GM CVR similar to that of controls (100%±3.5 N.S.). Those without active inflammation 
exhibited a reduced GM CVR of 21%(±9.5% p<0.05), compared to controls. Group level voxelwise 
analysis can be seen in figure 5-6 where mean CVR maps of patients’ first and second scans are shown, 
along with regions of enhanced CVR due to the presence of gadolinium enhancing lesions. Following 
commencement of IFN beta treatment there were no significant differences in GM CVR in either 
cohort of patients (those with or without active inflammation) compared to controls (15.4%±7.7 
reduction and 11.8%±8 reduction for active and inactive patients respectively) (figure 5-7).
Table 5-2 summarises ROI analysis performed following whole brain GM CVR assessment. Group level 
analysis demonstrated a significantly lower CVR in the frontal and occipital lobes, insula cortex, 
precentral gyrus as well as the anterior and posterior cingulate cortices in patients compared to 
healthy volunteers.  Extracting CVR values from each subjects’ ROI to assess CVR in those patients with 
and without active inflammation revealed that as with global GM CVR, patients with active 
inflammation exhibited a higher CVR than those without active inflammation. The frontal lobe, insula, 
precentral gyrus and thalamus all demonstrated a significantly lower CVR in patients without active 
inflammation than those with, across timepoints 1 and 2 (frontal lobe; 45% lower p=0.01, 39% lower 
p<0.01. Insula; 52% lower p=0.01, 37% lower p<0.05. Precentral gyrus; 47% lower p=0.01, 33% lower 
p=0.01. Thalamus; 37% lower p=0.05, 40% lower p<0.01 respectively). Comparing patient subgroups 
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to control values revealed a significant alteration in CVR in patients’ scans prior to treatment in frontal 
(p<0.01) and occipital lobes (p<0.05), insula cortex (p<0.01), precentral gyrus (p<0.01) as well as the 
posterior cingulate (p<0.01). 
Treatment with IFN beta reversed these differences (all values are percentage CVR differences in 
patients without active inflammation relative to patients with active inflammation: frontal lobe; 6% 
higher p=0.4, insula; 7% higher p=0.4, precentral gyrus; 11% higher p=0.3, thalamus; 2% higher p=0.4). 
There was a trend for IFN beta to assist in the restoration of CVR in patient subgroups in the anterior 
Figure 5-5 Percentage grey matter BOLD increases during breath hold comparing healthy controls to patients at each time 
point. There is a significant decrease in breath hold related BOLD increases in patients during their first scan compared to 
controls (p<0.05). Following treatment with interferon-beta with no significant differences between patients scan 3 and 
controls.
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and posterior cingulate cortices and occipital lobe, but did not reach overall significance (p=0.1, 0.2 
and 0.1 respectively compared to the frontal lobe p<0.05, insula p<0.05, precentral gyrus p=0.05 and 
thalamus p=0.05). Comparing these values to controls however, revealed that IFN beta treatment 
returned CVR values to a comparable level with controls, no significant differences in CVR at any ROI, 
at any time point or patient subgroup detected compared to controls (figure 5-8).
68
Figure 5-6 Voxelwise group analysis results of patients’ scan 1 and scan 2 average z-statistic maps (top row and 
every other row thereafter) compared to regions of significantly increased CVR due to the presence of gadolinium 
enhancing lesions in those patients (second row down and every other row thereafter). Images have a threshold of 
z>2.3 applied, no cluster thresholding.
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Figure 5-7 Percentage BOLD differences /mmHg during breath hold comparing healthy controls to patients at each time 
point separating patients with active and inactive inflammatory lesions. One way ANOVA on ranks revealed a significant 
difference between CVR of patients with active inflammation and those without in the first two scans (p<0.05), with no 
significant difference detected on the third scan following IFN-β treatment. There was no significant difference in the CVR of 
patients with active inflammatory lesions and healthy controls (p=0.5). However, there was a significant decrease in CVR in 
patients without active inflammatory lesions in scan 1 (p=0.01) and in scan 2 (p<0.05) compared to controls. This was 
normalised following commencement of interferon-beta treatment (p=0.3). * = p<0.05, ** = p<0.01
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Figure 5-8 ROI analysis showing regions of significantly altered CVR in patients with and without gadolinium enhancing lesions compared both within group and compared to controls. In 
patients the poster cingulate, frontal lobe, insula, precentral gyrus, thalamus and occipital lobe all demonstrated a significantly lower CVR compared to controls. This was then normalised 
following commencement of IFN-β treatment. Comparing patient sub groups revealed a lower CVR in the frontal lobe, insula, precentral gyrus, thalamus and occipital lobe in patients without 
active inflammation compared to those with acute inflammation in scans 1 and 2. This was then normalised in both sub groups, to a level comparable with healthy controls following IFN-β
treatment. There was a trend for the anterior cingulate to have a higher CVR in patients with active inflammation than those without in the first scan, but did not reach significance (p=0.06). 
CVR and p values are summarised in table 2. * = p<0.05, ** = p<0.01. Not corrected for multiple comparisons.
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Group average percent BOLD signal change/mmHg
Controls Patients scan 1
Active vs 
inactive 
inflammation 
p value
Patients 
scan 2
Active vs 
inactive 
inflammation 
p value
Patients 
scan 3
Active vs 
inactive 
inflammation 
p value
Across 
time 
point p 
value
Scan 1 and 
2 CVR p 
values 
compared to 
controls
ROI 
analysis
Anterior 
Cingulate
With active inflammation 
9.59
10.84
0.06
11.34
0.03
9.38
0.3 0.53 0.18
Without active inflammation 7.75 8.88 10.47
Posterior 
Cingulate
With active inflammation 
9.79
10.43
0.03
10.08
0.2
9.00
0.3 0.45 0.003
Without active inflammation 6.82 9.02 10.06
Frontal 
Lobe
With active inflammation 
7.12
8.32
0.01
9.10
0.003
7.15
0.4 0.50 0.008
Without active inflammation 5.09 6.29 7.59
Insula
With active inflammation 
4.77
5.56
0.01
5.43
0.02
4.35
0.4 0.67 0.004
Without active inflammation 3.04 3.66 4.72
Precentral 
Gyrus
With active inflammation 
6.42
7.53
0.01
7.98
0.01
6.14
0.3 0.49 0.003
Without active inflammation 4.48 5.84 6.86
Thalamus
With active inflammation 
7.30
8.58
0.05
9.73
0.002
7.40
0.4 0.66 0.006
Without active inflammation 5.87 6.75 7.58
Occipital 
Lobe With active inflammation 6.24 8.08 0.01 8.45 0.02 5.39 0.3 0.87 0.03
Table 5-2 Summary of ROI analysis comparing CVR in patients with and without acute inflammation defined as 22. Total changes in CVR between timepoints was determined by one way 
repeated measures ANOVA comparing mean CVR of each patient sub-group at each time point. The frontal lobe, insula, precentral gyrus and thalamus all displayed significant differences in 
CVR over time, with t-tests showing a significant reduction of CVR following treatment with IFN beta, with a trend in the occipital lobe Abbreviations: ROI = Region of interest; BOLD = Blood 
Oxygenation Dependent. No correction for multiple comparisons was performed.
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5-5 Discussion
The reduction in the number of patients exhibiting gadolinium enhancing lesions following treatment of IFN 
beta can be used as a marker to confirm the anti-inflammatory effects of IFN beta5,13. Inflammation has been 
shown to cause breakdown in the integrity of the blood brain barrier (BBB), once inflammatory mediators 
are removed integrity is restored26. This information can then be used to infer how the effects of CVR can be 
attributed to the anti-inflammatory effects of IFN-β.
We have demonstrated a decrease in cerebrovascular reactivity as indexed by BOLD signal changes in RRMS 
patients in response to hypercapnia, particularly in patients not currently exhibiting active inflammation. 
While whole brain GM CVR values were not able to demonstrate a significant effect of treatment with IFN 
beta compared to healthy controls, ROI analysis confirmed a normalisation of CVR following the 
commencement of IFN beta in patients not exhibiting active inflammation. This effect was particularly 
prominent in the frontal lobe, insula, precentral gyrus and thalamus, with a trend for treatment effects 
observed in the anterior and posterior cingulate cortices and occipital lobe but these did not reach 
significance. This was consistent with the finding that, following commencement of treatment, the number 
of patients exhibiting gadolinium-enhancing lesions decreased significantly. An effect well documented due 
to IFN-beta’s immunomodulatory effects56,59,161. However, no corrections for multiple comparisons was 
made, meaning some of significance may disappear once correction has been made.
VBM results only showed a decrease in GM density bilaterally in the thalamus, typical of patients early on in 
their disease stage40,162. As EDSS score increases, there is increasing involvement in the pre- and post-central 
regions along with anterior and posterior cingulate gyri and insula. As large differences in CVR was detected
in these regions in patients, particularly in those showing no active inflammation. It is possible that the 
changes in CVR could be a precursor to GM damage later in the disease course. Restoration of CVR could act 
to protect these regions – at least partially – from additional stress and damage. However, the effects through 
which IFN beta could normalise CVR are still not confirmed. 
Nitric oxide (NO) is a potent vasodilator released during physiological and pathological states as a method of 
controlling vascular resistance and blood flow. Cytokines released during inflammation (particularly TNF-α, 
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IFN- and IL-6) are known to increase activation of inducible nitric oxide synthase activity (iNOS). MS patients 
have been found to have increased levels of both iNOS activity and [NO], occurring both during relapses of 
acute inflammation and remission53,54,58,59,163,164. Elevated production of NO would result in basal 
hyperperfusion thereby reducing a vessel’s ability to dilate further in response to a vasoactive stimulus and 
reducing CVR. However, this is not corroborated by the evidence presented here; acute inflammation causes 
CVR to rise, something that would be less likely in basally hyperperfused subjects.
Several groups have demonstrated patients are instead cerebrally hypoperfused at baseline47–49,165. Many 
studies describing elevated levels of [NO] do not differentiate between RRMS patients in relapse or 
remission, or those who are primary or secondary progressive. It is therefore possible that NO levels could 
be affected depending on the disease course at the time of recording. In addition, there is growing evidence 
to suggest that endothelial dysfunction could be responsible for reductions in CO2 chemoreception and 
associated vascular reactivity. Dysfunction in the endothelium has been shown to cause a reduction in CVR 
in both human and animal models which was then be reversed following administration of an exogenous NO 
donor. This activity was found to be mediated primarily through eNOS disruption 93,148,166. 
Endothelin-1 (ET1), another vasoactive compound is one of the most potent endogenous vasoconstrictors 
known, working through two receptors – ETa and ETb. ETa receptors (ETaR) are found on vascular smooth 
muscle and brain endothelial cells which act to cause vasoconstriction51. While not typically produced under 
normal conditions, ET1 is released through several mechanisms including activation by TNF-α, IFN- and 
reactive oxygen species (ROS), all three of which are increased basally in MS52,167. Once released it causes 
vasoconstriction of surrounding arterioles as well as suppressing eNOS activity47,168. Suppression of eNOS aids 
in ET1’s vasoconstrictive activity by preventing NO release and normal vasodilation.
This could explain the greater reduction in CVR in patients who were not currently exhibiting active 
inflammatory lesions, as there is evidence to suggest ET1 is upregulated in the brains of MS patients basally47. 
During inflammation, however, there is a sharp increase in the expression of IFN-, TNF-α, IL-6 and IL-4 along 
with many other pro-inflammatory cytokines. While some of these (notably IFN- and TNF-α) increase the 
expression of ET1, many more activate iNOS found in vascular endothelial cells, with TNF-α also being 
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implicated in nNOS activation11,30,54,163,169. While ET1 decreases eNOS activity it has no effect on iNOS168. This 
allows NO production to proceed and could act to overpower the vasoconstrictory effects of circulating ET1 
and producing the enhanced CVR I have demonstrated here (figure.5-8).
IFN beta acts to reduce the expression of pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-gamma 
and is demonstrated here by the reduction in patients expressing Gd-positive lesions (figure. 5-3). All of these 
pathways would cause a reduction in both iNOS activity as well as ET1 expression thereby allowing eNOS to 
function normally59. This would cause the normalisation of the CVR responses seen patients during their 3rd
scan session.
It is possible that chronic hypoperfusion caused by ET1 expression could be the cause of neuronal energy 
deficiency occurring following demyelination. A positive feedback loop created as mitochondria experience 
further distress eventually leading to the release of ROS causing further ET1 release worsening the problem. 
During acute inflammatory attacks iNOS activity is increased allowing for a temporary increase in CVR. By 
treating with IFN-beta there can be a break in this positive feedback loop. A normalisation of both [NO] and 
circulating [ET1] could allow neurons to partially remyelinate, and help restore the energy balance, thereby 
slowing of the disease course.
There are however, several drawbacks to using BOLD contrast as a method for determining CVR. The BOLD 
response relies on several factors including cerebral blood flow (CBF), cerebral blood volume (CBV) and 
cerebral metabolic rate of oxygen consumption (CMRO2). While an increase in CBF can be measured in 
response to a vasoactive stimulus as I have used here, an alteration in any of the physiological factors 
mentioned above can cause results to vary. Therefore, this is a non-quantitative measure of CVR. Instead it 
would be preferable to use other techniques for measuring perfusion such as arterial-spin labelling.
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5-6 Conclusions
Here I have demonstrated a decrease in CVR in MS patients who are not currently exhibiting acute 
inflammation, which is normalised following treatment with IFN-β. Both effects are ameliorated 
following commencement of IFN beta treatment. It is still unclear as to the mechanisms through which 
the reduction in CVR could be taking place in this subset of patients or how IFN beta could be exerting 
its effects. Further work to examine the molecular methods behind this reduction of CVR would 
require investigation into cytokines present in both subsets of patients, with and without active + 
inactive inflammation. 
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Chapter 6: Developing a measure of neurovascular coupling using a
combined fMRI/MEG approach.
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6-1 Abstract
The present study aims to develop an empirical measure of neurovascular coupling using two 
alternate stimuli: a reversing square wave checkerboard at 2Hz; and a moving square wave grating. 
Both stimuli were shown at 7 contrast levels (0%, 25%, 40%, 55%, 70%, 85% and 100%). The 
checkerboard was used to detect changes in visual evoked field amplitude. The grating allowed for 
gamma band oscillations to be measured. Blood flow was studied using a simultaneous BOLD/ASL 
fMRI sequence. 10 healthy volunteers were recruited to undergo two scan sessions: The first for MEG 
the second for fMRI recordings. The amplitude of the P100m component of transient VEFs (T-VEFs) 
was analysed in two ways – first by taking the amplitude from 0, the other by measured peak 
activation from the bottom of N70m troughs – and regressed against mean blood flow changes. 
Regression coefficients of 0.83 (±1.96, p = 0.6) for P100m from baseline against CBF changes, 0.27 
(±0.05, p < 0.001) against BOLD, 1.42 (±1.64, p = 0.3) for P100m from N70m against CBF and 0.21 
(±0.05, p <0.001) against BOLD were found. Blood flow was then regressed against percentage 
changes in gamma power in the grating stimulus. A significant slope of -0.22 (±0.1, p < 0.001) and 0.08 
(±0.005, p < 0.001) was found in percentage CBF change and percent BOLD signal change respectively. 
However, due to the large inter-subject variability, the power of this study is insufficient to empirically 
determine NVC. Nevertheless, it is a promising first step in establishing a viable protocol.
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6-2 Introduction
The functional and structural integrity of the brain relies on a close balance between energy demands 
and substrate delivery from blood flow. The interaction between neurones, astrocytes and blood 
vessels endothelium to maintain sufficient cerebral blood flow is termed neurovascular coupling 
(NVC). NVC relies on cerebrovascular reactivity (CVR), which is the ability of vessels to dilate in 
response to a vasoactive stimulus. This has been shown to be impaired in several disease conditions 
from stroke and Alzheimer’s to multiple sclerosis34,147,170. 
Evoked potentials are used to study electrophysiological characteristics of task-related events in the 
brain and provide an empirical measure of a large population of neural activity. The most commonly 
assessed is the visual evoked potential as it is both non-invasive and has been shown to have several 
characteristics (most notably amplitude and latency) which have been shown to alter in relation to 
intensity of the stimulus171. 
Visual evoked potentials (VEPs when measured using EEG, but when collected using MEG are instead 
referred to as visual evoked fields (VEFs)) are used clinically, particularly to assess function in CNS 
disorders such as multiple sclerosis and neuromyelitis optica171–174. VEFs are comprised of 3 main 
components: the first a negative deflection (N70), occurring between 65-80ms following stimulus 
onset; followed by a positive P100 wave at 95-120ms; and finally, a negative N140 at between 130-
150ms after onset completes the VEP (fig. 6-1) 116,175.
The latency of the VEF is crucial to determining pathological states that may be occurring within the 
CNS. In degenerative diseases, such as multiple sclerosis (MS) the waves are differentially affected. 
P100 latency and amplitude is consistently affected in disease states reflecting demyelination and 
neuronal cell loss respectively and is therefore considered a hallmark of visual impairment. The N70 
peak can also be altered and but can fail to appear at all, particularly at low stimulus intensities. It 
should be noted that the N70 is considered to be inconsistent in its presentation between 
subjects174,176,177. Thus, the P100 has been the main focus of evoked potential studies in both disease 
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states and healthy volunteers. The neural generators of VEFs are not clearly defined, generally, early 
phases i.e. N70 waves are thought to be generated in the primary visual cortex, with P100 waves being 
split between V1 and extrastriatal regions. N140 waves however, appear to be generated deeper in 
the parietal lobes116,178
In order to study the relationship between cerebral activity and the alterations in blood flow, there 
have been studies performed to look at glucose utilisation using positron emission tomography 
(PET)171, blood flow changes using functional MRI (fMRI) to assess blood oxygenation level dependant 
(BOLD) and cerebral blood flow (CBF) measures as well as electroencephalographic (EEG) and more 
recently magnetoencephalographic (MEG) techniques for a more direct means of assessing neural 
activity119,179,180. 
Each of these techniques has its own advantages and shortcomings however, while PET allows for a 
direct measure of glucose and oxygen consumption. It is both expensive and involves exposure to 
ionising radiation which, due to ethical considerations can hinder any new study. Both EEG and MEG 
have very high temporal resolutions (on the order of milliseconds), but spatial resolution is poor due 
to this information being inferred via modelling of extra-cranial fields. In this respect, at least MEG 
confers a significant advantage over EEG, as magnetic fields are not hindered and distorted by the 
Figure 6-1 Representative trace of the three main components of the visual evoked potential. The first negative wave 
(N70) occurs between 65-80ms after stimulus onset. Followed by a positive deflection (P100) occurring between 95-
110ms after onset. Finally, a negative deflection between 130-150ms (N140) finishes off the evoked potential.
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scalp unlike electric currents. MEG also has the potential for more accurate source localisation, as 
modern MEG systems offer higher sensor densities compared to EEG systems, also increasing signal 
to noise ratios (SNR)119,175. Finally, fMRI has excellent spatial resolution (on the order of millimetres) 
but is limited by the haemodynamic response following neuronal activation meaning temporal 
resolution is limited to between 5 -10 seconds. 
FMRI offers several markers of blood flow, the most common of which being Blood Oxygenation Level 
Dependent (BOLD) contrast which relies on the balance between oxy- and deoxy-haemoglobin as a 
contrast agent105. It therefore has a complicated relationship with haemodynamic and neurovascular 
responses and can be confounded by alterations in blood volume, neurovascular coupling and basal 
blood flows, which can modify task-related contrast. It is therefore difficult to use this as a quantitative 
measure of CBF 105,119. Arterial Spin Labelling (ASL) involves labelling a bolus of blood coming up 
through the neck and assessing the magnetisation within a region of interest. While SNR is low it does 
enable a more accurate, quantitative approach to assessing cerebral perfusion181,182.  By combining 
MEG and fMRI, it is possible to gain measures that are both high in spatial and temporal resolutions 
as well as quantifying blood flow and direct cerebral activities.  
Previous work investigating the similarities between visual evoked potentials (VEPs) as measured by 
EEG and visual evoked fields (VEFs) measured via MEG has shown the two to be very comparable in 
terms of both observed waveforms and the latency of each peak175,183,184. This allows for a comparison 
of results seen in this study, using MEG, with previous work performed with EEG. There is, however, 
a difference in nomenclature as literature referring to VEFs append –m onto each wave to denote its 
magnetic field origins.
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Functional hyperaemia reflects vasodilation of arterioles in regions of neuronal activation and can be 
measured using BOLD or ASL. While it was originally assumed that coupling of neuronal activity and 
blood flow were due to local energy demands, work suggests that there is a direct signalling 
mechanism between neurons and smooth muscle within arterioles via astrocytes86,89,170. It is 
hypothesised that following synaptic firing secondary chemical messengers are released which causes 
a vascular response (fig. 6-2)89,119. Previous work using combined fMRI and EEG to model coupling 
between neural and haemodynamic responses, has demonstrated that a multi-modal approach to 
quantify neural and haemodynamic responses to a stimulus can be used gain a measure of 
neurovascular coupling180. 
In this present study, I aim to combine fMRI and MEG-based methods, to investigate visual evoked 
fields generated from a visual stimulus of increasing contrast in MEG, and regress this against blood 
flow alterations using a dual echo MRI sequence allowing simultaneous acquisition of ASL and BOLD 
weighted images. I hypothesise that as contrast increases so does the amplitude of VEFs and fMRI 
response within the visual cortex allowing us to develop an empirical measure of neurovascular 
coupling.
Figure 6-2 Schematic showing how MEG signals and fMRI are coupled. As a visual stimulus is presented there is 
a neural response causing the release of excitatory neurotransmitters (glutamate) resulting in further propagation 
of neural activity. This generates secondary chemical messengers (nitric oxide and K+) acting on vascular smooth 
muscle and leading to increases in CBF and CBV. Image taken from 119
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6-3 Methods
6-3-1 Subjects
10 healthy (Mage 23.9±2.16 (±SEM) years and 5 males, 5 females respectively) volunteers were 
recruited. Informed consent was taken for all participants under ethical approval from the Cardiff 
University School of Psychology Ethics Committee. All subjects apart from 4 required corrective lenses 
for daily use and were provided with MRI-safe spectacles throughout the experiment.
Subjects were then scanned once in MEG and once in MRI while a reversing checkerboard and moving 
grating were presented at 6 contrast levels.
6-3-2 Visual paradigm
There were two stimuli presented: the first was a reversing checkerboard, the second was a moving 
square wave grating. I was interested in two types of MEG recording from this study, the first was the 
presentation of VEFs and the other was changes in gamma power. These two stimuli had previously 
been used by other groups in CUBRIC to produce the same responses in MEG and are therefore 
excellent for modification and use in this pilot study121,122,185–187. Both were displayed at 7 contrast 
levels during both a MEG and MRI scan. Stimuli were generated in Matlab® at 6 (0%, 25%, 40%, 55%, 
70%, 85% and 100%) Michelson contrast levels. Checks were displayed centrally at 0.5 cycles per 
degree (cpd) with a reversal rate of 2Hz to preserve VEFs. The grating was displayed at 3cpd with a 
movement of 1 cycle per second from left to right. The entire stimulating field was 16° of visual angle. 
Subjects sat 80cm from the screen in MEG and 60cm in MRI, and the visual angle was matched in both 
scanners. Contrasts were displayed pseudorandomly for each participant, but contrast order was 
maintained between scan sessions for each subject. These paradigms were chosen to elicit both a 
measurable VEP response in MEG, evoked gamma oscillations, as well as producing a stimulus-induced 
increase in CBF122,186,188. 
Each checkerboard contrast was displayed for a total time of 2 minutes, split into 4 blocks of 30 
seconds. A rest period of a 0% contrast checkerboard was displayed for a total of 4 minutes, split into 
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8 30 second blocks. Each contrast block was displayed in a pseudo-random order. The grating followed 
the same display pattern as the checkerboard. However, each contrast block was not shown 
continuously, instead a 1 second on/1 second off design was employed during each 30 second block. 
Stimulus types were also presented pseudorandomly for each participant, but order was maintained 
between MEG and fMRI scans. Each stimulus lasted 16 minutes. Stimuli were displayed on a Sanyo 
XP41 LCD back-projection system in MEG and a Canon Xeed SX60 projector (1024x786 resolution 60Hz 
refresh rate) in MRI.
6-3-3 MRI
MRI data were acquired on a General Electric HDx scanner with eight channel receive only head RF 
coil (Medical Devices). Simultaneous ASL and BOLD imaging data was collected for each subject using 
a PASL proximal inversion and control for off resonance effects (PICORE). Quantitative imaging of 
perfusion using a single subtraction (PICORE QUIPSS II)189 imaging sequence with a dual-echo gradient 
echo (GRE) readout and spiral k-space acquisition (TE1 = 3ms, TE2 = 29ms, TR = 2.2s, flip angle = 
90degrees,FOV=22cm,matrix=64x64, 12 slices of 7 mm thickness with an inter-slice gap of 1 mm 
acquired in ascending order, voxel size 3.4mmx3.4mmx7mm, TI1 = 700ms, TI2 = 1600ms for the most 
proximal slice and was incremented by 54.6ms for subsequent slices, tag thickness = 20 cm, adiabatic 
hyperbolic secant inversion pulse, 10 mm gap between labelling slab and bottom slice, 10 cm QUIPSS 
II saturation band thickness). This resulted in the acquisition of 438 volumes (219 tag control pairs). A 
separate single shot (M0) scan was acquired (TR=infinity) with the same parameters as the functional 
run to measure the equilibrium brain tissue magnetisation for purposes of quantifying CBF. A 
minimum contrast image was also acquired to correct for coil sensitivity with the same acquisition 
parameters as the ASL run except for TE =11ms, TR = 2 s, and 8 interleaves. High resolution anatomical 
(1mm voxel size) FSPGR T1-weighted scans were acquired for use during registration.
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6-3-4 MEG
Whole head MEG recordings were acquired using a CTF-Omega 275-channel radial gradiometer 
system sampled at 1200Hz. An additional 29 reference channels were recorded for noise cancellation 
purposes and the primary sensors were analysed as synthetic third-order gradiometers185,190. Four of 
the 275 channels were switched off due to excessive sensor noise. The location of three fiduciary 
markers (nasion, left and right preauricular) was monitored continuously through the MEG acquisition 
at a frequency of 10 Hz. For each checkerboard reversal, a TTL pulse was sent to the MEG system, data 
was acquired continuously and epoched offline in a window that extended 40ms before and 200ms 
after the TTL pulse. Trials were manually excluded based on visibly identifiable artefacts.  Eye 
movements were monitored throughout data acquisition to ensure subjects were attending to the 
screen and not falling asleep. 
6-3-5 Analysis
6-3-5-1 MEG
Analysis of event related fields (ERFs) in sensor space was conducted using the FieldTrip toolbox for 
Matlab191. Time-locked analysis was performed on epoched raw data following baseline correction -
40–200ms around each reversal. 
Bandpass filtering was applied using an IIR Butterworth filter between 1-100Hz and limited from -40-
200ms following reversal to allow a full range of evoked potentials to be analysed. A SAM beamformer 
was used to generate pseudo-T statistic maps comparing rest blocks of 0% contrast to active contrast 
blocks. This revealed an area of increased power in the primary visual cortex, and virtual sensors were 
generated using SAM beamformer coefficients, returning the time-series from peak locations.The 
location of the highest pseudo-T statistic within the visual cortex was used as the location for a ‘virtual 
sensor’121. 
Following extraction evoked fields were baselined, a further IIR Butterworth filter was applied 
between 1-40Hz and demeaned. Filters have been applied in this way to enable source localisation to 
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be performed. Applying an initial filter of 1-40Hz rather than 1-100Hz resulted in a poor source 
solution during SAM processing. Therefore two filters have been applied in this way to mitigate this 
problem. Peak amplitudes were recorded for each subject at each contrast, as well as the average 
trace of all participants across contrasts. 
There is some conflict in the literature as to how and which peak of the evoked potential should be 
measured. Several peaks were recorded as part of the analysis: N70m, P100m, N70m-P100m peak 
difference, P100m latency, N140m and P100m-N140m peak difference. All peak amplitudes were 
calculated using matlab peak maxima functions in time windows expected for each peak (65-80ms, 
95-110ms and 130-150ms after checkerboard reversal for N70, P100 and N140 peaks respectively). 
This allowed for the most appropriate part to be regressed against any alterations in blood flow.
Gamma power was determined in a similar manner to calculating VEF amplitude; each dataset was 
epoched around each marker (-1s – 1s), the 1 second of ‘off’ period (-1s – 0s) was used as a baseline 
to compare to active periods (0 – 1s). Each epoch was then bandpass filtered using an IIR Butterworth 
filter to between 30-80Hz. A SAM beamformer was used to create a pseudo-T statistic map comparing 
baseline to active contrasts. This revealed an area of increased power in the primary visual cortex, and 
virtual sensors were generated using SAM beamformer coefficients, returning the time-series from 
peak locations. Time frequency analysis was performed using the Hilbert transform from 1-100Hz in 
0.5Hz steps and represented as a percentage change in gamma power from baseline, from this peak 
evoked gamma power change values from baseline were obtained122. There was a broad overlap of 
increased signal in the visual cortex between VEF-optimised statistic maps, and gamma power-
optimised maps. However, the peak pseudo-T statistic was not the same location for both datasets, 
therefore different locations for the virtual sensor were used for each subject and stimulus. Peak 
evoked gamma power was extracted using in house matlab® scripts.
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6-3-5-2 MRI
Preprocessing of functional images was performed by first brain extracting all images using FSL-BET155, 
motion correction was performed using MCFLIRT and highpass filtering of 120s was applied for BOLD 
and 70s for perfusion-weighted images and smoothed using a gaussian 5mm kernel. Functional 
images were registered first to subject’s high resolution T1 structural scan, limited to 6 degrees of 
freedom, then to Montreal Neurological Institute (MNI) 152 space with 12 degrees of freedom. Both 
steps were linear warps154. Physiological noise correction was carried out prior to data processing, a 
modified RETROICOR192, where 1st and 2nd harmonics of cardiac and respiratory cycles (and the 
interaction term) were calculated in addition to variance related to heart rate (HR)193 using a general 
linear model framework and regressed from the data.
As two echo times were used to generate perfusion and BOLD weighted images the two datasets were 
processed slightly differently. For BOLD weighted images, interpolated surround averaging of the tag 
and control images was performed, the average of each timepoint from the mean of its two 
neighbours, as described previously194 to remove the tag-control signal from the dataset.
Resulting images were then fed into FSL-FEAT153 where a GLM was used to regress the hemodynamic 
responses for each contrast. Regressors were made from timings of each visual contrast convolved 
with a HRF. For perfusion-weighted data a sawtooth design matching the TR of the function MRI 
sequence was applied to model alterations in intensity between tag-control slices, an interaction 
between this and the visual contrast GLM was used to model ASL data (fig. 6-3).
Masks were generated by multiplying an anatomical occipital lobe mask provided by FSL, with 
individual thresholded z-statistic images (z=2.3) of the maximal contrast responses. These were 
generated from FEAT report for each subject. Functional masks were created for each subject and 
used as an ROI when assessing responses from each visual contrast. These masks were used to define 
ROIs with which to calculate percentage changes in both BOLD and CBF data
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For BOLD data percentage changes were calculated using FEATQuery from the FSL toolbox. For 
perfusion-weighted data CBF changes were exctracted using the GLM model defined in fig. 6-3 and 
represented the absolute CBF of the ROI during stimulation. These values were divded by baseline CBF 
to obtain fractional CBF changes (percent CBF change) from baseline. 
6-3-5-3 Statistical Analysis
One-way ANOVA was performed on VEF amplitudes, percentage change in gamma power, percent 
BOLD signal change and percent CBF change to determine the alterations in the strength of responses 
with stimulus intensity (contrast). Linear regression was then performed of individual blood flow 
responses against individual neuronal measures for each type of stimulus (checkerboard or grating). 
Regression was performed for each subject’s responses individually, and then averaged for each 
stimulation type to give a mean regression coefficient. All results are mean values ± SEM unless 
otherwise stated.
Figure 6-3 Representative design matrix for analysis of perfusion weighted images. Box A represents contrast order. 
Box B shows the saw tooth design used to model tag/control pairs. Box C is the interaction between contrast and 
tag/control labels. Finally, box D shows the motion parameters added to the model, these were obtained from FSL 
MCFLIRT.
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6-4 Results
One-way ANOVA was used to determine alterations in the strength of response to each visual stimulus 
and are summarised in table 6-1.  
Out of the peaks measured from the evoked potentials here I focused on the P100m as it is the one 
most commonly used to assess CNS damage and optical integrity172,175. There is some conflict in the 
literature as to how to peak amplitudes. In P100m’s case this is whether to measure from 0 or to 
measure from the bottom of the N70(m) wave. For the checkerboard stimulus, P100m VEF amplitudes 
showed a main effect of contrast (F = 3.3 p = 0.01, F = 2.9 p = 0.02) when measured from baseline and 
from peak N70m respectively. BOLD signal increases and percent CBF increases showed no main effect 
or significant differences between contrasts (F = 1.3 p = 0.2, F = 0.9 p = 0.5 respectively).
Using the grating stimulus, no main effect was noted between each contrast response for gamma 
power (F = 0.65 p = 0.6). Figure 6-4 shows a single representative subject’s spectograms used to 
calculate evoked gamma power at each contrast (25% - 100%, A-F respectively). Figure 6-5 shows 
averaged time/frequency responses across all subjects. In addition to this there was no significant 
alterations in CBF responses across contrasts (F = 0.45 p = 0.8). There was however, a significant 
difference in BOLD signal responses (F = 3.3 p = 0.01). 
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Mean Response ± 
SEM
Contrast ANOVA results
25 40 55 70 85 100 P value
Checkerboard
Percent CBF change 31.9±1.3 34.5±2 33.2±2.8 32.2±1.8 39.5±3 35.4±2.3 0.2
Percent BOLD signal 
change 1.9±0.2 2.0±0.1 2.3±0.2 2.3±0.18 2.3±0.18 2.2±0.21 0.5
VEP amplitude from 
0 1.3±0.36 1.9±0.34 2.5±0.28 2.5±0.2 2.6±0.14 2.5±0.18 0.01
VEP amplitude from 
N70 2.1±0.4 2.5±0.4 3.2±0.32 3.3±0.26 3.5±0.22 3.3±0.2 0.02
Grating
Percent CBF change 15.0±4.3 24.1±10 15.3±6.5 20.4±6.6 11.9±3.9 14.7±4.1 0.8
Percent BOLD signal 
change 0.1±0.15 2.4±0.64 3.0±1 3.6±1.2 3.7±1.1 4.1±1.3 0.01
Percent gamma 
power change 33.2±5.9 43.8±9.3 52.7±11.2 54.2±9.2 59.6±12.1 57.9±10.3 0.6
Table 6-1 Summary of mean neuronal and blood flow responses to contrast in each of the stimuli presented. For the checkerboard, no significant differences in blood flow responses were noted 
between contrasts (p = 0.2 and 0.5 for percent CBF change and percent BOLD signal change from baseline respectively). VEP amplitude was sound to be significantly different between 
contrasts when measured both from 0 and from the trough of N70 (p = 0.01 and p < 0.05 respectively). For the grating however, no significant difference in response was seen in percent CBF 
change or percent gamma power change from baseline (p = 0.8 and p = 0.6 respectively). Blood flow responses seen using BOLD did show a significant difference between contrasts (p < 0.05).  
All values are mean ± SEM.
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Figure 6-6 shows the variability of VEF amplitude between contrasts, averaged VEFs (green line) along 
with standard error (grey shading) across subjects for each contrast. At low contrasts (figure 6-6A+B) 
the N70m wave is absent with P100m waves lacking sharp, defined peaks. As contrast increases there 
is a sharpening of the P100m peak along with N70m wave becoming more pronounced (fig. 6-6 C-F). 
Inter-subject variability also appears markedly higher at lower contrasts. 
Figure 6-7 shows a visualisation of each response measured for each contrast shown in the 
checkerboard (A+B) and grating (C+D), lines shown here are mean slopes following averaging of 
regression coefficients for each subject. Regression of changes in blood flow against P100m 
amplitudes returned slopes of 0.83 (±1.96, p=0.6) for P100m from 0 against percent CBF change and 
0.27 (±0.05, p < 0.001) against BOLD. A slope of 1.42 (±1.64, p=0.3) for P100m from N70m against CBF 
and 0.21 (±0.05, p < 0.001) against BOLD (figure 6-8A). Regression of gamma power against blood flow 
measures in the grating revealed a significant coupling between neuronal and blood flow measures. 
A significant slope of -0.22 (±0.1, p < 0.001) for gamma power regressed against percent CBF change. 
Percent change in BOLD weighted signal also returned a significant slope of 0.08 (±0.005, p < 0.001) 
(figure 6-8B).
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Figure 6-4 Individual time/frequency responses from the moving grating stimulus. Each contrast is represented in a separate image (A – 25%, B – 40%, C – 55%, D – 70%, E – 85%, F – 100%). As 
contrast increases, there is a larger increase in both broadband gamma power, and the frequency range of initial onset (30-80Hz, 0-300ms). This is then followed by a longer, sustained increase 
in gamma power around the 50Hz frequency mark. As contrast increases, the transient gamma power also increases.
Figure 6-5 Subject averaged time/frequency responses from the moving grating stimulus. Similar to figure 3, onset of the stimulus resulted in transient increases in broadband gamma power 
followed by a narrower sustained gamma band response. As contrast increased so did the intensity of the response, each image represents a contrast (A – 25%, B – 40%, C – 55%, D – 70%, E –
85%, F – 100%).
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Figure 6-6 Subject averaged evoked potentials from the checkerboard stimulus (green line) with standard error shown (grey shading) 
for 25% (A), 40% (B), 55% (C), 70% (D), 85% (E) and 100% (F) contrasts. N70m peaks are highly variable and do not appear to show 
easily at lower contrasts (25% and 40%), but progressively become more prominent at higher contrasts. Similarly, P100m waves 
appear blunted at lower contrasts but amplitude increases with stimulus intensity, along with a reduction in standard error and a 
sharpening of the peak.
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Figure 6-7 Subject averaged responses in the checkerboard (A+B) and grating (C+D). A) Shows VEF amplitude measured from 0 
(red) and from the base of N70m to peak P100m (blue). B) Displays blood flow responses BOLD (red) and percent CBF change (blue). 
C) Illustrates percent gamma power change as measured from the initial evoked gamma power spike. D) Shows the associated 
BOLD signal increases (red) and percent CBF change (blue) with each grating contrast. In A-C as contrast increases in the stimulus 
average reponse strength also increases in a non-linear trend. In D – the grating stimulus – very little change in blood flow reponse 
is noted. Lines shown are mean regression slopes following averaging of indivudal regression coefficients. Error bars show the 
standard error about the mean for each averaged response at each contrast.
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Figure 6-8 A) Regression charts of average subjects' changes in P100m amplitude from 0 against changes in BOLD 
(red) and percent CBF change (blue) with contrast. Regression coefficients for VEF amplitude vs CBF was 0.83 (±1.96, 
p = 0.6) and 0.27 (±0.05, p < 0.001) for BOLD. When P100m amplitude was measured from N70m regression 
coefficients were 1.42 (±1.64, p = 0.3) when compared against CBF and 0.21 (±0.05, p <0.001) against BOLD signal 
changes (data not shown). B) Subject averaged BOLD (red) and percent change in CBF (blue) regressed against 
percentage change in gamma power. A significant slope of -0.22(±0.1, p <0.001) is seen in the CBF-based NVC 
measure. BOLD-weighted signal-based NVC returned a significant linear regression of 0.08 (±0.005 p<0.001).
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Figure 6-9 Image showing source localisation solution of visual evoked fields in MEG (A) from a single representative subject following a 
100% contrast checkerboard stimulus. B) shows the same subject’s BOLD response following a 100% contrast checkerboard stimulus in an 
fMRI setting. Spatial resolution in MEG is known for not being as accurate as fMRI, however, similar response locations can be seen 
indicating a strong likelihood of the neural generators of the MEG signal being responsible for the BOLD response see in fMRI.
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6-5 Discussion
In this study I compared two methods of measuring NVC using different stimuli – a reversing 
checkerboard and a moving grating. Peak P100m VEF amplitudes were recorded in the 
checkerboard, whilst gamma power was measured for the grating. These were both obtained 
from MEG recordings, whilst BOLD/ASL-fMRI responses were collected for both stimuli. The 
aim was to regress neuronal measures against blood flow markers in an attempt to define 
empirically NVC.
Only VEF amplitude reliably increased with stimulus strength. Percent BOLD signal change 
measured in the grating stimulus also showed a significant increase in response to contrast 
levels. All other measures in each stimulus only exhibited a trending increase in response 
strength. 
N70m waves were difficult to detect at low contrasts. At higher contrasts (50% and above), 
however, all three peaks (N70m, P100m and N140m) were clearly visible. I focussed on P100m 
as this is considered to be the most clinically relevant wave and the main focus of the EEG 
studies I am comparing to172,188. Source localisation of P100m and gamma oscillatory activity 
consistently revealed one peak location of activity around the calcarine sulcus in 8 out of 10 
subjects in agreement with the accepted location of generators of P100m waves116. Locations 
of peak activation for P100m waves and gamma oscillations were slightly different from each 
other. This could possibly be due to two different neural generators of these measures, or 
could be due to slightly different source reconstruction in each case, possibly owing to the 
different parameters of the visual stimulus188. Group fMRI data demonstrated increased 
BOLD/perfusion-weighted signal in locations similar to that seen in MEG.
Regression between VEF amplitudes and fMRI responses only returned a significant 
dependency when regressing P100m amplitudes against BOLD signal change (fig. 6-8). 
Measuring NVC using percent CBF change derived from ASL data revealed no significant 
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relationship. This is likely due to the low SNR of this type of measurement, in addition the 
number of participants recruited not being high enough to give the measurement enough 
statistical power. Regressing blood flow measures against percent gamma power change in 
the grating stimulus yielded a significant coupling with both BOLD and ASL-derived 
measurements. Again due to the low SNR seen in ASL measures, the coupling here appeared 
negative, an unexpected result, but as there was no significant difference between percent 
CBF change at each contrast level, it is possible for this negative appearing coupling to be a 
false positive. 
One reason for this could be the compromise being reached between MEG and fMRI 
measures. To gain reliable transient VEFs (T-VEFs) a reversal rate of 1-2Hz is typically 
employed. In fMRI it is more common to use a higher frequency of 8Hz to confer the largest 
possible BOLD/CBF response115,116,171,175,183. Using a high frequency of reversal would not allow 
full separation of VEFs in MEG but a low reversal frequency would not gain the necessary SNR 
in fMRI for us to measure a change in blood flow in a short period of time. Here I compensated 
and used a reversal of 2Hz which allows for measurement of T-VEFs and to gain a reasonable 
SNR in fMRI within a smaller timeframe. However, there is some evidence to suggest that 
while an increase in reversal rate up to 8Hz causes a much larger CBF response in fMRI; this is 
met with a reduction in CMRO2171. In addition to this, the contrast range used in this study 
was limited, and focussed towards the top end of the scale, therefore the scope of the 
dynamic range available for the fMRI response would be limited171,195.
The grating stimulus used here did not provide the significant alterations in blood flow that 
was expected. Due to the 1 second on/off design of the stimulus it is possible this reduced the 
rises in blood flow for each contrast. Using this stimulus however, did provide a possibility of 
using gamma power in creating a measure of neurovascular coupling. Gamma power has been 
shown to increase with stimulus intensity128, and has been corroborated here. 
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Due to the lack of clear difference in blood flow responses, the low SNR of ASL could be one 
problem here, and as BOLD signal relies on a balance between oxygenated and deoxygenated 
haemoglobin it is possible to get an increase in CBF without measuring a difference in BOLD 
signal changes i.e. the ‘ceiling effect’105,171. However, another problem could be the limited 
range of contrasts selected for the stimulus. Other studies, using a wider range of contrasts 
have demonstrated robust alterations in blood flow171, implying the high contrasts used here 
do not fully capture subtler changes in flow. In refining this measure of NVC it would be 
advisable to utilise a wider range of visual contrasts, spaced further apart than what was used 
here. 
Figure 6-7 shows a non-linear relationship of both blood flow and neuronal measures with 
respect to contrast. If a wider range of contrasts were to be used when refining the NVC 
protocol, using a power law function to characterise the relationship between responses and 
stimulus intensity as well as neuronal and blood flow coupling is likely to characterise the 
relationship better compared to using a standard linear regression model. The grating 
stimulus used here yielded poor results with respect to blood flow measurements. This is likely 
due to a combination of the higher-end contrasts used, as well as the 1s on/off design yielding 
low blood flow responses and high noise within the data. Indeed, as the overall aim of this 
thesis is to use a NVC protocol in MS patients, it would be best to have as short a scan time as 
possible. Two 16-minute MEG scans, followed by two 16-minute fMRI scans, as well as 
additional structural imaging and baseline blood flow measurements could prove too long for 
patients. As patients fatigue, motion artefacts can contaminate any data collected, as well as 
the risk of patients falling asleep during scanning. Therefore, for these reasons when refining 
this protocol, the grating paradigm should be withdrawn, and instead focus on the 
checkerboard stimulus with a wider contrast range. It is possible that evoked gamma power 
can be extracted from the responses gathered from the checkerboard stimulus instead. Given 
the high volume of trials that are collected with this stimulus, a good signal should be available 
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for analysis. If the PING model is indeed accurate in explaining the source of gamma 
oscillations, using gamma power would be a valuable tool for assessing the health of 
neurovascular units and the efficiency of communication between neurons and 
interneurons/astrocytes and the underlying vasculature. As both gamma power and VEF 
amplitude have previously been shown to be stable over time, an assessment of their 
repeatability should be undertaken to ensure an empirical measure of NVC will be similarly 
stable115,185.
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Chapter 7: Assessing the repeatability of neurovascular coupling:
a combined MEG/fMRI approach
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7-1 Abstract
This study aims to define and compare empirical measures of neurovascular coupling defined 
from MEG and fMRI data and assess their respective stabilities. 15 healthy volunteers were 
recruited to undergo 4 scan sessions consisting of two pairs of MEG and MRI. The two MEG 
sessions were performed Mdays 10.6±2.6 apart, MRI sessions were Mdays 12.5±2.7 apart. A 
reversing square wave checkerboard was used at 2Hz and shown at 5 contrast levels (6.25%, 
12.5%, 25%, 50% and 100%) to detect changes in P100m visual evoked fields, gamma power 
and blood flow alterations, measured via MEG and BOLD/ASL fMRI respectively. Transient 
P100mVEF amplitudes were measured, along with increases in gamma power from baseline 
in MEG. These measures were then regressed against alterations in BOLD- and perfusion-
weighted signal changes in MR, the regression coefficients defining an empirical measure of 
neurovascular coupling (NVC). Intra-class correlation coefficients (ICC (3,1)) was used to 
establish repeatability of individual neuronal and haemodynamic measures and the 
empirically defined NVC. P100m amplitudes were found to be unstable over time, displaying 
an ICC around 0. BOLD, gamma power, and perfusion weighted measures however, were 
more stable with significant ICC values of 0.67, 0.9 and 0.5 respectively. The regression 
coefficients across sessions revealed an unstable NVC measure was created using P100m 
amplitudes as part of a NVC measure. Instead, gamma power increases correlated more 
strongly with MR-based CBF measures and were found to be stable across time making CBF-
gamma power a strong candidate for empirical assessment of NVC.
104
7-2 Introduction
The functional and structural integrity of the brain relies on a close balance between energy 
demands and substrate delivery from blood flow.  The complex interaction between neurons, 
arterioles and supporting cell types helps to maintain cerebral blood flow, and is termed 
neurovascular coupling (NVC). NVC relies on preserved cerebrovascular reactivity (CVR), 
which is the ability of vessels to dilate in response to a vasoactive stimulus, and has been 
shown to be impaired in several disease conditions from stroke and Alzheimer’s to multiple 
sclerosis34,147,170. Therefore, by defining NVC, it would be possible to establish the extent to 
which alterations, particularly in blood flow and substrate delivery to the brain could be 
contributing to the pathology of a disease state, as well as having a use as a target marker for 
damage when establishing new lines of treatment.
In order to study NVC a measure of both neuronal activity and associated changes in blood 
flow is required. Electroencephalography (EEG) and magnetoencephalography (MEG) are 
widely used investigate neuronal activity through evoked potentials, or oscillatory power. 
Similarly, functional magnetic resonance imaging (fMRI) enables researchers to study blood 
flow within the brain and alterations thought to correspond to changes in neuronal activation. 
There are several ways this can be achieved, however, these are typically variations centred 
around blood oxygenation level dependent (BOLD) weighted signal, or arterial spin labelling 
(ASL) techniques. As all of these techniques are well established throughout the research 
community it would desirable to assess these methods when establishing a measure of NVC.
Evoked potentials are used to study task-related events in the brain. One of the most 
commonly assessed is the visual evoked potential (VEP) as it is can be measured non-
invasively, and has been shown to have several characteristics, (most notably amplitude and 
latency) which can be altered in relation to intensity of the stimulus 171. 
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Visual evoked potentials (VEPs) are used clinically, to assess function in CNS disorders such as 
multiple sclerosis and neuromyelitis optica 171–174. VEPs are comprised of 3 main components; 
the first a negative deflection (N70) occurring between 65-80ms following stimulus onset, 
followed by a positive P100 wave at 95-120ms and finally a negative N140 at between 130-
150ms after onset completes the VEP 116,175.
It should be noted that the N70 is considered to be inconsistent in its presentation between 
subjects 174,176,177. Thus the P100 has been the main focus of evoked potential studies in 
disease states and healthy volunteers. 
Oscillations in brain activity, particularly the gamma band have been demonstrated by several 
groups to be modulated during task-related events. 127. However, the gamma band has been 
of particular interest in this study due to its  ability to be modified by a range of stimulus 
effects – such a spatial frequency, contrast and orientation – when subjects are presented 
with a visual task 118. Invasive LFP studies have also demonstrated a generation of high 
contrast gamma oscillations in V1 the primary visual cortex (V1), with an analogous effect 
being found in human MEG recordings 121,196.
Blood Oxygenation Level Dependent (BOLD) contrast is commonly used as a proxy for blood 
flow, and can be used to measure relative changes in CBF. However, BOLD relies on the 
balance between oxy- and deoxy-haemoglobin as a contrasting agent, resulting in alterations 
that can be susceptible to other physiological factors such as venous drainage, CMRO2, 
neurovascular coupling and high basal CBV 105,119,181,182. Arterial Spin Labelling (ASL) involves 
labelling a bolus of blood coming up through the neck and capturing the decay of 
magnetisation within a region of interest. Though SNR is low, it does enable a more 
quantitative approach to CBF measurement 106,111. 
Previous work investigating the similarities between visual evoked potentials (VEPs) as 
measured by EEG and visual evoked fields (VEFs) measured via MEG has shown the two to be 
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very comparable in waveform and peak latency 175,183,184. Visually induced gamma band 
modulation occurs primarily in V1 and co-localises well with BOLD signal increases when 
presented with the same stimulus 122. Co-localisation between these two measurements 
implies a similar source of signal for both modalities meaning either VEF amplitude or gamma 
band power can be used to assess V1 neuron activity along with BOLD, and by extension ASL-
weighted measures used to assess related blood flow changes during a visual task.
In this study, I combine fMRI and MEG-based methods to empirically define NVC and assess 
its stability across multiple measurements to determine its suitability for use in patient
populations. I aim to do this using blood flow alterations assessed through ASL and BOLD 
weighted images, generated from a visual stimulus of increasing contrast, regressed against 
visual evoked fields and gamma band oscillatory power in MEG as a neuronal measure. I 
hypothesise that as contrast increases so does VEF amplitude/gamma power and fMRI 
response within the visual cortex, allowing us to define NVC and assess its stability across 
measurements.
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7-3 Methods
7-3-1 Subjects
15 healthy (mean age 23.9±2.16 (±SEM) years and 6 male 9 female respectively) volunteers 
were recruited. Informed consent was taken for all participants under ethical approval from 
the Cardiff University School of Psychology Ethics Committee. Subjects underwent 4 scans, 
conducted in 2 pairs; MEG-MRI, MEG-MRI. 5 subjects underwent the first pair of scans on the 
same day. 7 undertook the second pair on the same day. All other subjects had each scan on 
different days, but scans were conducted in the same pair order. The two MEG sessions were 
performed 10.6±2.6 days apart, MRI sessions were 12.5±2.7 days apart.
7-3-2 Visual paradigm
Contrast acuity for each eye was assessed on the first MEG session using a SLOAN letter chart 
at 100%, 25%, 10%, 5%, 2.5%, 1.25% and 0.6%, and all subjects apart from 4 required 
corrective lenses for daily use and wore them throughout the experiment. SLOAN letter charts 
consist of 10 specially formed letters which are also used in the more well known Snellen and 
logMAR charts. However SLOAN charts are readily available in a wide range of contrasts and 
therefore allows testing of a subject’s acuity across their whole contrast detection range, 
rather than just at 100% contrast.
The main stimulus was a reversing checkerboard that was displayed at 6 contrast levels during 
both a MEG and MRI scan. Unlike in chapter 6, no grating was shown and a wider range of 
contrasts was utilised. The checkerboard was generated in Matlab® at 6 (0%, 6.25%, 12.5%, 
25%, 50% and 100%) Michelson contrast levels in an attempt to accurately characterise the 
whole contrast response in both modalities and follows a similar approach used by Stevenson 
et al. (2011) where an attempt compare β- and -band responses across a range of stimulus 
strengths was made. This compares to Liang et. al.  (2013) where only 1%, 5%, 10% and 100% 
contrasts were used, thereby leaving the middle, and upper contrast ranges relatively 
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uncharacterised by comparison. Checks were displayed at 1 cycles per degree (cpd) with a 
reversal rate of 2Hz. The entire stimulating field was 16° of visual angle. Subjects sat 80cm 
from the screen in MEG and 60cm in MRI, and the visual angle was matched in both scanners. 
Contrasts were displayed pseudorandomly for each participant, but contrast order was 
maintained between scan sessions for each subject.  This paradigm was chosen in order to 
elicit both a measureable VEP response in MEG, evoked gamma oscillations, as well as 
producing a stimulus-induced increase in CBF. 
As in chapter 6 each contrast was displayed for 30 seconds and repeated 4 times for a total 
viewing time of 2 minutes, rest periods of 0% contrast were displayed for a total of 4 minutes. 
The whole stimulus lasted 14 minutes and was repeated twice in each modality, once for each 
eye an example schematic of the contrast order can be seen in figure 7-1. The eye not being 
tested was covered using cotton makeup removal pads held in place with micropore tape. 
Eyes were switched round in each session so both eyes were tested. Eyes were tested 
separately in an effort to account for the effects of differences in visual acuity. If a subjects’ 
visual acuity differs significantly between eyes, which is a concern with patients suffering from 
MS, then response magnitude can be affected. Responses could appear lower if both eyes are 
open but one eye has a significantly lower acuity than the other. However, there might not be 
a significant difference in measured acuity with both eyes open, due to a subject 
compensating for a reduced acuity in one eye with the unaffected eye. Therefore by testing 
eyes separately differences in acuity can at least partially be controlled for when assessing 
response strength. Checkerboards were displayed on a Sanyo XP41 LCD back-projection 
system in MEG and a Canon Xeed SX60 projector (1024x786 resolution 60Hz refresh rate) in 
MRI.
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7-3-3 MRI
The main imaging protocol was kept identical to chapter 6. Images were captured on a 3 T 
whole body MRI scanner (GE Excite HDx, Milwaukee, WI, USA) with eight channel receive only
head RF coil (Medical Devices). Simultaneous ASL and BOLD imaging data was collected for 
each subject during the checkerboard task using a PASL proximal inversion and control for off 
resonance effects (PICORE) Quantitative imaging of perfusion using a single subtraction 
(PICORE QUIPSS II) 189 imaging sequence with a dual-echo gradient echo (GRE) readout and 
spiral k-space acquisition (TE1 = 3ms, TE2 = 29ms, TR = 2.2s, flip angle = 90°, FOV=22cm, 
matrix=64x64, 12 slices of 7 mm thickness with an inter-slice gap of 1 mm acquired in 
ascending order, voxel size 3.4mmx3.4mmx7mm, TI1 = 700ms, TI2 = 1600ms for the most 
proximal slice and was incremented by 54.6ms for subsequent slices, tag thickness = 20 cm, 
Figure 7-1 Representative schematic showing the randomised presentation of checkerboard contrast. Each bar 
represents 30 seconds of presentation with the height representation contrast. Sections of missing bars show the 
location of rest periods.
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10 mm gap between labelling slab and bottom slice, 10 cm QUIPSS II saturation band 
thickness). This resulted in the acquisition of 382 volumes (191 tag control pairs). At the 
beginning of each session a calibration scan was captured for quantification of perfusion maps 
to calibrate longitudinal magnetisation of CSF (M0) with the same scan parameters as the 
perfusion-weighted scan, but with no labelling and being captured at a fully relaxed state. Coil 
sensitivity was mapped using a minimum contrast image, acquired with the same acquisition 
parameters as before except TE = 11ms, TR = 2 s, and 8 interleaves.
A secondary, resting state scan was also performed to establish baseline CBF, allowing for 
absolute CBF change with contrast to be calculated.The resting state perfusion-weighted scan 
was performed with multiple inversion time (MTI) PASL 197 (10 inversion times (TIs)): 300ms, 
400ms, 500ms, 600ms, 700ms, 800ms, 1000ms, 1100ms, 1400ms, 1700ms and 2000ms). A 
PICORE tagging scheme was used with a QUIPSS II cutoff at 700ms for TIs>700ms. Label 
thickness was 200mm, 16 control-tag pairs were acquired for each inversion time. High 
resolution anatomical (voxel size = 1x1x1mm3, TE=29ms, repetition time = 7.8ms) FSPGR T1-
weighted scans were acquired for use during registration.
7-3-4 MEG
MEG data capture was identical to the method laid out in chapter 6 for the checkerboard. 
Whole head MEG recordings were acquired using a CTF-Omega 275-channel radial 
gradiometer system sampled at 1200Hz. An additional 29 reference channels were recorded 
for noise cancellation purposes and the primary sensors were analysed as synthetic third-
order gradiometers 185,190. Three of the 275 channels were switched off due to excessive 
sensor noise. The location of three fiduciary markers (nasion, left and right preauricular) was 
monitored continuously through the MEG acquisition at a frequency of 10 Hz. For each 
checkerboard reversal, a TTL pulse was sent to the MEG system, data was acquired 
continuously and epoched offline in a window that extended 40ms before and 200ms after 
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the TTL pulse. Trials were manually excluded based on visibly identifiable artefacts.  Eye 
movements were monitored throughout data acquisition to ensure subjects were attending 
the screen. 
7-3-5 Analysis
7-3-5-1 MRI
The same analysis of functional data was performed here as described in chapter 6. 
Preprocessing of functional images was performed by first brain extracting all images using 
FSL-BET 155, motion correction was performed using MCFLIRT and highpass filtering of 
120s was applied for BOLD and 70s for perfusion-weighted images and smoothed using 
a gaussian 5mm kernel. Functional images were registered first to subject’s high 
resolution T1 structural scan, limited to 6 degrees of freedom, then to Montreal 
Neurological Institute (MNI) 152 space with 12 degrees of freedom. Both steps were linear 
warps 154.
Physiological noise correction was carried out prior to data processing, using a modified 
RETROICOR 192. 1st and 2nd harmonics of cardiac and respiratory cycles (and the interaction 
term) were calculated in addition to variance related to heart rate (HR) 193 using a general 
linear model framework and regressed from the data. 
For BOLD weighted images, interpolated surround averaging of the tag and control images 
was performed. The average of each slice was subtracted from the mean of its two 
neighbours, as described previously 194 to remove the tag-control signal from the dataset.
Resulting images were then analysed in FSL-FEAT 153 where a GLM was created for each 
checkerboard contrast, convolved with hemodynamic response factor, a temporal derivative 
was also added to represent a regressor of no interest.. 
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For perfusion-weighted images, a sawtooth design was applied to model tag-control intensity 
alterations. The interaction between this and the contrast regressors were used to model ASL 
data (figure 7-2).
Region of interest analysis was performed by multiplying an anatomical occipital lobe mask 
provided by FSL with binarised Z-statistic images (Z = 2.3) of averaged contrast activation 
generated from FEAT. Brain extracted functional images were registered to MNI-152 standard 
space via T1-structual image. The transformation matrix was then inverted and applied to the 
occipital mask prior to restriction. Thus, a mask was generated for BOLD and perfusion images 
using the corresponding BOLD/CBF Z-statistic image. These masks were used to define ROIs 
with which to calculate percentage changes in both BOLD and CBF data in subject space in 
Figure 7-2 Representative design matrix of perfusion weighted images. Box A represents contrast order. Box B is the 
sawtooth design to model tag/controls pairs. Box C is the interaction term between contrast and tag/control labels, 
along with a temporal derivative EV. Finally box D shows motion parameters added to the model, these were 
obtained from FSL MCFLIRT.
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response to the visual stimuli. The Harvard Oxford atlas for cortical and subcortical structures, 
available within FSL was used to obtain the occipital mask. 
BOLD percentage changes in signal were calculated using FEATQuery from the FSL toolbox. 
For ASL data, mean tag-control signal difference extracted from FEAT analyses was used to 
define CBF during rest periods in the design. The ROI masks were then used for each subject 
to average voxel intensities for each visual contrast and divided by intensities for rest periods 
to generate a percentage signal change in CBF. 
In addition to the task-related functional data baseline perfusion was calculated using a 
protocol as described by (Warnert et al., 2014) using FSL BASIL. Briefly, CSF images were 
registered to perfusion series’ using FSL-FLIRT 154. This was used to create a mask of the lateral 
ventricles for calculation of M0,CSF allowing the equilibrium magnetization of blood (M0,Blood) to 
be calculated  189. A two compartment kinetic curve model as described in 113 was fitted to 
multi-inversion time data to calculate baseline perfusion in ml/100g/min along with mean 
arrival time 113,198. A separate multi TI sequence was acquired for both scan sessions and was 
used with the percentage CBF increases during the task to determine increases in cerebral 
blood flow during each active contrast period. 
7-3-5-2 MEG – VEF amplitude
Analysis of event related fields (ERFs) in sensor space was conducted using the FieldTrip 
toolbox for Matlab 191. Time-locked analysis was performed on epoched raw data, following 
baseline correction, -40–200ms around each reversal. 
Bandpass filtering was applied between 1-100Hz as described by185 and limited from -40-
200ms following reversal to allow a full range of evoked potentials to be analysed. 
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Source localisation using a multiple-spheres forward model199 was derived from fitting 
spheres to the brain, extracted using FSL-BET 153. Estimate maps of signal to noise were then 
embedded into MNI space with a smoothing of 8mm and peak activity was extracted. 
A synthetic aperture magnetometry (SAM) beamformer derived from CTF software 141 was 
used to create differential images of evoked source power (pseudo-T statistics). This was then 
used calculate evoked related field activity comparing 0.04s (-0.04s-0s) prior to checkerboard 
reversal to 0.2s (0-2s) following checkerboard reversal. 
Manual inspection of SAM images demonstrated subjects had between 2 and 3 peaks of 
activation within the right and left occipital lobes. To remove bias, the location of the peak 
with the strongest pseudo-T statistic was used as the location for placement of a ‘virtual 
sensor’ 121. 
Following extraction, evoked fields were baselined, Butterworth filtered to 1-40Hz and 
normalised. Peak amplitudes were calculated by subtracting N70m amplitudes from P100m 
for each subject at each contrast, these were averaged across contrasts to give a single 
amplitude measure for each contrast and each participant.  
7-3-5-3 MEG – Gamma power
Gamma power was determined in a similar manner to calculating VEF amplitude; each dataset 
was bandpass filtered using an IIR Butterworth filter to between 30-80Hz. Again, a SAM 
beamformer was used to create a pseudo-T statistic map comparing 0.24s (-0.04 – 0.2s) of 
rest averaged across a whole block to the same 0.24s of active checkerboard for each contrast. 
This revealed an area of increased power in the primary visual cortex, and virtual sensors were 
generated using SAM beamformer coefficients, returning the time-series from peak locations. 
Time frequency analysis was performed using the Hilbert transform from 1-100Hz in 0.5Hz 
steps and represented as a percentage change in gamma power from baseline, from this peak 
evoked gamma power change values from baseline were obtained122.
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7-3-6 Statistical analysis
Three-way ANOVA was used to assess the relationship between responses for each eye, 
session and stimulus contrast for each modality. Separate eye responses were then averaged 
and a power law was used to characterise coupling between MEG and fMRI-based 
measures200. A log-log plot was used to calculate the exponent and scaling factors of the 
relationship:
Repeatability was assessed using intraclass correlation coefficient (3,1) of the exponent (n) 
as described in 201. All resultant values are shown as mean±SEM unless otherwise stated, 
though multiple comparisons have been corrected for using the Holm-Sidak method 202.
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7-4 Results
Out of 15 participants, 3 were excluded due to excessive head motion. Excessive motion was 
characterised by movement within the MEG of greater than 20mm. Another participant was 
excluded for excessive artefacts in MEG that could not be corrected and resulted in SAM 
images without a main area of activation. 11 participants went through to final analysis. 
Two way ANOVA testing visual acuity across contrasts revealed no significant difference 
between left and right eyes (p=0.5). An expected difference in acuity across contrasts was 
seen (p < 0.001). There was no interaction effect between visual acuity and eye (fig. 7-3).
No significant difference between eyes was observed (P=0.5) P100m amplitude showed a 
main effect of contrast (F = 7.43, P < 0.001) but no further effects of eye (F = 0.377, P = 0.5) or 
session (F = 0.58, P = 0.45) with no interaction effect seen between any factor. 
Figure 7-4 shows VEF responses for each contrast in session 1 from a single representative 
subject. 
Figure 7-3 Average visual acuity for left and right eyes across contrast of a SLOAN letter chart. No 
significant difference between eyes was observed (P=0.5)
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Gamma power similarly exhibited a main effect of contrast (F = 68.12, P < 0.001) and again no 
effect of eye (F = 1.85, P = 0.18) or session (F = 0.029, P = 0.87), no interaction effects were 
seen between any factor. 
Figure 7-5 shows a single representative subject’s spectograms used to calculate evoked 
gamma power at each contrast (6.25%-100% left to right), with the top row representing 
session 1, and the bottom row, session 2. Figure 7-6 shows the grand averaged spectograms 
of all subjects used in the analysis.
Figure 7-4 Representative trace of the three main components of the visual evoked potential from a single subject showing 
changes in amplitude with contrast. The first negative wave (N70) occurs between 65-80ms after stimulus onset (red circle). 
Followed by a positive deflection (P100) occurring between 95-110ms after onset (green circle). Finally, a negative deflection 
between 130-150ms (N140) finishes off the evoked potential. P100 amplitude was determined by subtracting peak N70 
amplitude from P100 amplitude. Black = 6.25%, cyan = 12.5%, Blue = 25%, red = 50% and green = 100% contrast.
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Figure 7-5 Trial averaged spectograms from a single representative subject (subject 13) showing full frequency responses of all contrasts: 6.25%, 12.5%, 25%, 50% and 100% for the left eye 
(A-E respectively) and right eye (F-J respectively). Images were generated from MEG virtual sensors constructed from peak locations in the visual cortex. As contrast increases there is a 
marked increase in broad band gamma power (40-100Hz), along with a continuous alpha/beta band suppression (9-12Hz/ 12-30Hz). All energy values are shown as percentage increases 
from baseline.
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Figure 7-6 Grand averaged spectograms across contrasts from MEG virtual sensors constructed from peak locations in the visual cortex for session 1 (A-E) and session 2 (F-I). As with the 
individual spectograms in figure 4, as contrasts increases there is a strong increase in gamma power around two main frequency bands 30-50Hz and 50-70Hz. Suppression of the alpha band 
remains throughout all contrasts (9-12Hz). Energy values are represented as percentage change from baseline.
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Time frequency responses were averaged across eyes for each subject, then averaged across subjects 
to create average spectrograms for each contrast at each time point. 
There was no difference in occipital baseline CBF between session 1 and session 2 (66.4+/-
4.3ml/100g/min and 69.94+/-3.6ml/100g/min P = 0.36 respectively. There was a significant alteration 
in stimulus induced CBF, with main effects of contrast (F = 11.42, P < 0.001) and session (F = 41.85, P 
< 0.001) but not eye (F = 3.39, P = 0.07), and no interaction effects between any factor were seen. 
Finally, BOLD-weighted signal also demonstrated a significant main effect of contrast (F = 58.44, P < 
0.001) but not eye (F = 0.377, P = 0.5) or session (F = 0.62, P = 0.43). No interaction effects were 
observed. The changes in respective signals are shown in figure 7-7; with the left column displaying 
data from the first session, and the right showing the second session (figure. 7-7). As there were no 
significant differences in responses between left and right eyes for any modality, this allowed 
averaging of responses across the two eyes. 
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To assess the repeatability of each modality, the exponent (n) values for each subject were calculated 
from a log-log plot of MR and MEG values against contrast at both time points. This allowed for 
ICC(3,1) to be performed for each modality between time points. All ICC values are summarised in 
table 7-1. Visualisation of response stability between sessions can be seen in figure 7-8; responses 
with the highest stability exhibited a similar n values for session 1 and 2 in each modality.  The R2 
values in table 7-1 were calculated from a trend line fitting these plots.
Exponent N
Visit 1 vs Visit 
2 ICC F P R2
VEF -0.067 0.87 0.6 0.001
Gamma 0.9 14 <0.001 0.8
CBF 0.5 3.3 0.045 0.3
BOLD 0.67 5 0.0086 0.6
Table 7-1 Summary of ICC values for the β for each modality regressed against contrast level for session 1 and session 2. All 
show a highly significant, positive ICC value, apart from VEF amplitude. This signifies a high level of stability of the 
measurements between sessions for percentage gamma change, CBF and BOLD signal change with contrast but not VEF 
amplitude
Finally, to assess stability of the overall measure of NVC, n was extracted by regressing each MR 
measure against each MEG measure. Both for each modality’s corresponding session and again for 
the other time point (e.g. MEG responses on the first visit vs MR-based responses on the first visit, 
then MEG responses on the second visit vs MR-based responses on the first visit). ICC values in table 
7-2 were calculated for each combination of session in respective modalities to determine if the effect 
session order had on ICC calculations. Plotting n values shows a high R2 for gamma-based measures of 
Figure 7-7 All graphs show responses in each modality against contrast of visual stimulus for left (blue lines) and right (red 
lines) eyes. A shows P100M VEF amplitudes against each contrast in the first session, B for the second session. A significant
difference was observed between contrasts at both timepoints (p<0.001), with no significant difference in P100M amplitude 
detected between eyes or timepoint. E displays CBF changes with respect to contrasts for each eye tested at the first 
timepoint, F shows the second. A significant difference between CBF values for each contrast was demonstrated (p<0.001) 
and timepoint (p<0.001) but not between eyes. G displays BOLD-weighted signal changes between each contrast for left 
and right eyes at the first timepoint, H displays the second time point. A significant alteration in BOLD signal was observed 
between contrasts (p<0.001) but not between timepoint or eye. No interaction effects were seen between any factor for 
each modality. Blue = left eye, red = right eye.
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NVC regardless of session order (figure 7-9 A, B, E, F), but not VEF-based measures of NVC (figure 7-9 
C, D, G, H).
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Figure 7-8 Neuronal and blood flow measures regressed against contrast and N values plotted for session 1 and session 2. VEF amplitudes demonstrated poor stability between the two sessions 
(A) with an ICC value of -0.67 (p=0.6). B shows gamma power regressed against contrast for session 1 vs session 2. This exhibited high stability (ICC = 0.9 p < 0.001). BOLD-based blood flow 
measures (C)  also showed a good stability over the two sessions (ICC = 0.67 p = 0.0086). As did CBF measured through perfusion-weighted imaging (D) (ICC = 0.5 p = 0.045).
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Figure 7-9 Neuronal and blood flow measures regressed against each other and N values plotted for session 1 and session 2. Gamma oscillatory-based measures of neuronal activity regressed 
against blood flow measures shows good stability between sessions (A and B, ICC = 0.63 p = 0.01 and ICC = 0.69 p = 0.0013 respectively). VEF-amplitude-based coupling with blood flow 
measures does not show the same tight coupling and stability between sessions (C and D, ICC = 0.07 p = 0.42 and ICC = 0.11 p = 0.37 respectively). Mixing session order for each modality 
revealed a similar tight coupling between gamma-based NVC measures (E and F, ICC = 0.69 p = 0.0068 and ICC = 0.72 p = 0.0041 respectively)), but VEF-based NVC still exhibited weak stability 
between sessions (G and H, ICC =0.1 p =0.37 and ICC = 0.28 p = 0.19 respectively).
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Regressing MRI with MEG measures, and using a one sample T-test, assessing the mean regression 
slope across eye and session to be greater than 0, revealed a significant relationship between VEF 
amplitude and CBF across contrasts (P < 0.01, CBF = 48.2*VEF amplitude0.177), VEF and BOLD (P < 0.05, 
BOLD signal change = 1.34*VEF amplitude1.69). Regression of gamma power against MRI measures also 
yielded a significant relationship between gamma power and CBF (P < 0.001, CBF = 46.4*Gamma 
Power0.064) as well as with BOLD-weighted signal (P < 0.001, BOLD signal change = 0.5*Gamma 
Power0.53) (table 7-2). This relationship is shown more clearly in figure 7-10, here, contrast responses 
have been averaged across eyes and session to demonstrate the coupling between the two measures 
of neuronal activity and CBF. 
Linear 
Regression
Coefficient order ICC F P R2
Exponent 
N P 
VEF 1 - CBF 1 vs VEF 2 - CBF 2 0.11 1.26 0.37 0.02 0.177 <0.01
VEF 2 - CBF 1 vs VEF 1 - CBF 2 0.28 1.79 0.19 0.06 0.178 <0.01
Gamma 1 - CBF 1 vs Gamma 2 - CBF 2 0.86 13.3 0.0013 0.8 0.063 <0.001
Gamma 2 - CBF 1 vs Gamma 1 - CBF 2 0.72 6.14 0.0041 0.6 0.064 <0.001
VEF 1 - BOLD 1 vs VEF 2 - BOLD 2 0.07 1.1 0.42 0.006 1.69 <0.05
VEF 2 - BOLD 1 vs VEF 1 - BOLD 2 0.1 1.22 0.37 0.008 1.39 <0.01
Gamma 1 - BOLD 1 vs Gamma 2 - BOLD 2 0.63 4.3 0.01 0.5 0.53 <0.001
Gamma 2 - BOLD 1 vs Gamma 1 - BOLD 2 0.69 5.3 0.0068 0.5 0.52 <0.001
Table 7-2 Summary of ICC and linear regression results for different session orders. The β of each pair of measurements at 
the shown sessions were used to calculate ICC. The order of session of gamma power and MRI measures does not appear to 
influence the ICC of these measures, gamma-CBF coupling ICC show similar results of 0.79 and 0.63 for corresponding and 
mixed session orders, other of which remain significant. The same is seen for gamma power-BOLD coupling, both exhibit an 
ICC of 0.8 and remain highly significant. The same cannot be seen in VEF-MRI coupling; with VEF-CBF coupling having a low 
non-significant ICC of 0.22 when comparing corresponding sessions, and a more positive but still non-significant ICC of 0.48 
with mixed sessions. VEF-BOLD coupling appears to be more stable with both corresponding and mixed session analysis 
showing positive ICC values. However, only corresponding sessions have a significant ICC, with mixed sessions showing a 
trend towards significance but not quite reaching it. Finally, the significance of the regression was checked by averaging β 
coefficients from each combination of session/modality, with a one-way T-test being used to check for a significant difference 
from 0. All modalities and all combination of sessions exhibited a significant regression with each other
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Figure 7-10 Average regression plots of VEF amplitudes against MR measures and percentage gamma power 
alteration against MR measures. Each point represents a contrast. There was a significant relationship between 
VEF amplitude and perfusion-weighted signal (p<0.001), however there was no significant relationship between 
VEF amplitude and BOLD-weighted signal changes when interrogating individual subject relationships (p=0.1), even 
though there appears to be one when data is averaged. Gamma power-CBF coupling was promising with a 
significant logarithmic relationship exhibited (p<0.001), with a similar relationship seen in gamma-BOLD coupling 
(p<0.001).
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7-5 Discussion
Here I attempted to empirically define and assess the stability of neurovascular coupling in the human 
visual cortex across multiple measurements. The attempt to use VEF amplitude to gain a temporally 
stable method for measuring NVC was unsuccessful, the poor temporal stability shown here would 
make it a poor longitudinal measure of NVC. I have been able to define a temporally stable method 
for assessing NVC using gamma power as the neuronal component of NVC. Both BOLD and ASL-based 
methods for measuring change in blood flow were temporally stable and therefore could both be used 
for studying NVC.
There is little consensus over the nature of the relationship between event related potentials and 
vascular measures. Several groups reporting conflicting results, finding both linear and nonlinear 
correlations with stimulus intensity171,203,204. Here I noted a non-linear relationship with stimulus 
intensity with vascular responses, saturating at higher contrasts (figure 7-7 E-H). 
VEF amplitude also exhibited a non-linear relationship with contrast, but a non-linear relationship was 
noted between gamma oscillatory power and contrast (figure 7-7 A-D) in agreement with previous 
studies128. It has been previously noted that P100 amplitude is the most stable and reliable of the 
three VEF components 205. As the N75 peak is highly variable, particularly at low contrast, it is likely a 
large proportion of the between session variability seen for VEF measurements is due to my method 
for determining P100 amplitude. 
Due to the slow time course of the haemodynamic activity, it has often considered as a summation of 
fast acting neuronal responses over time, and has therefore assumed to be a linear coupling between 
the two121,206. Studies combining neuronal measures with flow-based techniques have instead noted 
a saturation effect of blood flow at high neuronal activation levels in the visual cortex. While evoked 
potential amplitude increases linearly with stimulus intensity (contrast or flicker rate), saturation of 
blood flow is observed, in agreement with this study206,207.
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Over long stimulation periods both BOLD and VEF amplitudes have been shown to exhibit habituation, 
resulting in a lower response over time for a given stimulus intensity 117,203. As there are many factors 
affecting BOLD signal change other than cerebral blood flow, it is not a quantitative measure of CBF, 
but could have potential use as an indicator of relative CBF changes in NVC. Furthermore, ASL-based 
measures of CBF have been shown to have a higher stability over time compared to BOLD 112. 
The low ICC exhibited by VEF amplitude would indicate a lower temporal stability and would therefore 
be less suitable for NVC measurement, contradicting other groups’ findings of high test-retest stability 
of VEP amplitudes 105,115. 
This does not apply when coupling vascular measures to gamma oscillatory power. Both induced and 
evoked gamma band responses have been shown to increase linearly with respect to contrast, a 
similar relationship seen here (figure 7-7 C+D)125. This is a trend also observed in intracranial 
recordings in monkey, suggesting my data is a good representation of the underlying 
neurophysiology118,127,187,208. As evoked gamma is a broadband activity with some subjects showing 
augmentation across the whole gamma range (figure 7-5) it does not suffer from the same dissociation 
from neuronal firing rates seen in narrowband-induced gamma127. High ICC values for evoked gamma 
amplitude are also in agreement with185, demonstrating high test-retest stability of measurements 
over time, and shows promise in defining NVC.
The high stability of coupling using gamma power is summarised in table 7-2, where ICC values remain 
similar and with a high significance for gamma-based NVC measures regardless of session order during 
analysis. As a similar trend cannot be seen in VEF-based NVC calculations it would seem to be a poor 
representation of underlying neurophysiology with one group finding significant correlations between 
VEP amplitude and CBF180. Instead, what I observe here is a brief spike in broadband gamma oscillatory 
power in response to checkerboard reversal. Blood flow increases saturate at high contrast levels 
however, presumably due to the limit of arterioles’ ability to dilate further. 
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In conclusion, the methods presented here represent an attempt to empirically define neurovascular 
coupling, and assess the stability of this measure across time. I have been able to demonstrate a 
relationship between two neuronal measures and two blood flow measures in response to a contrast-
based visual task. VEF amplitude showed poor stability over time, making it a poor candidate for 
further investigation of NVC, with evoked gamma band oscillatory power instead being a better 
choice. Both BOLD and ASL-weighted measures of CBF showed strong coupling with gamma band 
power. This remains true even when the order of sessions is mixed during analysis adding weight to 
this measure being the most useful in further investigating NVC. 
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Chapter 8: Neurovascular coupling in multiple sclerosis
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8-1 Abstract
Following on from chapter 7 where I assessed the most reliable method for measuring neurovascular 
coupling, I aimed to determine the extent to which this is affected in a pathological state such as 
multiple sclerosis given the reduced CVR seen in this patient group. 14 patients with relapsing-
remitting multiple sclerosis (RRMS) and 12 age and sex matched healthy volunteers underwent an 
MEG and fMRI scan that were performed on the same day. A reversing square wave checkerboard 
was used at 2Hz and shown at 6 contrast levels (0%, 6.25%, 12.5%, 25%, 50% and 100%) to detect 
changes in gamma power and blood flow alterations, measured via MEG and BOLD/ASL fMRI 
respectively. The neuronal measure (gamma power) was then regressed against alterations in BOLD-
and perfusion-weighted signal changes in MR, the exponent (n) values of a power law defining an 
empirical measure of neurovascular coupling (NVC). Patients exhibited a significantly lower gamma 
power increase in response to the reversing checkerboard contrast compared to healthy controls (p < 
0.05). However, none of the blood flow measures (absolute CBF, percent/absolute CBF change and 
percent BOLD signal change) showed any significant difference. When determining neurovascular 
coupling (defined as the exponent of a power law function regressing blood flow measures against 
gamma power change), there was a strong trend towards a lower NVC in patients when using absolute 
CBF as a blood flow measure in NVC (p = 0.1). There is promise for this technique to be used to assess 
the link between neural activity and CBF, particularly disease states
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8-2 Introduction
Cerebrovascular reactivity is crucial to maintaining proper NVC. As we have seen in chapter 5, CVR is 
impaired in Multiple Sclerosis patients, and is normalised following interferon-β treatment. Using the 
new methods for testing NVC outlined in chapter 7, I aim to test to what extent NVC is altered in MS 
patients given their impaired CVR to CO2. If there is an alteration in NVC in MS patients, this could 
have wide implications for both the mechanism through which axonal loss could be occurring as well 
as possible avenues of MS treatment to halt further damage.  As several histopathological studies 
have shown hypoxia-like tissue injury in MS brains, this lends support to the notion of impaired NVC 
as well as CVR in MS34,145,209. In addition to this, increased nitric oxide (NO) and endothelin-1 (ET-1) 
expression have a range of implications for the state of perfusion in MS sufferers. There is conflict in 
the literature about whether MS sufferers are chronically hyper- or hypo-perfused at rest due to the 
expression of these two vasoactive compounds respectively48,51,52,57,166,209,210. However, in either case 
this could have a severe impact on NVC and the response of the vasculature to a neuronal stimulus. 
One of the common initial presentations of multiple sclerosis (MS) is optic neuritis (ON). ON is an acute 
unilateral visual impairment characterised by a reduction in visual acuity and reduced structural 
connectivity values in affected optic radiations, optic nerves and associated visual pathways5,205. Even 
in the absence of visual impairment patients with MS exhibit optic nerve atrophy, demyelination and 
axonal loss in the retinal nerve fibre layer211. Clinically, pattern reversal visual evoked potentials (VEPs) 
are used, along with high contrast visual acuity tests to assess damage to the visual pathway, and 
make up part of Kurtzke’s extended disability score (EDSS). Here the P100 portion of the evoked 
potential is used as it is the least variable of the three portions of the VEP (the other two being N75 
and N145 mentioned previously)205. During both ON and MS P100 latency increases and amplitude 
decreases compared to healthy controls which is thought to represent demyelination and axonal loss 
along the optic pathway respectively174,211,212. It is therefore important to still use VEPs to assist in 
determining the damage along the visual pathway of any patient group. It is important to note 
however, while high contrast Snellen charts are typically used to assess visual acuity in MS, results 
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from these tests do not correlate well with disease activity, EDSS score, or optic nerve demyelination 
measures. Instead researchers are moving towards using SLOAN low contrast charts to determine 
visual acuity, as it appears to be more sensitive to damage and therefore is more appropriate to use 
in pathological states involving the visual pathway211–213.
I have been able to demonstrate altered vascular reactivity in MS patients, which is restored following 
treatment with interferon beta in chapter 5. This alteration gives considerable indication to the
disruption of normal vessel function caused by both inflammation and other vasoactive compounds 
such as NO and ET-1. As only CO2 was used in chapter 5 to assess vascular reactivity a more 
appropriate, neurological stimulus would be useful to determining how far this dysfunction can occur. 
Cerebral hypoperfusion has been established in the literature and has been indicated to be caused –
in part – by the action of ET-1 acting through ET-1a receptors in smoother muscle cells47,48,51,209. 
However, as the actions of ET-1 do not appear to have any effect on inducible isoforms of NOS (iNOS) 
coupling between neurons and blood flow might still be preserved214.  
In chapter 7 we concluded that P100m amplitude is less appropriate a neural measure compared to 
gamma power to use in NVC due to its high temporal variability contradicting previous work187,208. 
Here I intend to focus on using gamma power as a neuronal activation marker and, along with blood 
flow measures using ASL/BOLD imaging attempt to distinguish any alteration in NVC given the reduced 
vascular reactivity to CO2 seen in chapter 5. As in chapter 5 I was able to demonstrate a decrease in 
vascular reactivity in MS patients compared to healthy volunteers, I am expecting to see a decrease in 
the haemodynamic response in MS patients from neuronal stimulation. As there is evidence of GM 
damage in patients, even in the early stages of MS, representing neuronal cell loss, I am also expecting 
to see a decrease in the gamma power of patients in response the visual checkerboard task. As 
inflammation is known to interfere with multiple forms of cell-cell signalling, I also hypothesise a 
decoupling of neurovascular coupling in MS patients compared to healthy volunteers.
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8-3 Methods
8-3-1 Participants
14 patients with a diagnosis of MS according to the revised diagnostic criteria (Polman C et al, 2005), 
were eligible to start IFN beta, but were not currently on any disease modifying treatments, and had 
not experienced a relapse in the last 3 months were recruited at University Hospital Wales, Cardiff. 
Patients were assessed with behavioural measures before MEG and MRI scans were undertaken. 12 
age-matched healthy volunteers were assessed with the same behavioural measures. Participants 
were not asked to alter their lifestyle habits prior to scanning. Participants' written consent was 
obtained according to the protocol approved by REC Wales, and NHS R&D Wales.
8-3-2 Visual paradigm
Contrast acuity was assessed prior to the MEG scan session using the same protocol as described in 
chapter 7-3-2. A SLOAN letter chart was shown at 100%, 25%, 10%, 5%, 2.5%, 1.25% and 0.6% to 
establish acuity across the contrast range, and all subjects apart from 5 required corrective lenses for 
daily use and wore them throughout the experiment.
The main stimulus was the same one used in chapter 7, with no modifications. The reversing 
checkerboard displayed at 6 contrast levels displayed during both a MEG and MRI scan. The
checkerboard was generated in Matlab® at 6 (0%, 6.25%, 12.5%, 25%, 50% and 100%) Michelson 
contrast levels, the same contrasts that were used in chapter 7. Checks were displayed at 1 cycle per 
degree (cpd) with a reversal rate of 2Hz. The entire stimulating field was 16° of visual angle. Subjects 
sat 80cm from the screen in MEG and 60cm in MRI, and the visual angle was matched in both scanners. 
Contrasts were displayed pseudorandomly in the same order for both MEG and MRI for each 
participant and session. This paradigm was chosen to elicit both a measureable VEP response in MEG, 
and evoked gamma oscillations, as well as producing a stimulus-induced increase in CBF. 
Timings for each contrast were kept the same as in chapter 7. In the previous chapter, there were no 
differences in responses between eyes, but as there were no significant differences in visual acuity 
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between subjects’ eyes, this is to be expected. However, due to optic neuritis being a common 
complaint in MS patients, eyes are tested separately here, as the likelihood of a significant difference 
in visual acuity between eyes being much higher than in healthy volunteers. Checkerboards were 
displayed on a Sanyo XP41 LCD back-projection system in MEG and a Canon Xeed SX60 projector 
(1024x786 resolution 60Hz refresh rate) in MRI.
8-3-3 MRI
The whole imaging protocol was kept identical to chapter 7-3-3. Images were captured on a 3-T whole 
body MRI scanner (GE Excite HDx, Milwaukee, WI, USA) with eight channel receive only head RF coil 
(Medical Devices). Simultaneous ASL and BOLD imaging data was collected for each subject during the 
checkerboard task using a PASL proximal inversion and control for off resonance effects (PICORE) 
Quantitative imaging of perfusion using a single subtraction (PICORE QUIPSS II)189 imaging sequence 
with a dual-echo gradient echo (GRE) readout and spiral k-space acquisition (TE1 = 3ms, TE2 = 29ms, 
TR = 2.2s, flip angle = 90°, FOV=22cm, matrix=64x64, 12 slices of 7 mm thickness with an inter-slice 
gap of 1 mm acquired in ascending order, voxel size 3.4mmx3.4mmx7mm, TI1 = 700ms, TI2 = 1600ms 
for the most proximal slice and was incremented by 54.6ms for subsequent slices, tag thickness = 20 
cm, adiabatic hyperbolic secant inversion pulse, 10 mm gap between labelling slab and bottom slice, 
10 cm QUIPSS II saturation band thickness). This resulted in the acquisition of 382 volumes (191 tag 
control pairs). At the beginning of each session a calibration scan was captured for quantification of 
perfusion maps to calibrate longitudinal magnetisation of CSF (M0) with the same scan parameters as 
the perfusion-weighted scan, but with no labelling and being captured at a fully relaxed state. Coil 
sensitivity was mapped using a minimum contrast image, acquired with the same acquisition 
parameters as before except TE = 11ms, TR = 2 s, and 8 interleaves. To establish baseline CBF allowing 
for absolute CBF change with contrast to be calculated, an additional resting perfusion-weighted scan 
was performed with MTI PASL197 (10 inversion times (TIs)): 300ms, 400ms, 500ms, 600ms, 700ms, 
800ms, 1000ms, 1100ms, 1400ms, 1700ms and 2000ms). A PICORE tagging scheme was used with a 
QUIPSS II cut-off at 700ms for TIs>700ms. Label thickness was 200mm, 16 control-tag pairs were 
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acquired for each inversion time. High resolution anatomical (voxel size = 1x1x1mm3, TE=29ms, 
repetition time = 7.8ms) FSPGR T1-weighted scans were acquired for use during registration.
8-3-4 MEG
The MEG data acquisition was identical to what was described in chapter 7-3-4. Whole head MEG 
recordings were acquired using a CTF-Omega 275-channel radial gradiometer system sampled at 
1200Hz. An additional 29 reference channels were recorded for noise cancellation purposes and the 
primary sensors were analysed as synthetic third-order gradiometers185,190. Three of the 275 channels 
were switched off due to excessive sensor noise. The location of three fiduciary markers (nasion, left 
and right preauricular) was monitored continuously through the MEG acquisition at a frequency of 10 
Hz. For each checkerboard reversal, a TTL pulse was sent to the MEG system, data was acquired 
continuously and epoched offline in a window that extended 40ms before and 200ms after the TTL 
pulse. Trials were manually excluded based on visibly identifiable artefacts.
8-3-5 Analysis
8-3-5-1 MEG 
Gamma power was determined in the same manner as described in section 7-3-5-3; each dataset was 
bandpass filtered using an IIR Butterworth filter to between 30-80Hz. A SAM beamformer was used 
to create a pseudo-T statistic map comparing 0.24s (-0.04 – 0.2s) of rest block to 0.24s of active 
checkerboard for each contrast. This revealed an area of increased power in the primary visual cortex, 
and virtual sensors were generated using SAM beamformer coefficients, returning the time-series 
from peak locations. Time frequency analysis was performed using the Hilbert transform with 
time/frequency spectrograms displayed as a percentage change in gamma power from rest 122.
8-3-5-2 MRI
All MRI analysis was performed in the same way described in 7-3-5-1. Pre-processing was performed 
by first brain extracting all images using FSL-BET155, motion correction was performed using 
MCFLIRT and high pass filtering of 120s was applied for BOLD and 70s for perfusion-weighted 
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images and smoothed using a Gaussian 5mm kernel. Functional datasets were registered first to 
subject’s high resolution T1 structural scan, limited to 6 degrees of freedom, then to Montreal 
Neurological Institute (MNI) 152 space with 12 degrees of freedom. Both steps were linear warps 
performed using FSL-FLIRT154.
Physiological noise correction was carried out prior to data processing, using a modified 
RETROICOR192. 1st and 2nd harmonics of cardiac and respiratory cycles (and the interaction term) 
were calculated in addition to variance related to heart rate (HR)193 using a general linear model 
framework and regressed from the data. 
For BOLD weighted images, interpolated surround averaging of the tag and control images was 
performed. The average of each slice was subtracted from the mean of its two neighbours, as 
described previously194 to remove the tag-control signal from the dataset.
Resulting images were then used in FSL-FEAT153 where a GLM was created for each contrast, with a 
gamma hemodynamic response factor added as well as a temporal derivative (figure 7-2). 
For perfusion-weighted images, a sawtooth design was applied to model tag-control intensity 
alterations. The interaction between this and the contrast regressors were used to model ASL data
(see figure 7-2 for an example).
Region of interest analysis was performed by multiplying an anatomical occipital lobe mask provided 
by FSL with binerised Z-statistic images (threshold z = 2.3) of averaged contrast activation generated 
from FEAT. Thus, a mask was generated for BOLD and perfusion images using the corresponding 
BOLD/CBF Z-statistic image for each subject. These masks were used to define ROIs with which to 
calculate percentage changes in both BOLD and CBF data in subject space. The Harvard Oxford atlas 
for cortical and subcortical structures, available within FSL was used to obtain the occipital mask. Brain 
extracted functional images were registered to MNI-152 standard space via T1-structual image. The 
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transformation matrix was then inverted and applied to the occipital mask prior to restriction using 
the appropriate Z-statistic image.
BOLD data percentage changes in signal were calculated using FEATQuery from the FSL toolbox. For 
ASL data, mean tag-control signal difference extracted from FEAT analyses were used to define CBF 
during rest periods in the design. The ROI masks were then used for each subject to average voxel 
intensities for each contrast and divided by intensities for rest periods to generate a percentage signal 
change in CBF. 
Baseline perfusion was calculated using a protocol as described by Warnert et al., 2014 using FSL 
BASIL. Briefly, CSF images were registered to perfusion series’ using FSL-FLIRT154. This was used to 
create a mask of the lateral ventricles for calculation of M0,CSF allowing the equilibrium magnetization 
of blood (M0,Blood) to be calculated189. A two compartment kinetic curve model as described in113 was 
fitted to multi-inversion time data to calculate baseline perfusion in ml/100g/min along with mean 
arrival time 113,198. A separate multi TI sequence was acquired and used with the percentage CBF 
increases during the task to determine increases in cerebral blood flow during each active contrast 
period. 
8-3-6 Statistical Analysis and modelling of neurovascular coupling
Separate eye responses were averaged together following two-way ANOVA to assess the relationship 
between eye and contrast. A power law function was then used to characterise the relationship 
between each modality and contrast:
Coupling was then assessed using a similar power law fitting changes in gamma power and blood flow 
response. The exponent of which (n) was used as the measure of NVC:
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Multiple regression was used to assess how age, visual acuity, cohort, checkerboard contrast and 
baseline CBF could affect NVC in these subjects. All resultant values are shown as mean±SEM unless 
otherwise stated, though multiple comparisons have been corrected for using the Holm-Sidak 
method202.
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8-4 Results
Of the 27 subjects recruited to take part, all but 5 needed corrective lenses for the visual acuity tests 
and during scans. Of the patients 1 was excluded for excessive movement in MEG defined as 
movement >20mm and 1 felt claustrophobic in the MRI meaning that part of the study was not 
completed. Of the controls one due to be scanned was excluded due to not meeting the screening 
criteria and another was excluded due to excessive motion in MEG. In total 13 patients and 10 controls 
went through to analysis. A summary of volunteer characteristics can be found in table 8-1. 
One-way ANOVA testing visual acuity between left and right eyes revealed no significant difference in 
acuity between eyes in either cohort (F = 1.42, P = 0.2 and F = 0.73, P = 0.4 in controls and patients 
respectively). Following this, visual acuity scores were averaged across eyes. Multiple regression was 
performed for visual acuity data, changes in visual acuity could be determined by a combination of 
SLOAN letter contrast and age (p <0.001 and p <0.05 respectively) with group (healthy control or 
patient) having no significant contribution (p = 0.98) (fig. 8-1). 
Two-way ANOVA was used to assess modality responses in each eye for patients and controls to 
further determine any difference between eyes. 
In controls: Percent CBF change showed no significant effect of eye (F = 3.4, P = 0.7) or contrast (F = 
3.2, P = 0.07), absolute CBF exhibited no significant effect of eye (F = 0.01, P = 0.9) or contrast (F = 
0.06, P = 0.9). Absolute CBF change however, exhibited no significant effect of eye (F = 1.1, P = 0.3) 
but a main effect of contrast was seen (F = 9.8, P < 0.001), percent BOLD signal change demonstrated 
no significant effect of eye (F = 0.007, P = 0.9) with a main effect of contrast (F = 34.7, P < 0.001), finally 
percent gamma power change revealed no significant effect of eye (F = 0.7, P = 0.4) but a main effect 
of contrast (F = 33.2, P < 0.001). 
In patients: Percentage CBF change showed no significant difference between eyes (F = 0.9, P = 0.4) 
but a main effect of contrast (F = 3.1, P < 0.05), absolute CBF exhibited no significant difference 
between eyes (F = 0.03, P = 0.9), and no significant difference between contrasts (F = 1.9, P = 0.1). 
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Absolute CBF change displayed no significant difference between eyes (F = 1.1, P = 0.3) but a main 
effect of contrast (F = 8.8, P < 0.001), similarly percent BOLD signal change had no significant difference 
between eyes (F = 1.2, P < 0.001). Finally, percent gamma power change demonstrated no significant 
difference between eyes (F = 4.5, P = 0.06) but a significant main effect of contrast (F = 14.3, P < 0.001).
As there was no significant difference in responses between eyes, all responses were averaged across 
eyes for all subjects for further analysis. 
Figure 8-2 shows full time/frequency responses to the checkerboard in a single representative subject 
in MEG; healthy volunteer on the top row (A-E) and patient on the bottom row (F-J). Contrasts are 
shown from left to right (6.25% - 100%). Subject averaged responses are shown in figure 8-3; healthy 
volunteers on the top row (A-E); patients on the bottom row (F-J). 
As in chapter 7 a power law (equation 1) was used to describe the relationship between each modality 
and checkerboard contrast. This was done using a log-log plot of each modality response against 
contrast. To determine the contributing factors for each set of responses, multiple regression was 
performed for each modality, results are summarised in table 8-2. Following this the exponent (m) 
value were then used to compare responses of each cohort and is summarised in table 8-3. 
Visualisation of response plots is shown in figure 8-4.
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Figure 8-1 Average visual acuity for healthy volunteers (green) and patients (blue). No significant difference between 
volunteer group was seen (P = 0.98), main effects of age and SLOAN letter contrast significantly contributed to any difference 
in visual acuity (p <0.05 and p <0.001 respectively).
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Figure 8-2 Trial- and eye-averaged spectrograms of a representative healthy volunteer (subject 2 A-E top row) and patient (subject 1 F-J bottom row), showing full frequency responses at all 
checkerboard contrasts: 6.25%, 12.5%, 25%, 50% and 100% (left to right respectively). Images were generated from MEG virtual sensors constructed from peak locations in the visual cortex. As 
contrast increases there is a marked increase in broad gamma band activity (30-80Hz), along with a desynchronisation in the alpha/beta bands (9-12Hz/12-30Hz). Gamma band activity was 
markedly higher in the healthy volunteer compared to the patient, all energy values are shown as a percentage change compare to baseline.
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Figure 8-3 Grand averaged spectrograms across contrasts and subjects, healthy volunteers (A-E) and patients (F-J). Contrasts shown increase from left to right (6.25%, 12.5%, 25%, 50% and 
100%). As with the spectrograms in figure 2, broadband gamma band power (30-80Hz) increases with contrast with desynchronization in the alpha and beta bands (9-12Hz/12-30Hz). Overall 
a weaker gamma band response is seen in patients compared to healthy volunteers. All energy values are shown as a percentage change compare to baseline.
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Behavioural 
characteristics
Mean
Controls Patients P
M/F 2/8 5/8 0.3
Age 40.3±3.3 43.3±2.9 0.5
9HPT 22.4±0.8 25.1±0.9 0.05
PASAT 
3 49.1±3 47.5±2.4 0.7
PASAT 
2 36.1±2.5 31±1.9 0.1
25FW 9.6±0.2 12.6±1.4 <0.05
Baseline
V1 CBF 50.4±3.7 48±2.6 0.3
EDSS 3 (0-4.5)
P100 
Latency 
(ms)
108±0.003 119±0.003 <0.05
Whole 
Brain 
Volume 
(mm3)
1,523,327 1,493,231 0.2
Gamma 
Power at 
rest
0.95 1.09 0.053
Table 8-1 Behavioural characteristics of each cohort. The only significant difference in behavioural measures between 
patients and controls was in the 9-hole peg test (9HPT) and 25 ft walk (25FW). Patients were slower to complete the 9HPT 
than controls 25.1±0.9s and 22.4±0.8s p = 0.05 respectively patients were also slower to complete the 25 ft walk compared 
to controls 12.6±1.4s and 9.6±0.2s p <0.05 respectively. In addition to this P100 latency of the VEF was longer in patients than 
controls 19±0.003ms compared to 108±0.003ms p < 0.05 respectively. There was also a trend for resting gamma power to be 
higher in patients than controls (1.09 and 0.95 respectively) but this did not reach significance p = 0.053. Resting gamma was 
measured using the same virtual sensor position used when measuring active task responses.
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Table 8-2 Summary of multiple regression significance for each modality. Percentage CBF change showed a significant 
dependence on a combination of checkerboard contrast and baseline CBF (p < 0.001 or both), with a strong trend for a 
difference between subject groups (p = 0.055). Absolute CBF also exhibited the same dependence on checkerboard contrast 
and baseline CBF (p < 0.001), a significant difference between subject groups was also noted (p < 0.001). Absolute CBF change
was shown to be influenced heavily by checkerboard contrast (p < 0.001) and baseline CBF, but to a lesser extent (p < 0.05). 
Percent BOLD signal change also demonstrated a strong dependence on checkerboard contrast (p < 0.001) as well as subject 
visual acuity (p < 0.05). Finally, percent gamma power change was composed of a combination of checkerboard contrast, 
baseline CBF, visual acuity and subject group (p < 0.001, p < 0.05 and p < 0.01 respectively). Age did not appear to have any
significant effect on responses in any modality, but a slight trend was seen in percent BOLD signal change, but did not reach 
significance
Multiple regression P values
Contrast Age Baseline CBF
Visual 
Acuity
Subject 
Group
Percent 
CBF <0.001 0.3 <0.001 0.9 0.055
Absolute 
CBF <0.001 0.2 <0.001 0.9 <0.001
Absolute 
CBF 
change
<0.001 1 <0.05 0.7 0.6
BOLD <0.001 0.07 0.2 <0.05 0.07
Gamma <0.001 0.3 <0.05 <0.01 <0.01
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Modality responses vs contrast
Mean M ± SEM Mean K ± SEM
Modality Controls Patients P Controls Patients P
Percent 
Gamma 
power change
0.917±0.08 0.621±0.12 <0.05 0.84±0.23 0.51±0.13 0.1
Percent CBF 
change
0.514±0.15 0.34±0.073 0.1 6.2±1.7 8.5±2.2 0.2
Absolute CBF 0.0647±0.007 0.0467±0.009 0.08 51±3.5 48.7±2.4 0.3
Absolute CBF 0.605±0.15 0.416±0.08 0.1 3±0.8 3.9±0.96 0.3
Change
Percent BOLD 
signal change 0.0496±0.036 0.511±0.091 0.4 0.28±0.032 0.24±0.054 0.3
Table 8-3 Summary of exponent (m) values of responses in each modality vs contrast in patients and healthy volunteers along 
with statistical significance. Only percent change in gamma power n showed any statistical difference between patients and 
controls (0.34±0.073compared with 0.514±0.15 p <0.05 respectively). There was a distinct trend for absolute CBF to be altered 
between patients and controls (0.0467±0.009 and 0.0647±0.007 p=0.08 respectively), but did not reach statistical 
significance. The exponent from the power law model for both absolute and percentage change in CBF showed an interesting 
trend towards an alteration between patients and controls (absolute CBF change:  0.416±0.08 and 0.605±0.15 respectively, 
percent CBF change: 0.34±0.073 and 0.514±0.15 respectively. P = 0.1 in both). But no significant difference in the n of percent 
BOLD signal change with respect to contrast between patients and controls was observed (0.511±0.091 and 0.0496±0.036 p 
= 0.4).
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Figure 8-4 Visualisation of responses to a reversing checkerboard at different contrast levels. Controls are shown in green, patients in blue. A 
power law function was used to describe the relationship between the magnitude of response and contrast level. A) Shows the absolute at each 
checkerboard contrast used. The exponent (n) of the power law was used as my measure of NVC, there was a non-significant difference between 
patients and controls. B) Shows the percent BOLD signal change at each checkerboard contrast, there was a non-significant difference between 
patients and controls. C) Shows the percent CBF change at each checkerboard contrast, there was a non-significant difference between patients 
and controls. D) Shows the absolute CBF change at each checkerboard contrast, there was a non-significant difference between patients and 
controls. E) Shows the percent gamma power change at each checkerboard contrast, there was a significantly reduced gamma power increase 
at each contrast in patients compared to controls (p <0.05).
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Figure 8-5 Visualisation of NVC in healthy volunteers (green) and patients (blue). All points represent one contrast of the reversing 
checkerboard. A) Shows power law plots of NVC as measured using percent gamma power change regressed against absolute CBF change in 
ml/100g/min. There was a strong trend for NVC to be altered in patients compared to controls, but did not quite reach significance (p = 0.1). 
B) Uses absolute CBF as a blood flow measure for NVC, there was on significant difference between patients and controls (p = 0.2). C) Percent 
CBF change was used as a blood flow measure in NVC, there was a trend towards a significant difference in NVC between patients and controls 
(p = 0.1). D) Percent BOLD signal change as a blood flow measure showed the smallest difference in NVC between patients and controls (table 
4) and as such was clearly not significant (p = 0.3).
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Each blood flow measure was then regressed against Percent gamma power change using the power 
law function described in equation 2. Visualisation of the resulting NVC measures are shown in figure 
8-5, with the exponent (n) summarised in table 8-4. T-tests were performed to establish the extent to 
which any difference between patients and controls could be seen. Both percent CBF change and 
absolute CBF change showed notable, non-significant trends for an alteration in NVC in patients. 
Healthy volunteers exhibited an NVC relationship that could be described as: 
Compared to patients’ coupling:
Absolute CBF showed a slight trend towards a significant alteration in NVC in patients when comparing 
the two mean exponent values for healthy volunteers and patients respectively: 
Finally, BOLD signal-based NVC did not show an obviously significant trend when comparing the 
exponents of healthy volunteers and patients respectively: 
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Blood Flow vs Gamma Power
Mean N Mean K
Modality Controls Patients P Controls Patients P
Percent 
CBF 0.61±0.2 0.44±0.1 0.1 8.2±2.4 12.4±2.5 0.1
Absolute 
CBF 0.081±0.01 0.051±0.01 0.2 53±3.9 51.2±2.5 0.3
Absolute
CBF 0.8±0.2 0.46±0.1 0.1 3.95±1.1 4.7±1.1 0.2
Change
BOLD 0.55±0.07 0.48±0.1 0.3 0.41±0.06 0.55±0.1 0.07
Table 8-4 Summary of exponent n values used as a measure of NVC in patients and controls. Overall there was no significant 
difference in NVC measures between the two cohorts, however a strong trend for patients to have a lower NVC than controls 
when either absolute or percent CBF change as a blood flow measure (p = 0.1). Percent BOLD signal change showed the 
smallest difference in NVC measures between the two groups when gamma power was regressed against it.
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8-5 Discussion
Building on the previous chapter assessing the stability of measures of neurovascular coupling I have 
attempted to investigate neurovascular coupling can be affected in disease states. There is a trend for 
neurovascular coupling to be altered in multiple sclerosis but did not reach statistical significance here. 
It is worth noting that a significant alteration in the gamma band responses to the reversing 
checkerboard between patients and controls was seen and was the largest response alteration seen 
in any modality. Absolute CBF change showed a clear trend of being altered in patients compared to 
controls, but like all other blood flow measures did not quite reach significance. Overall however, 
responses were generally seen to be lower in patients with MS compared to controls, irrespective of 
whether they were significantly different from healthy volunteers or not. 
One of the leading models for the source of gamma oscillatory power comes from the Pyramidal 
Interneuron Gamma (PING) network127,128,187,215. Here, gamma is modelled by the interaction between 
inhibitory and excitatory drives, spiking from excitatory neurones is quickly stopped by inhibitory 
neurones which briefly shut down the network. The re-establishment of this network drives what is 
seen as gamma oscillations. Stronger excitatory drives – derived from a stronger stimulus for example 
– cause a faster recovery from these inhibitions resulting in higher oscillatory frequencies and an 
increase in amplitude128,187. In LFP studies spiking activity has been shown to saturate or even decrease 
at high contrast levels whereas human MEG has had conflicting reports between linear and non-linear 
increases in gamma power with contrast127,128,187,208. This can (at least partially) be explained by the 
difference in recording methods used, as LFP studies have very small recording sites, any changes in 
spatial coherence of these signals could results in the apparent saturation or reduction in recording 
measures. In MEG however, an increase in spatial coherence of gamma oscillations would manifest as 
an increase in amplitude and is in agreement with the findings here as well as other studies121,122,185,187. 
The decreased gamma responses in patients compared to healthy volunteers for each checkerboard 
contrast are evidence – along with the increase P100m latency – that even though these patients are 
still in the early stages of the disease with a low EDSS and only an increased 25 foot-walk (FW) time 
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there are significant neuronal alterations in these patients. Indeed, P100 latency has long been shown 
to be lengthened in CIS and very early RRMS patients, even before some lesions can be 
detected5,173,174. 
The increase in P100m latency in patients compared to controls implies there is damage along the 
visual pathway in these early stage MS patients, even though this did not result in a significantly 
altered visual acuity. As increases in gamma power, interpreted under the PING model, rely on an 
increasing strength of the input (in this case contrast of the visual stimulus). Damage to the visual 
pathway seen in MS presents as a reduction in visual acuity, and therefore would impact the perceived 
contrast of the checkerboard. The implication of this is that depending on the severity of damage to 
the visual pathway, the measure of neurovascular coupling we see here could be restricted as we 
would not be able to elicit a maximal response from neurons in V1 and therefore would not be able 
to fully measure the associated haemodynamic response. I attempted to control for differences in 
visual acuity by using corrective lenses during scan sessions, however, while patients remarked these 
lenses helped increase their acuity, corrective lenses would not compensate for differences in acuity 
due to damage along the visual pathway.  As no T2 scans were collected it is not possible to determine 
the WM damage in these patients, and therefore it isn’t possible to determine if the decrease in 
gamma power seen here is due to a genuine decrease in neuronal activation, or if it is a result of 
decreased input to V1, but NVC is preserved.
Peak gamma frequency has also been previously used as a measure of neural activity which, along 
with high temporal stability also alters with stimulus contrast of a visual checkerboard185,186. However, 
any alteration appears to plateau at 40% contrast of a visual grating meaning it would have been 
unsuitable for use in this study where I am trying to capture as wide a range of neurovascular coupling 
as possible187,196. Indeed, as I have already assessed the stability and usefulness of using gamma power 
in measuring neurovascular coupling in chapter 7, as this study yielded some good properties in 
measuring neurovascular coupling, the same protocol was used here in patients.
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Gamma oscillatory power and BOLD responses have been previously shown to be decoupled under 
certain stimulatory circumstances 122,135. Here it seems that a similar decoupling between gamma 
power and BOLD signal changes can be seen in patients with MS. Due to the complicated nature of 
the BOLD signal this is not entirely unexpected as many other factors could be confounding the 
coupling between BOLD signal change and gamma power (such as CMRO2 and CBV alterations), 
particularly in a pathological state such as MS. However, there was a non-significant trend towards a 
lower absolute change in CBF for each stimulus contrast in patients compared to healthy volunteers. 
The extent of this was not quite as large as the change in gamma power and, also implies some degree 
of decoupling between the two measurements. 
We have previously mentioned the interference of nitric oxide synthase (NOS) activity in chapter 5 in 
inflammatory active patients. Higher levels of circulating endothelin-1 (ET-1) would be acting to 
supress endothelial NOS (eNOS) activity93,148. Due to the close relationship between neurons, 
astrocytes and vascular smooth muscle cells it would be reasonable to infer that neural activity plays 
a key role in helping to regulate resting vascular tone. This could provide an explanation for the higher 
resting gamma power seen in patients compared to healthy volunteers. Increased oscillatory activity 
of the PING network could be indicative of extra neuronal signalling. It is possible this extra neuronal 
activity is due to damage along the visual pathway, with extra processing being required by the visual 
cortex to compensate for alterations in visual acuity. The higher resting gamma power, signalling for 
dilation of vascular smooth muscle cells, may be why no cerebral hypoperfusion was seen in these 
patients, contradictory to many other studies48,150,209. Indeed, as these patients were still early on in 
their disease course, any decreases in gamma power could be indicative of early damage, as gamma 
power has been shown to negatively correlate with cortical thickness and therefore cell count125. 
As with many neuroimaging studies the current study here also indicates a similar problem. While the 
exponent of many of the blood flow-based measurements and NVC in patients were almost half the 
value of what was seen in healthy controls along with low standard error significance was still not 
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reached. When comparing two populations a larger sample size would have been desirable. However, 
due to the time constraints placed on this study, along with the selective enrolment criteria this was 
not possible. Given that these patients were still in the early stages of their disease, later stage patients 
could have produced much large difference in NVC than the ones seen in the present study. However, 
with more advanced patients comes the additional confound. Different therapies and drugs to 
manage both the disease and symptoms, many of which being psychoactive would cause further 
complications to assessing if, and how NVC could be affected in this pathological state. Patients who 
are prescribed DMTs tend to be further along in their disease course, and therefore would have 
suffered further damage to their visual system, resulting in a greater impairment to their 
electrophysiological responses.
In conclusion, I attempted to use the methods laid out in chapter 7 to establish whether there was an 
alteration in neurovascular coupling in patients with multiple sclerosis, given their altered CVR. While 
a significant decrease in gamma power in response to the reversing checkerboard was seen in patients 
compared to healthy volunteers, no significant alterations in blood flow were noted. Due to the 
haemodynamic response being relatively unaltered in MS patients despite the decrease in gamma 
power implies there was a stronger blood flow response in patients for a given increase in gamma 
power. However, as there is also no way to separate out whether the decreases in gamma power are 
due to damage along the visual pathway, decreased neuronal activation, or a combination of the two, 
it is difficult to definitively assess whether neurovascular coupling is altered or preserved in these early 
stage MS patients.
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Chapter 9: General Discussion
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9-1 Summary of findings
Data collected from the Sapienza institute in Rome and analysed in this thesis, investigating the effects 
multiple sclerosis has on cerebrovascular reactivity and the role treatment plays in its restoration, was 
used as a prelude to inform the direction future research should take into the possibility of establishing 
a non-invasive method for measuring neurovascular coupling. This was developed using a multi-modal 
MEG/fMRI approach to gain an understanding for the role high frequency oscillatory activity 
(interpreted under the PING model) plays in altering blood flow, and how multiple sclerosis can alter 
this essential dynamic. 
The first experiment found in chapter 5 using data gathered from the Sapienza institute in Rome, 
found a wide difference in the vascular reactivity of early RRMS patients in response to CO2 depending 
on whether the patients were undergoing acute inflammation. Patients who did not exhibit any 
indications of being acutely inflamed demonstrated a significantly decreased cerebrovascular 
reactivity compared to healthy volunteers and patients who were acutely inflamed. This effect was 
reversed following commencement of treatment with the disease modifying drug interferon-β1a (IFN-
β1a).
Based on these results, a pilot study was performed using a neuronal stimulus to elicit a blood flow 
response. I am interested in blood flow changes in response to a neuronal stimulus as CO2 only tests 
the ability of vessels to dilate, rather than full NVC. Using MEG and fMRI to measure neuronal 
responses and blood flow changes respectively, a graded visual paradigm was designed to modulate 
the strength of the response measured. Two visual tasks were shown, designed to obtain two different 
neuronal responses; a checkerboard was used to gather visual evoked field (VEF) responses, a classical 
measure used clinically to assess neuronal damage along the visual pathway, and a moving grating to 
elicit sustained gamma band oscillatory activity. In chapter 6 I noted the checkerboard appeared to 
produce the most consistent results when measuring VEF amplitude and percent BOLD signal/CBF 
change. The grating paradigm resulted in a high degree of variability between participants and was 
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deemed unsuitable to be used to measure neurovascular coupling (NVC). The likely reason for this is 
the design of the stimulus; compared to the reversing checkerboard which allowed for a continuous 
30s block at each contrast, the grating was shown in a 1s on/off design. This means that for each 30s 
block, the grating was only shown for 15s, and making the stimulus too weak to elicit a strong, stable 
response.
This protocol was refined further in chapter 7, where the repeatability of each neuronal and blood 
flow measure was assessed. As I established in chapter 6, that a checkerboard task appeared to be 
the most appropriate stimulus for gaining stable neuronal and blood flow response. This task was 
repeated, but was altered to utilise a wider range of stimulus strengths to characterise the full spread 
of the NVC relationship. Using a power law function to characterise the relationship between stimulus 
strength (in this case percentage contrast of the checkerboard) and response strength, gamma 
oscillatory power was found to be highly stable over time, as was absolute CBF change and percent 
BOLD signal change in relation to stimulus strength. VEF amplitude however, was found to be less 
stable, with a high variability between time points. 
With the protocol established I aimed to finally build on the results from chapter 5, and further 
investigate the NVC relationship in multiple sclerosis. Gamma power was found to be significantly 
depressed at each contrast of the visual stimulus compared to healthy volunteers, but no 
corresponding decrease in CBF was noted. Using the same power law function utilised in chapter 7 I 
demonstrated a strong trend for a decoupling between gamma power and absolute CBF change in 
multiple sclerosis patients compared to healthy volunteers, but this did not reach significance. 
9-2 Interpretation and future research
9-2-1 Decreased cerebrovascular reactivity (CVR) in multiple sclerosis
Previous studies have demonstrated chronic hypoperfusion in both normal appearing white matter 
(NAWM) and grey matter (GM) in MS patients34,46–48. Disruptions in normal blood flow at rest could 
result in long term low level hypoxia to neurons, which would be extremely damaging as it puts 
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considerable strain on mitochondria to produce enough ATP to maintain proper resting membrane 
potentials. The production of endothelin-1 (ET-1) has been implicated in overcoming the normal 
regulation of luminal diameter51,214, causing the vasoconstriction and associated reduction in blood 
flow in MS patients. Loss of normal vascular reactivity in response to a vasoactive stimulus, broadly in 
line with previous work using 5% hypercapnia145,216, implies there is a greater level of interference 
from the constant presence of pro-inflammatory cytokines or vasoconstrictive mediators. It is 
interesting to note that patients exhibiting signs of acute inflammation also had a higher vascular 
reactivity than those who were not acutely inflamed. This would be possible due to the higher levels 
cytokines such as TNF-,IFN- and IL-6, all of which cause increases in inducible nitric oxide synthase 
(iNOS) activity and would therefore allow for an increase in vascular reactivity, as iNOS would not be 
activated in non-inflamed patients. The administration of IFN-, while reducing pro-inflammatory 
cytokine activity, also greatly reduces the level of ET-1 production and helps to explain the 
normalisation of CVR following the commencement of treatment.
These interpretations are somewhat speculative, however, as no biological samples were taken from 
patients during this study. It is, therefore, impossible to confirm the presence of these biomarkers. 
Instead I have had to rely on the literature for possible explanations to the differences in in CVR in 
these subsets of patients, and why both groups appear to have their vascular reactivity restored 
following administration of a DMT such as IFN-. 
9-2-2 Increased inter-subject variability using a moving grating stimulus.
When first attempting to establish a measure for NVC using the protocol outlined in chapter 6, it was 
noted there was a high level of variability between subject responses using a moving grating compared 
to the reversing checkerboard. Originally this was thought to be an issue with the gamma power 
measure being unreliable. However, the results persisted in the blood flow measurements, which also 
showed a higher level of variability compared the same contrasts in the checkerboard, along with a 
lower average response. 
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As this was an attempt to replicate the work of Muthukumaraswamy (2009). In this study 
Muthukumaraswamy et al. used a square wave grating to elicit gamma band oscillations. The visual 
task was presented at two contrast levels (30% and 100%) and presented in a similar on/off pattern, 
5s on 10s off in both contrasts. However, as I was testing a larger range of contrasts (40%, 55%, 70%, 
85% and 100%) the protocol was altered to a 1s on/off pattern but presenting each contrast in 30s 
blocks. 
The lower blood flow response could be due to the relatively transient nature of the design protocol. 
As each grating was only presented for 1s before moving to a 0% contrast block for 1s does not give 
the haemodynamic response (HR) sufficient time to increase to the same level as the checkerboard 
would, as each contrast was presented continuously for 30s. Instead as the HR requires around 5s to 
reach its peak this would explain the relatively flat regression slope show in fig. 6-6D, as well as the 
high inter-subject variability.
Muthukumaraswamy (2010) et al. noted that induced gamma power had a high level of inter-subject 
variability compared to evoked responses. This would help to explain the high variability seen between 
subjects and the large SEM in fig. 6-6C compared to VEF amplitudes. Indeed, Muthukumaraswamy 
went on to show evoked gamma oscillatory power to be highly stable over time and between subjects, 
and lead to the refinements to the protocol seen in chapter 7. 
9-2-3 Repeatability of NVC and compromises in the protocol
We were able to demonstrate, in line with other studies, that evoked responses exhibited the smallest 
amount of inter-subject variability. This was used to refine the protocol when looking to establish the 
repeatability of each neuronal response. To that end the checkerboard was used as the only visual 
stimulus in chapter 7. However, it was possible that differences in visual acuity might affect both 
neuronal and blood flow responses as a lower visual acuity would have the effect of reducing the 
perceived contrast of any stimulus. To account for this possible confound the visual acuity of each eye 
was assessed prior to the commencement of each scan session. During both MRI and MEG scans the
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responses from each eye were measured separately. Averaging of responses between eyes was only 
done when it was established there was no significant difference in acuity between eyes. In addition 
to this, the contrast range was also increased to cover a wider range of stimulus responses. Previous 
studies had shown that VEF amplitudes and percent BOLD signal changes plateau at high contrasts 
meaning the only way to get a full representation of NVC was to use a range of contrasts from 0%-
100%. 
Evoked gamma oscillatory power has also been shown to have a low inter-subject variability185, so 
here I aimed to alter the protocol that would allow the measurement of VEF amplitudes, gamma 
oscillatory power, percent BOLD signal change and absolute CBF change in the respective scan 
sessions. For this reason, a checkerboard of 2Hz and 1 cycle per degree of visual angle (cpd) was 
selected. In an fMRI setting a reversal rate of 8Hz and a high cpd has been shown to be the most 
effective at eliciting a maximal CBF response217. This is in contrast to MEG studies, which have shown 
that for checkerboard stimuli, a low reversal rate of 0.5-1Hz and low cpd prove to be the most effective 
(and most commonly seen in the literature) of evoking a maximal response128,218,219. Indeed, as the 
aim in this study was to measure evoked field amplitude and evoked gamma oscillatory spikes, the 
former of which has been shown to require 200ms to complete – or longer in the case of MS patients 
– a maximal reversal rate of 2Hz was set. A similar compromise had to be reached regarding the spatial 
frequency of the checkerboard. Fortunately, it has previously been shown that the BOLD response is 
less sensitive to the spatial frequency of a visual stimulus than either VEF amplitudes or gamma power 
is122. Spatial frequency was therefore maintained at 1cpd, to gain the largest neuronal response –
particularly as these measurements have a lower signal to noise ratios (SNR) compared to blood flow 
measurements in MRI. 
A different compromise could have been reached in regards to this protocol. Steady state VEFs 
amplitudes and phase (the latter being comparable to latency in transient VEFs) could have been 
utilised instead184,220,221. This would have allowed for a higher reversal rate of the checkerboard 
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allowing for maximal blood flow responses and still gathering a measure of neuronal activity. The 
higher reversal rate would prevent the measurement of evoked gamma oscillatory power, and instead 
the responses would be more akin to induced gamma responses, something that had already been 
shown to have a high inter-subject variability. I have already shown a proof of concept with the NVC 
measure in chapter 6 using a low spatial frequency/low reversal rate stimulus. Having two neuronal 
measures would also offer more options in case a low repeatability score was found in any of the 
individual measures. As time was critical I concluded that for these reasons it would be best to stay 
with the measures I had already identified and tested. 
Intraclass correlation coefficient 3,1 (ICC 3,1) was used to assess the repeatability of each response, 
as well as the repeatability of each NVC measure – defined as the exponent value of a power law 
function between neuronal and blood flow responses. Contradicting previous reports, I found 
transient VEF (T-VEF) amplitudes to have an ICC value close to 0: indicating low repeatability between 
measurements115. Evoked gamma oscillatory power, however, proved to be highly stable with an ICC 
value of 0.9. 
The low repeatability seen here is likely to be due to the design of the checkerboard protocol. As each 
reversal succeeded another, there was no opportunity to establish a resting baseline period with 
which to compare individual evoked responses prior to averaging. This meant that the baseline of 
each T-VEF was a small 400ms window between the end of one T-VEF and the start of the next. During 
this time, neuronal responses would still be resetting, therefore could provide an unstable baseline 
with which to measure the new T-VEF amplitude. This is would be particularly noticeable if a subject 
had a higher T-VEF latency which could result in part of the N145m wave being captured in the 
baselining window. It would have been ideal to have a boxcar design whereby each checkerboard 
reversal was preceded by a blank 0% contrast screen. Due to the time constraints imposed using such 
a wide range of contrasts, 30s of active checkerboard being needed to be repeated 4 times to allow 
for a high enough SNR in an fMRI setting and subject tolerances of the stimulus I was forced to 
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compromise and calculate VEF amplitude in this way. As gamma oscillatory power was baselined 
according to the 30s rest blocks interspersed throughout the protocol, a more stable baselining would 
have been likely to occur. Due to these factors it is a likely explanation for the differences in results 
shown here compared to the literature. 
As both BOLD signal changes and absolute CBF were found to have a significant, positive ICC value, 
both measures were brought forward to the final protocol to be used in patients. As a dual echo MRI 
sequence was being used to capture these two responses simultaneously, there was little time penalty 
associated with collecting both contrasts with this method. However, it is known that the ASL 
techniques have an inherently lower SNR compared to BOLD signal and could be at least partially 
responsible for the lower ICC value seen in chapter 7. my results here are similar to what has been 
concluded by other studies. 
Regressing blood flow responses against neuronal measures using the power law function mentioned 
previously yielded a stable NVC measure when using evoked gamma oscillatory power. This stability 
was found to occur even when the order of the scans was swapped (session 2 neuronal responses 
against session 1 blood flow changes and vice versa). This held true with both BOLD and absolute CBF. 
As T-VEF amplitude were found to be too variable over time, a NVC measure based on this neuronal 
response was found exhibit the same low ICC value as VEF amplitude on its own when regressed 
against visual stimulus contrast. 
9-2-4 Neurovascular coupling in MS
The final study, to investigate how NVC is affected in patients with early MS prior to DMT 
commencement demonstrated a significantly reduced gamma band response compared to healthy 
volunteers. While there was a strong trend for absolute CBF change to be reduced compared to 
healthy volunteers it did not quite reach significance (p = 0.08). Similarly, coupling between gamma 
power and absolute CBF change showed a strong trend for NVC in patients almost half of that of age 
and sex matched healthy volunteers, with no significant alteration in baseline perfusion. 
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However, what does appear to be clear is that even MS patients at such as early stage (mean EDSS 3) 
in their disease course are already showing profound alterations in NVC compared to healthy controls. 
This is generally in line with similar research into visual responses in MS patients172,174,222,223. Patients 
tend to exhibit lower blood flow response for each contrast compared to healthy volunteers, as well 
as a longer latency and lower VEF/VEP amplitudes222,224. 
9-2-5 Our approach to measuring neurovascular coupling
Our aim was to develop a protocol for defining and measuring neurovascular coupling in humans via 
non-invasive means. I chose to focus on the visual system as it has the advantages of being one of the 
most extensively studied regions of both human and non-human brains, with responses that are easily 
measured, and have a wide supporting literature base with which to easily design the type of protocol 
that would allow for the measurement of a graded neuronal and haemodynamic response. As the aim 
of this thesis was to further extend the method for testing neurovascular coupling in an inflamed brain, 
using the visual system had the added advantage that similar visual tasks are used clinically to assess 
disease progression and damage, thereby allowing for a comparison of experimental results shown 
here and clinically accepted patient responses. 
Using a non-invasive method was also crucial. Unlike some notable severe epilepsy studies where 
patients undergo placement of electrocorticography nets (ECOG) during pre-planned surgery to 
pinpoint the locations of seizure activity, multiple sclerosis patients, or many neurodegenerative 
patients do not have such dangerous, highly invasive, expensive surgeries occurring during their 
treatment. Indeed, proposing such surgeries to allow for direct measurement of neural activity would 
be irresponsible, and the proposed benefits (of which none would be immediately available or clear) 
would be negligible. Similarly, catheterisation of an artery close to the region of interest to get an 
absolute, continuous measure of blood flow would represent a highly risky proposition for any subject 
thinking about participating in a study, especially it is not required for treatment. Finally, the use of 
non-invasive methods for measuring neurovascular coupling means that there are far fewer ethical 
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implications when proposing new studies, along with any subject group (patient or healthy volunteer) 
being easier to recruit than if highly invasive methods were used. 
However, the use of non-invasive recordings does have its drawbacks, particularly when attempting 
to measure neural activity. Namely I do not have the certainty that the gamma power changes 
measured do in fact relate to the LFP and individual firing patterns found in invasive animal 
studies127,225. Several mathematical models have been proposed that attempt to explain the 
physiology behind the gamma oscillatory signal, but without invasive recordings I cannot be certain 
that any signals measured here can be compared directly to animal studies127,128,138,142,226.
With additional time, it would have been preferable to obtain a larger cohort of MS patients to 
determine if the trend for altered NVC in patients would reach statistical significance. However, the 
exclusion criteria were extremely restrictive as it is critical for patients to begin disease modifying 
treatments as soon as they become eligible, meaning only a small window of opportunity was present 
to allow for recruitment of participants. As in the first study into CVR in MS patients, having the 
opportunity to investigate the effects of IFN- treatment on this alteration in NVC would be extremely 
informative as to finding if, like CVR, the likely alteration in NVC is reversible with treatment. If so, the
measure of NVC used here would be a potential marker for assessing the effects of new treatments, 
as well as exploring NVC in other diseases of the CNS. 
167
Appendix A
Design matrix of group level patient GLM. Box A contains the averaging model for patients at time point 
1, 3, and 2 (left to right). Box B contains a model for whether a patient exhibited acute inflammation, 
determined by the presence of gadolinium enhancing lesions. Box C contains the model for whole brain 
grey matter densities as determined from FAST segmentation as part of FSL VBM.
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